0001493152-23-012561.txt : 20230417 0001493152-23-012561.hdr.sgml : 20230417 20230417164631 ACCESSION NUMBER: 0001493152-23-012561 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230417 DATE AS OF CHANGE: 20230417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bright Green Corp CENTRAL INDEX KEY: 0001886799 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41395 FILM NUMBER: 23824463 BUSINESS ADDRESS: STREET 1: 401 EAST LAS OLAS BLVD. STREET 2: SUITE 1400 CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: (201)370-1140 MAIL ADDRESS: STREET 1: 401 EAST LAS OLAS BLVD. STREET 2: SUITE 1400 CITY: FT. LAUDERDALE STATE: FL ZIP: 33301 10-K 1 form10-k.htm
0001886799 false FY 0001886799 2022-01-01 2022-12-31 0001886799 2022-06-30 0001886799 2023-04-14 0001886799 2022-12-31 0001886799 2021-12-31 0001886799 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember 2020-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2020-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001886799 us-gaap:RetainedEarningsMember 2020-12-31 0001886799 2020-12-31 0001886799 us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-12-31 0001886799 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2022-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-12-31 0001886799 us-gaap:SecuredDebtMember 2022-12-31 0001886799 us-gaap:BuildingMember 2022-01-01 2022-12-31 0001886799 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001886799 2022-10-03 0001886799 2022-10-02 2022-10-03 0001886799 BGXX:UnsecuredLineOfCreditMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-02 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:VotingAgreementMember 2022-01-01 2022-12-31 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember BGXX:MergerAgreementMember 2019-05-27 2019-05-28 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember BGXX:MergerAgreementMember BGXX:GreenHouseMember stpr:NM 2019-05-28 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember BGXX:MergerAgreementMember stpr:NM 2019-05-28 0001886799 BGXX:GGGMergerAgreementMember BGXX:GrantsGreehouseGrowersIncMember 2020-10-28 2020-10-30 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementOneMember BGXX:GrantsGreehouseGrowersIncMember 2021-01-01 2021-06-30 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementOneMember BGXX:GrantsGreehouseGrowersIncMember 2021-07-01 2021-12-31 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementOneMember BGXX:GrantsGreehouseGrowersIncMember 2022-01-01 2022-01-01 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementOneMember BGXX:GrantsGreehouseGrowersIncMember 2022-01-01 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantsGreehouseGrowersIncMember 2022-01-01 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantsGreehouseGrowersIncMember 2020-10-21 2020-10-21 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GrantsGreehouseGrowersIncMember 2022-01-01 2022-01-01 0001886799 BGXX:GGGMergerAgreementMember BGXX:RealEstateOptionAgreementMember BGXX:BlackScholesModelMember 2022-01-01 2022-12-31 0001886799 BGXX:NaseebIncMember 2022-12-31 0001886799 BGXX:NaseebIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-01-01 2021-12-31 0001886799 BGXX:VenloStyleGreenHouseMember stpr:NM 2022-12-31 0001886799 stpr:NM 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember us-gaap:PrimeRateMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-01-01 2022-12-31 0001886799 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-02-01 0001886799 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-03-14 2023-03-14 0001886799 us-gaap:SubsequentEventMember 2023-03-14 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-12-31 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-12-31 0001886799 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockOneMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockOneMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 BGXX:CommonStockTwoMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockTwoMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 BGXX:CommonStockThreeMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockThreeMember srt:ChiefExecutiveOfficerMember 2022-12-31 0001886799 us-gaap:WarrantMember BGXX:SecurituesPurchaseAgreementMember 2022-09-06 2022-09-07 0001886799 us-gaap:WarrantMember 2022-09-06 2022-09-07 0001886799 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2023-01-29 2023-02-01 0001886799 2022-09-12 2022-09-12 0001886799 us-gaap:CommonStockMember BGXX:TwentyEightAccreditedMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThirtyAccreditedMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThirtyAccreditedMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThirtyAccreditedMember BGXX:JanuaryTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThirtyAccreditedMember BGXX:DecemberTwentyTwentyMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThirtyAccreditedMember BGXX:MarchTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:MayTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwentyEightAccreditedMember BGXX:JuneTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:SeptemberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OctoberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember 2021-01-01 2021-09-30 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember BGXX:OctoberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:OneHundredEightyEightAccreditedMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember 2021-01-01 2021-09-30 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember BGXX:OctoberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember BGXX:DecemberTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwelveAccreditedMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:FiveConsultantsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:FiveConsultantsMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:FiveConsultantsMember BGXX:JanuaryTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:FiveConsultantsMember BGXX:MayTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeDirectorsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeDirectorsMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeDirectorsMember BGXX:JanuaryTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeDirectorsMember BGXX:FebruaryTwentyTwentyOneMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwoDirectorsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:TwoDirectorsMember 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeConsultantsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember BGXX:ThreeConsultantsMember 2021-12-31 0001886799 us-gaap:DomesticCountryMember 2022-12-31 0001886799 us-gaap:DomesticCountryMember 2021-12-31 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2022-01-01 2022-12-31 0001886799 BGXX:FiveDirectorsMember 2021-01-01 2021-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccruedLiabilitiesMember 2022-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2023-01-31 2023-02-01 0001886799 us-gaap:SubsequentEventMember 2023-02-01 0001886799 us-gaap:SubsequentEventMember 2023-02-02 0001886799 us-gaap:LineOfCreditMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-03-27 0001886799 us-gaap:SubsequentEventMember 2023-03-27 2023-03-27 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-03-30 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:acre xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-K

 

 

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

 

Commission File Number 001-41395

 

BRIGHT GREEN CORPORATION

(Exact name of Registrant as specified in its Charter)

 

Delaware   83-4600841

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

1033 George Hanosh Boulevard

Grants, NM

   87020
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (833) 658-1799

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange on which registered
Common stock, $0.0001 par value per share   BGXX   The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2022, was $141,818,084.

 

The number of shares of the registrant’s common stock outstanding as of April 14, 2023, was 174,423,810.

 

 

 

 

 

 

Table of Contents

 

    Page
  References to Bright Green ii
  Special Note Regarding Forward Looking Statements ii
  Trademarks and Tradenames iii
  Market Data and Forecasts iii
PART I  
Item 1. Business 4
Item 1A. Risk Factors 16
Item 1B. Unresolved Staff Comments 39
Item 2. Properties 40
Item 3. Legal Proceedings 40
Item 4. Mine Safety Disclosures 40
     
PART II  
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 41
Item 6. [Reserved] 41
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 41
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 46
Item 8. Financial Statements and Supplementary Data 46
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 46
Item 9A. Controls and Procedures 47
Item 9B. Other Information 47
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 47
     
PART III  
Item 10. Directors, Executive Officers and Corporate Governance 48
Item 11. Executive Compensation 53
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 62
Item 13. Certain Relationships and Related Transactions, and Director Independence 63
Item 14. Principal Accounting Fees and Services 65
     
PART IV    
Item 15. Exhibits, Financial Statement Schedules 66
Item 16. Form 10-K Summary 67

 

i

 

 

References to Bright Green

 

Unless otherwise indicated in this Annual Report on Form 10-K (this “Annual Report”), “Bright Green Corporation,” “Bright Green,” “BGC,” “the Corporation,” “the Company,” “we,” “us” and “our” refer to Bright Green Corporation.

 

Special Note Regarding Forward-Looking Statements

 

This Annual Report and the documents incorporated by reference herein may contain “forward-looking statements” within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part I, Item 1.A, “Risk Factors” in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:

 

  ● the initiation, design, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish our goals;
  ● the completion of our proposed transactions with third-parties, including but not limited to our proposed transaction with Alterola Biotech Inc.;
  ● the likelihood or timing of any regulatory approval;
  ● our ability to successfully commercialize, and our expectations regarding commercial potential with respect to, our products;
  ● the rate and degree of market acceptance of our products;
  ● the size and growth potential of the markets for our products, and our ability to serve those markets;
  ● our ability to obtain and maintain intellectual property protection;
  ● interactions with regulatory authorities in the United States and foreign countries;
  ● our ability to attract and retain experienced and seasoned scientific and management professionals to lead the Company;
  ● the performance of our third-party suppliers and manufacturers, including our ability to scale-up manufacturing levels as necessary;
  ● our ability to attract collaborators with relevant development, regulatory and commercialization expertise;
  ● future activities to be undertaken by our strategic alliance partners, collaborators and other third parties;
  ● our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;
  ● our ability to avoid, settle or be victorious at costly litigation with shareholders, former executives or others, should these situations arise;
  ● our ability to obtain and deploy funding for our operations and to efficiently use our financial and other resources;
  ● our ability to continue as a going concern; and
  ● the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing.

 

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted the same in light of additional research, preclinical and clinical trial results. The forward-looking statements contained in this Annual Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the “SEC”). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

ii

 

 

Trademarks and Tradenames

 

The Bright Green logo and other trademarks of Bright Green appearing in this Annual Report are the property of Bright Green. All other trademarks, service marks and trade names in this Annual Report are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the ® or ™ symbols.

 

Market Data and Forecasts

 

Unless otherwise indicated, information in this Annual Report concerning economic conditions, our industry, and our markets, including our general expectations and competitive position, market opportunity and market size, is based on a variety of sources, including information from independent industry analysts and publications, as well as our own estimates and research. Our estimates are derived from industry and general publications, studies and surveys conducted by third-parties, as well as data from our own internal research. These publications, studies and surveys generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information, and we have not independently verified industry data from such third-party sources. While we believe our internal research is reliable and that our internal estimates are reasonable, such research has not been verified by any independent source and our internal estimates are based on our good faith beliefs as of the respective dates of such estimates. We are responsible for all of the disclosure in this Annual Report.

 

iii

 

 

PART I

 

Item 1. Business.

 

Overview

 

Our Mission & Vision

 

Bright Green’s mission is to be the premier federally-authorized provider of cannabis in North America. Our vision is to improve the quality of life across a broad spectrum of demographics through the opportunities presented by medicinal applications of plant-based therapies, particularly cannabis-derived products.

 

Our Company

 

We are a first-mover in the U.S. federally-authorized cannabis space. We are one of a few companies who have received conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration (the “DEA”) to produce federally legal cannabis and have entered into a Memorandum of Agreement (“MOA”) with the DEA which permits us to proceed towards a Federal Registration for the Bulk Manufacturing of cannabis under DEA Document Control Number W20078135E.

 

Unlike state-licensed cannabis companies who engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, subject to the milestones and requirements set forth herein, we are conditionally authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations. We plan to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

 

In addition to research and pharmaceutical supply sales, Bright Green will be able, and has received the DEA’s express permission, to sell certain cannabinoids, such as CBN (cannabinol) and CBG (cannabigerol) as hemp isolates or extracts, and plans to sell CBN and CBG hemp products to consumers where such products are fully legal under all applicable laws. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”), which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under a Federal Registration for the Bulk Manufacturing of cannabis, if and when we receive such registration

 

Because cannabis is still a Schedule I Controlled Substance in the U.S., it has been historically under-researched. Though the majority of Americans now live in states where cannabis is legal, the full potential of the cannabis plant for medicinal use remains understudied due to limited access to federally-approved cannabis. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, we received conditional approval from the DEA, based on already agreed upon terms set forth in the MOA. Final approval from the DEA is contingent on, among other things, completed construction of manufacturing and production facilities and systems. Completion of construction is subject to the risk factors described herein and also requires successful fundraising.

 

Final registration under the MOA is anticipated in the second quarter of 2023, and is contingent upon completion of construction and a successful inspection by the DEA of BGC’s facilities. Additionally, BGC must comply with the terms agreed upon pursuant to the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

4
 

 

Following final approval from the DEA, we will be permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. There is no guarantee that we will receive final approval from the DEA. Upon receipt of the Federal Registration for the Bulk Manufacturing of cannabis, our activities will be legal under federal law, which sets BGC apart from most other U.S. cannabis companies, if and when we receive such approval.

 

We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe position us as a future industry leader in the production of cannabis.

 

Current Operations

 

BGC owns a 70-acre parcel of land on agricultural property, which includes an existing 22-acre greenhouse structure. The Company also owns a 40-acre parcel of land nearby, and holds options for two additional 300-acre properties which are adjacent to the owned properties (one is known as the “Candelaria” property, and the other is known as the “Azuz” property).

 

We are engaged in a phased development process consisting of the following:

 

  ● Renovation of BGC’s existing 22-acre production facility, which is close to completion;
     
  ● the potential acquisition of Alterola Biotech, Inc. (“Alterola”) and research and development of Alterola assets;
     
  ● development of a 118-acre state-of-the-art agricultural manufacturing and research facility; and
     
  ● future greenhouse developments.

 

When completed, we believe the project will be one of the nation’s largest federally authorized manufacturing and research facility for plant-based therapies, supplying researchers across the United States and internationally with high-quality cannabis and derivatives and will be capable of producing up to approximately 100,000 grams of resin per day with a concentration of a minimum of 85% useful cannabinoids.

 

Phase 1 of the project consists of the renovation of the BGC’s existing 22-acre production facility to process medicinal plants, including cannabis and hemp, as well as the purchase of 25% of Alterola common stock, which occurred on October 3, 2022. 2023 operations of Phase 1 greenhouse acreage are expected to result in a net profit of $163.4 million, which will be available for Phase 2 capitalization, as necessary.

 

Phase 1

 

First, we will retrofit the 22-acre existing greenhouse to make it operational. Once the project is completed, we plan to use the existing 22-acre greenhouse to cultivate non-cannabis herbs and medicinal plants. We expect to complete renovations of the existing 22-acre greenhouse in in the second quarter of 2023. Within the first 10-acres of the existing greenhouse retrofit, we will include a two-acre university greenhouse (the “University Greenhouse”) to house our cannabis research, development, cultivation and manufacturing operations.

 

Phase 2

 

In addition to the existing greenhouse, we plan to construct two new 57-acre greenhouses, one on the Candelaria property and one on the Azuz property.

 

We have engaged Dalsem Complete Greenhouse Projects, B.V. (“Dalsem”) and Universal FAB to complete the construction of these facilities and have negotiated an agreement with them, which our legal team is drafting.

 

BGC will leverage automation throughout the facility to ensure that all of BGC’s processes are reliable and consistent, including the Visser transplanter robot or Visser potting robot, and automated growing systems. New Mexico’s uniquely predictable climate and abundant sunshine make it an ideal setting for cultivation of cannabis in a greenhouse. BGC will use state-of-the-art technology to cultivate cannabis in an efficient, standardized, and cost-effective way. The technologies specific to our planned greenhouses include:

 

  ● technologically advanced greenhouse design, which allows for maximum environmental control, cost-efficiency, and a low carbon footprint;
  ● environmentally sustainable cultivation methodology and practices in harmony with New Mexico’s unique climate, using naturally available resources;

 

5
 

 

  ● cultivation at a large scale to provide consistent, secure supply for researchers and the pharmaceutical industry;
  ● a patented air ventilation system, which uses ambient physical properties to generate optimal indoor conditions based upon the data driven growing strategy, with minimum use of energy, which in turn enables the highest yield and quality of crop in the shortest time;
  ● ebb-flood irrigation to enable the use of mildew resistant cultivars;
  ● fully-implemented pest/disease scouting system;
  ● controlled output through Pharma grade drying and extraction;
  ● extraction and separation techniques allowing for specific combinations of cannabinoids and other properties from cannabis for targeted therapeutics; and
  ● tamper-proof track & trace and record keeping system.

 

Our agricultural property has adequate utilities and water and is ideally situated to cultivate and process cannabis in harmony with the surrounding environment, using the most advanced technology. We believe the result will be consistent, pure, high-quality cannabis and cannabis extracts that will provide reliable, safe inventory for cannabis researchers around the nation.

 

Planned Business Lines

 

Domestic Cannabis for U.S. Researchers and Registered Manufacturers

 

We plan to sell cannabis to research institutions, pursuant to our conditional approval from the DEA. Sales of THC cannabis products will be made only via bona fide supply agreements from existing DEA registrants, and will not be directly to consumers under current scheduling rules. Following final approval from the DEA, we plan to cultivate and manufacture cannabis for sale to federally authorized research institutions and other purposes. There is no guarantee that we will receive final approval from the DEA.

 

Once we are authorized to begin operations by the DEA, we will be permitted to supply DEA-registered research institutions with cannabis that contains high levels of THC. Additionally, we plan to conduct in-house research at our own facilities. Our license will also allow us to provide our products to in-house researchers, which we believe will allow us to conduct cutting edge research into plant-based therapies using cannabis. We have been granted several patents for cannabis based products. See “Item 1. Business-Intellectual Property”.

 

Given the competitiveness of the process to obtain a DEA registration to cultivate and process cannabis, and the continued federal illegality of cannabis in the U.S., we believe we will be uniquely positioned to capture significant parts of the cannabis research supply market. The market for clinical research has grown exponentially over the past decades, and we project cannabis research to take a similar trajectory.

 

Cannabis for International Export

 

Our DEA registration will allow us to export cannabis to researchers internationally. Given our state-of-the-art facility in development, as well as the cannabis manufacturing expertise of our team, the unique climate of New Mexico and its suitability for a cannabis crop, we anticipate significant demand for our high-quality cannabis products from international markets.

 

Cannabis for U.S. Pharmaceutical and Production – CBN and CBG

 

A DEA registration will allow us to sell cannabis to DEA-registered pharmaceutical companies to produce medicinal cannabis or cannabis preparations, and we can also sell CBN and CBG to other companies developing products. There is significant potential for revenue from pharmaceutical companies that currently manufacture or desire to manufacture drugs containing cannabis extracts, either on an over-the-counter or on a prescription basis, and we anticipate a significant demand for CBN and CBG for the development of other products.

 

6
 

 

CBG and CBN are cannabinoids, like CBD, which can be extracted from the cannabis plant. The CBG and CBN extracts that we plan to produce would be sold to pharmaceutical companies and other market participants. We are in preliminary discussions with several pharmaceutical companies in connection with proposed supply contracts for CBN and CBG high-grade oil extracts, to be used in healthcare, hormone balance and anti-aging studies. We plan to distinguish ourselves by focusing on the CBN and CBG cannabinoids, which offer alternative health and wellness benefits to CBD. By focusing on cannabis-derived CBN and CBG rather than hemp-derived CBD, we will leverage the potential growth opportunity offered by these alternative compounds. The cannabis plant contains hundreds of cannabinoids and other compounds, and due to the ongoing federal illegality, severely restricting research on these components, many believe that there is health and wellness potential in some of these plant derivatives that has not yet been studied.

 

On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN and CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the 2018 Farm Bill, which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under a Federal Registration for the Bulk Manufacturing, if and when we receive such registration.

 

FDA Supply

 

The FDA has stated that it recognizes that there is significant interest in the development of therapies and other consumer products derived from cannabis. The FDA has stated that it is committed to protecting the public health while also taking steps to improve the efficiency of regulatory pathways for the lawful marketing of appropriate cannabis and cannabis-derived products. The FDA has stated that it is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds. BGC will be well-positioned to act as a partner to the FDA as it advances these efforts, and we will be one of the few federally registered suppliers of cannabis available to the FDA for any of its research or exploration efforts in the space. As noted elsewhere, it is also possible that the FDA may move forward with regulating cannabis products, which could materially affect our business plan depending on what the future regulatory requirements would be. Moreover, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA, which may inhibit our business prospects even in the case that the federal government were to legalize cannabis.

 

CBG and CBN Hemp Products to Consumers

 

We plan to sell high-end CBN and CBG cannabis derived, hemp isolate products directly to consumers. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the 2018 Farm Bill, which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under our Federal Registration, if and when we receive such registration.

 

7
 

 

Production Capabilities

 

BGC has adopted a phased approach to increase production on its site in Grants, New Mexico. In the first phase, the existing 22-acre Venlo greenhouse will be renovated and an initial 10-acres will be prepared for operations. The University Greenhouse will be contained within those first 10-acres. Subsequently, both of the two larger greenhouses will be built in Phase 2.

 

Timeline

 

The existing 22-acre Venlo greenhouse is currently under renovation. The first 10-acres of the greenhouse are expected to be completed in the second quarter of 2023, though there may be delays due to global supply chain issues. The University Greenhouse will be located within the first 10-acres of the existing Venlo greenhouse and the 10-acre facility will be operational upon receiving final approval from the DEA and will provide the initial supply of marijuana and marijuana extracts. Our first harvest will begin once we receive final approval from the DEA and will be complete approximately two months from the first planting. We plan to implement a phased approach to the build out of Phase 1 and Phase 2 and to plant intermittently as phases of each greenhouse reach completion with estimated planting dates to be completed in tranches as follows: September 2023, March 2024, September 2024. 

 

Based on the targeted production plan, BGC will have capacity for the following outputs once all of the greenhouse facilities are complete:

 

  ● 50,000 cannabis plants in the facility at all times and at different maturity levels;
  ● Annual harvested plants approximately 300,000 (multiple harvests per year); and
  ● Capacity to process 5,000 lbs. of plant material per day, using supercritical CO2 extraction.

 

BGC plans to cultivate marijuana and focus on the production of dried flower, and oils and marijuana extracts. BGC may also produce edibles which contain extracts, if permitted by DEA regulations and requested by customers.

 

The BGC process draws on expertise from Controlled Environmental Agriculture Design, by Larssen (“Larssen”), who have completed over 50 fully legal cannabis projects in jurisdictions throughout the world, including Canada, Australia and Denmark. BGC is in discussions to enter into a supply agreement with cannabis tissue supplier Nordic Supreme. Following execution of a definitive supply agreement, Nordic Supreme will supply BGC with proven cannabis genetics from their facilities in Denmark. We plan to finalize and enter into a definitive agreement with Nordic Supreme in the second quarter of 2023.

 

We have not yet entered into a formal agreement with Larssen for consulting and the development of best practices for our cultivation and manufacturing operations. Larssen will provide BGC with technical design services related to the greenhouse retrofit and construction in Grants, New Mexico. The scope of our agreement with Larssen will be tailored to support and complement Dalsem and Universal FAB. Larssen will first consult on the retrofit for the existing 22-acre greenhouse and then consult on the Dalsem build of the two new greenhouses. Larssen will then implement a Quality Management System, along with the applicable documents, forms, logbooks, and SOPs required to achieve GACP/GMP and DEA compliance.

 

8
 

 

Dalsem and Universal FAB will be BGC’s principal suppliers of the greenhouse building materials which will include hot dipped galvanized steel, aluminum system profiles for the outside cladding and horticultural glass as covering. Dalsem and Universal FAB will also provide irrigation building materials and components for building the Visser Transplanter. There could be price fluctuations for these materials depending on the cost of raw materials like steel, glass, and aluminum. PlantLogic will supply plastic pots and water collection for the coco peat insert material to grow plants, and Fertoz will provide organic soil for our facility. Octillo Lumber supplied the steel mesh, and barbed wire for the property’s perimeter fence. The parts for the security fencing are currently onsite.

 

Intellectual Property

 

BGC holds four issued patents, and other approved patent applications, applications pending review and applications submitted for review. The patents held by the Company are: Patent No. 10,668,045 for topical massage oil and cream containing CBD, CBN, Curcumin and Boswellia Resin; Patent No. 10,946,307 Extraction of Cannabinoids, Curcuminoids and Ginsenosides; Patent No. 10,946,308 Enzymatic Method for Extraction and Purification of Phytocannabinoids; and Patent No. 11,197,833 Fortified CBD oil for treatment of PTSD.

 

If the Company successfully exercises its call option to acquire the remaining outstanding shares of Alterola, the BGC patent portfolio will increase significantly to include the Alterola patents for the Cannabinoid and Cannabinoid like medicines.

 

Patents Issued

 

Patent Name 

Type of Patent Protection (composition of matter, method, or use)

 

Patent Number

 

Expiration Date

  Jurisdiction
Topical massage oil and cream containing CBD, CBN, Curcumin and Boswella Resin  Method & Composition  10,668,045  7/12/2039  U.S.
Extraction of Cannabinoids, Curcuminoids and Ginsenosides  Method  10,946,307  7/12/2039  U.S.
Enzymatic Method for Extraction and Purification of Phytocannabinoids  Method  10,946,308  7/12/2039  U.S.
Fortified CBD oil for treatment of PTSD  Method  11,197,833  7/12/2039  U.S.

 

Patent Applications Submitted

 

Patent Application Name  Type of Patent Protection (composition of matter, method, or use)  Patent Application Number  Patent Application Filing Date  Jurisdiction
Fortified CBD oil for Treatment of PTSD  Composition  17/523,464 November 10, 2021  U.S.
Dissolution of Curcuminoids from Turmeric in Cannabis oil  Method & Composition  63/279,396 November 15, 2021  U.S.
Fortified cannabis oil and beverages containing cannabis oil and curcuminoids  Method  63/279,406 November 15, 2021  U.S.
Fortified Cannabis Oil Topical Preparations for Dermal (Skin) Health  Method  63/279,413 November 15, 2021  U.S.
Chromatographic separation of THC, CBD and other cannabinoids  Method  63/279,419 November 15, 2021  U.S.
Cannabinoid Mixture  Method & Composition  63/279,369 November 15, 2021  U.S.
Chromatographic separation of THC, CBD and other cannabinoids  Method  63/279,428 November 15, 2021  U.S.
Method for enriching Cannabinol (CBN) in Cannabis oil  Method  63/279,442 November 15, 2021  U.S.
Generation of new varieties of cannabis by ethyl methane sulfonate (EMS) Mutagenesis of cannabis seeds  Method  63/279,446 November 15, 2021  U.S.
Selection of new varieties of cannabis through somatic embryogenesis  Method  63/279,451 November 15, 2021  U.S.
Fortified cannabis oil for treating sleep disorders  Method  63/279,456 November 15, 2021  U.S.
Selection of New Varieties of Cannabis Plants expressing Cannabinoids by Cell Culture  Method  16/594,714 December 2022  U.S.

 

9
 

 

Current Licenses Held

 

In May 2021, BGC entered into an MOA with the DEA to grow cannabis for federally sanctioned research.

 

Final registration is anticipated in the coming months, and is contingent upon completion of construction (which will require successful fundraising required to complete construction), and a successful inspection by the DEA of BGC’s facilities, based on the terms agreed upon pursuant to the MOA. The MOA with the DEA is effective for a one-year term, renewable for up to four additional one-year terms. There is no guarantee that we will obtain the necessary authorization now, or in the future for renewal purposes. On July 23, 2020, BGC received approval from the State of New Mexico Board of Pharmacy to conduct Controlled Substances Manufacturing of Cannabis Products in the state, pursuant to receiving approval from the DEA to do so. On March 23, 2023 we were notified that the Board of Pharmacy no longer has jurisdiction over cannabis as New Mexico has de-scheduled the substance.

 

BGC is applying to renew a State of New Mexico Continuous Hemp Commercial Research Production License.

 

BGC holds a State of New Mexico Cannabis Control Division, Cannabis Research Laboratory License. No. CCD-2023-RSCH-001. Issued 3/23/2023. Expires 3/23/2024.

 

Industry Overview

 

US Market Overview

 

The U.S. cannabis industry is undergoing rapid growth and change, particularly with the recent opening of opportunities for federally sanctioned research on cannabis in partnership with the DEA, as well as the federal legalization of hemp, and corresponding state and federal hemp research programs.

 

BGC plans to operate in the U.S. market for federally sanctioned cannabis — as a supplier of cannabis for research or DEA Registered Manufacturing purposes, and as a researcher itself. Importantly, all of BGC’s proposed activities will comply with all existing or future federal and state regulations.

 

Legal Background – Cannabis

 

Thirty-nine U.S. states, the District of Columbia, Puerto Rico and Guam have legalized some form of whole-plant cannabis cultivation, sales and use for certain medical purposes (medical states). Twenty-one of those states and the District of Columbia and Northern Mariana have also legalized cannabis for adults for non-medical purposes (sometimes referred to as adult use). Under U.S. federal law, however, those activities are illegal. Cannabis, other than hemp (defined by the U.S. government as Cannabis sativa L. with a THC concentration of not more than 0.3% on a dry weight basis), is a Schedule I controlled substance under the U.S. Controlled Substances Act (21 U.S.C. § 801, et seq.) (the “CSA”). Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis in-state or where those activities are deemed involved in interstate commerce, all violate the CSA and are punishable by imprisonment, substantial fines and forfeiture. Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA, or conspire with another to violate the law, and violating the CSA is a predicate for certain other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law.

 

10
 

 

While the U.S. government has not enforced those laws against companies complying with state cannabis laws, it retains the authority to do so, and as such the likelihood of any future adverse enforcement against companies complying with state cannabis laws remains uncertain. In 2018, then U.S. Attorney General Jefferson Sessions rescinded the United States Department of Justice’s (“DOJ”) previous guidance (the Cole Memo) that had given federal prosecutors discretion not to enforce federal law in states that legalized cannabis, as long as the state’s legal regime adequately addressed specified federal priorities. The Sessions memo, which remains in effect, states that each U.S. Attorney’s Office should follow established principles that govern all federal prosecutions when deciding which cannabis activities to prosecute. As a result, federal prosecutors could and still can use their prosecutorial discretion to decide to prosecute state-legal cannabis activities. Since the Sessions memo was issued nearly five years ago, U.S. Attorneys have not targeted state law compliant entities. The policy of not prosecuting companies complying with state cannabis laws is likely to continue under current U.S. Attorney General Merrick Garland. In April 2022, Attorney General Garland reiterated that prosecuting the possession of cannabis is “not an efficient use” of federal resources, especially “given the ongoing opioid and methamphetamine epidemic[s]” facing the nation. Recent statements made by Garland suggest that the DOJ may issue further guidance on cannabis enforcement, though the timing of such guidance remains unknown. In March 2023, Garland testified in a Congressional hearing that the DOJ was continuing its work on a new memorandum regarding cannabis enforcement. He stated that the policy will be “very close to what was done in the Cole memorandum” but was yet to be finalized. While these statements are not promises to avoid federal interference with state cannabis laws, and do not amount to desuetude, it does signal that the enforcement priorities of DOJ lie elsewhere. Notwithstanding the comments made by the Attorney General, there is no guarantee that the current presidential administration will not change its stated policy regarding the low-priority enforcement of U.S. federal cannabis laws that conflict with state laws. The Biden administration could reverse course and decide to enforce U.S. federal cannabis laws vigorously.

 

Since 2014, versions of the U.S. omnibus spending bill have included a provision prohibiting the DOJ, which includes the DEA, from using appropriated funds to prevent states from implementing their medical-use cannabis laws. In USA vs. McIntosh, the U.S. Court of Appeals for the Ninth Circuit held that the provision prohibits the DOJ from spending funds to prosecute individuals who engage in conduct permitted by state medical-use cannabis laws and who strictly comply with such laws. However, the court noted that, if the spending bill provision were not continued, prosecutors could enforce against conduct occurring during the statute of limitations even while the provision was previously in force. Other courts that have considered the issue have ruled similarly. This affords some extra protection for medical cannabis businesses, but does not apply to adult use businesses. Furthermore, any change in the federal government’s enforcement posture with respect to state-licensed cannabis sales, including the enforcement postures of individual federal prosecutors, is still a possibility.

 

Despite the ongoing federal illegality of cannabis, the DEA authorizes certain institutions to conduct research using cannabis, and recently expanded those efforts. Between January 2017 and January 2019, the DEA’s projections for federally approved cannabis research projects increased dramatically, and as a result, the DEA more than quadrupled its production quota. In that time, the number of federally registered cannabis researchers increased by more than 40 percent, from 384 to 542. Subsequently, the DEA announced that it would, for the first time in decades, open up opportunities for additional cultivators to supply cannabis for this research.

 

On August 26, 2019, the DEA announced that it will further facilitate and expand scientific and medical research for cannabis in the United States, including registering additional entities to produce cannabis for researchers, to increase the amount and variety of cannabis available for research. The DEA intends this to “facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.” In other words, the U.S. government believes that cannabis research is in the public’s interest. Furthermore, this public statement acknowledges the possibility that medical cannabis or related products may, in the future, require FDA approval and come under the FDA’s FDCA jurisdiction. However, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA. Additionally, the costs of compliance with any future FDA requirements are unknown and our ability to meet those requirements is also unknown, which may increase our operating costs and inhibit our business prospects even in the case that the federal government were to legalize cannabis.

 

11
 

 

On December 18, 2020, the DEA finalized new regulations pertaining to applications by entities seeking to become registered with the DEA to grow cannabis as bulk manufacturers for authorized purposes. Under these and other applicable regulations, applicants are responsible for demonstrating they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion.

 

On May 14, 2021, the DEA announced memorandums of agreement were provided to an unspecified and unnamed number of companies to collaborate with the DEA “to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations as well as other applicable legal standards and relevant laws.” To the extent these memorandums of agreement are finalized, DEA anticipates issuing DEA registrations to these manufacturers. Each applicant will then be authorized to cultivate cannabis – up to an allotted quota – in support of the more than 575 DEA-licensed researchers across the nation. As individual manufacturers are granted DEA registrations, that information will be made available on DEA’s Diversion Control website. As of April 14, 2023, a total of seven companies have been granted DEA registrations to bulk manufacture cannabis.

 

In addition to anticipated expenses related to the DEA, we face expected costs related to compliance with existing environmental and other regulations at the local, state, and federal level, as well as future environmental or other regulations.

 

Recent Federal Cannabis Bills

 

Industry observers were hopeful that a Democrat-controlled House and Senate, along with a Biden presidency, would increase the chances of federal legalization of cannabis or some piecemeal policy reform. During his campaign, President Biden promised federal reform on cannabis, including decriminalization generally. In 2022, President Biden signed into law the Medical Marijuana and Cannabidiol Research Expansion Act, a bill aimed at easing restrictions on cannabis research -- bipartisan legislation which is the first standalone cannabis reform bill to pass both the House and Senate. Additionally, on October 6, 2022, President Biden issued a presidential proclamation pardoning federal convictions for simple marijuana possession offenses, encouraging state governors to do the same on the state level where permissible, and requesting that the Secretary of Health and Human Services and the Attorney General initiate an administrative process to review cannabis’s Schedule I classification under the CSA. This process could, but is not guaranteed to, change the legal status of cannabis on a federal level. Regardless of the ultimate outcome on CSA scheduling, both actions represent significant milestones in the evolution of federal cannabis policy.

 

While the timing of federal reform is unknown, there is bipartisan support for cannabis reform on the federal level. Members of the U.S. Congress from the Democratic and Republican parties have introduced bills to end the federal cannabis prohibition, by de-scheduling cannabis completely and regulating it. In the 117th Congress, Senators Cory Booker (D-NJ), Ron Wyden (D-OR), and Chuck Schumer (D-NY) filed the Cannabis Administration And Opportunity Act, a bill that would regulate cannabis and expunge prior cannabis convictions; and Rep. Nancy Mace (R-SC) filed the States Reform Act, which would repeal the federal prohibition of and further regulate cannabis on the federal level. This session has seen additional incremental reform bills, including a bill that would direct the Attorney General of the United States to amend the CSA to move cannabis from Schedule I to Schedule III of the Act (the “Marijuana 1 to 3 Act”), and a bill to allow medical cannabis patients to purchase and possess firearms (the “Second Amendment Protection Act”). While the timing of federal reform remains unknown, it is expected that federal policy on cannabis will continue becoming more, rather than less, permissive, and legislative efforts to legalize cannabis or cannabis banking at the national level are likely to continue in 2023.

 

Future pathways to, and chances of, federal legalization or even further reform benefiting the state regulated, but federally illegal operators remain uncertain and speculative. Regardless of the future status of federal legalization of cannabis, there are already tremendous opportunities for fully legal medical cannabis researchers, suppliers, and product developers.

 

Market Growth

 

In the medical market, the demand for cannabis for research is likely to increase significantly over the next few years and decades, due to the increasing number of states legalizing cannabis and the strong public support for cannabis legalization. By 2025, 5.4 million Americans, or 2.4% of U.S. adults, are predicted to be registered patients in medical cannabis states, according to a report by New Frontier Data (“New Frontier”). New Frontier also projects that the medical cannabis market will nearly double to over $16 billion in that time, taking into account more geographies within the U.S. legalizing cannabis, which will lead to market expansion, the normalization of cannabis which will increase the number of consumers, and medical cannabis patients turning to cannabis as an alternative to prescription drugs. The global medical cannabis market is projected to reach $87.4 billion by 2027, according to Global Market Insights (“GMI”). The DEA’s aggregate production quotas for cannabis are 6,675 kg in 2023 for dried flower (an estimated $73 million market) and 1,000 kg for cannabis extract (an estimated $100 million market). These aggregate production quotas are expected to continue increasing to meet increasing demand for cannabis research in the U.S. In addition to government funding, some institutions are already receiving private investment in cannabis research. For example, Harvard and MIT received a $9 million donation to fund research into cannabis’ influence on brain health and behavior. Additionally, CB2 insights has noted that average prescriptions for qualifying conditions such as chronic pain, PTSD, sleep disorders, epilepsy and anxiety saw a decline in 11% in favor of medical cannabis replacement leading the analysts to estimate that more than $4 billion in sales that currently go to pharmaceutical products could be redirected towards medical cannabis. Further research on cannabis legalization and its impact on public health are needed and are likely to take place over the coming years, as the DEA has recognized the increased need for cannabis related research.

 

12
 

 

In 2021, large pharmaceutical companies in the U.S. spent $102.3 billion on drug research and development, and the number has continued to increase each year. The private research market, like the federal DEA research program, has an interest in investigating the uses and risk of cannabis and hemp derivatives, not only in states that have legalized medical cannabis, but also in anticipation of potential full legalization. Research topics of interest include :

 

  ● therapeutic benefits and risks of cannabis for common conditions for military veterans, including PTSD and chronic pain;
     
  ● therapeutic benefits and risks of cannabis for opioid addiction treatment, as well as other medical conditions and disabilities;
     
  ● cognitive effects of THC use in the developing brain of adolescents;
     
  ● prevention of and treatment for cannabis use disorder;
     
  ● effects of different levels of THC potency levels;
     
  ● accurate roadside testing to detect driving while impaired with cannabis and related topics;
     
  ● availability of inaccurately labeled and adulterated cannabis;
     
  ● effective cannabis packaging requirements for consumer and child safety;
     
  ● effect of cannabis legalization on workplace testing and workplace safety for safety-sensitive jobs, including the use of synthetic THC;
     
  ● effect of cannabis use on mental health and addiction;
     
  ● effect of cannabinoids on immunological responses against bacterial or viral infections.

 

Regarding the cannabis market generally, the industry is large and is growing. In 2020, there were $17.5 billion in annual industry sales, a 46% increase from 2019. As of May 2021, capital raises in cannabis reached $6 billion, signaling increased confidence in projections of aggressive cannabis market growth. According to a report by New Frontier Data, the U.S. legal cannabis market is predicted to more than double by 2025, reaching $41.5 billion in sales, and producing a 21% compound annual growth rate (“CAGR”). Therefore, BGC will be entering a sizeable market with the first-mover advantage of a federally compliant business as cannabis enters a new stage of growth and development, once it obtains authorization from the DEA to begin operations.

 

Competition

 

We will face intense competition from the illicit market as well as other more regulated companies, some of which may have longer operating histories and more financial resources and manufacturing and marketing experience. With potential consolidation in the cannabis industry, we could face increased competition by larger and better financed competitors.

 

Growers of cannabis and retailers operating in the illicit market continue to hold significant market share in the United States and are effectively competitors to our business. Illicit market participants divert customers away through product offering, price point, anonymity and convenience.

 

Outdoor cultivation also significantly reduces the barrier to entry by reducing the start-up capital required for new entrants in the cannabis industry. It may also ultimately lower prices as capital expenditure requirements related to growing outside are typically much lower than those associated with indoor growing. Further, the licensed outdoor cultivation capacity is extremely large. While outdoor cultivation is almost exclusively extraction grade, its presence in the market will have a negative effect on pricing of extraction grade wholesale cannabis.

 

13
 

 

Competition is also based on product innovation, product quality, price, brand recognition and loyalty, effectiveness of marketing and promotional activity, the ability to identify and satisfy consumer preferences, as well as convenience and service.

 

Internationally, cannabis companies are limited to those countries which have legalized aspects of the cultivation, distribution, sale or use of cannabis. The barrier to entry for competitors in these is significantly influenced by the national regulatory landscape with respect to cannabis and the economic climate subsisting in each region.

 

We expect more countries to pass regulation allowing for the use of medical and/or recreational cannabis. While expansion of the global cannabis market will provide more opportunities to grow our international business, we also expect to experience increased global competition.

 

Our Corporate History

 

BGC was incorporated on April 16, 2019 under the Delaware General Corporation Law (the “DGCL”). On May 28, 2019, BGC entered into a merger agreement (the “BGGI Agreement”) with Bright Green Grown Innovation LLC, a limited liability company (“BGGI”), whereby BGC issued to BGGI an aggregate of 123,589,000 shares of common stock (the “BGGI Merger”). In connection with the BGGI Merger, BGC acquired two parcels of land, consisting of one 70-acre parcel and one 40-acre parcel, and a completed greenhouse structure in Grants, New Mexico. Lynn Stockwell received 18,000,000 shares for the 70-acre parcel including the Greenhouse. She additionally received 9,500 shares for the 40 acre parcel. Share certificates were issued accordingly.

 

BGC entered into an agreement and plan of merger with Grants Greenhouse Growers, Inc., a New Mexico corporation (“GGG”) on October 30, 2020 (the “GGG Agreement”), whereby BGC issued to GGG an aggregate of 1,000,000 shares of common stock (the “GGG Merger”). In connection with the GGG Merger, BGC received an option to purchase approximately 510 acres of land near BGC’s Grants, New Mexico property at the purchase price of $5,000 per acre.

 

BGC entered into an agreement and plan of merger (the “Naseeb Agreement”) with Naseeb Inc. (“Naseeb”) on November 10, 2020, whereby BGC issued to Naseeb an aggregate of 10,000,000 shares of common stock (the “Naseeb Merger”). In connection with the Naseeb Merger, BGC received certain intangible property, including rights to certain patents and patent applications, licenses to operate cultivation facilities, and rights to additional licenses if-and-when issued.

 

On May 17, 2022, we completed a direct listing of our common stock (the “Direct Listing”), on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BGXX.” We incurred fees related to financial advisory service, audit, and legal expenses in connection with the Direct Listing and incurred approximately $4,000,000 in general and administrative expenses during the year ended December 31, 2022. In addition, in connection with the Direct Listing, and pursuant to a financial advisory agreement by and between the Company and EF Hutton, division of Benchmark Investments, LLC (the “Advisor Agreement”) dated April 8, 2022, on June 3, 2022, we issued representatives and affiliates of the Advisor and related parties, an aggregate of 787,245 shares of common stock , and representatives of Entoro Securities LLC (“Entoro”) an aggregate of 787,245 shares of common stock. The shares were issued by the Company’s transfer agent.

 

Bright Green EB-5 Program

 

On February 1, 2023, we initiated a private placement offering of our common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. As of April 14, 2023, we have sold 44,010 shares of common stock at $39.99 per share, receiving proceeds of $1.76 million and have received executed subscription agreements from 37 investors to purchase 814,185 shares of common stock for $32.6 million. For more information, see “Item 1.A. Risk Factors – Although we have received executed subscription agreements from investors to purchase shares of common stock under our EB-5 Program, such investors may never receive the requisite approvals to participate in our EB-5 Program”.

 

14
 

 

Arrangement with Alterola

 

On August 25, 2022, we entered into a non-binding letter of intent (the “Alterola Agreement”) with Alterola pursuant to which we agreed to explore a merger transaction with Alterola. Pursuant to the Alterola Agreement, the Company agreed to acquire 25% (the “Initial Shares”) of the issued and outstanding shares of common stock, par value $0.001 per share of Alterola (“Alterola Stock”), subject to customary due diligence and applicable regulatory approvals. Additionally, pursuant to the Alterola Agreement, we received a six-month option (the “Alterola Option”) to acquire all remaining issued and outstanding shares of Alterola Stock, subject to customary due diligence, and regulatory, stockholder and other necessary approvals. On April 4, 2023, we announced our intention to exercise the Alterola Option.

 

Pursuant to the Alterola Agreement, on October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity (“Phyto”), Equipped4 Holdings Limited, a United Kingdom entity (“Equipped”), TPR Global Limited, a United Kingdom entity (“TPR”) (Phyto, Equipped and TPR, each, a “Seller” and collectively, the “Sellers”) and Alterola providing for the purchase by Bright Green of the Initial Shares from the Sellers.

 

The Sellers in aggregate sold 201,761,982 shares of Alterola Stock to Bright Green for a purchase price of $3,999,999 pursuant to the payment schedule set forth in the Secondary SPA. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its shares of Alterola Stock pursuant to a loan agreement.

 

The Sellers held 67% of the total outstanding shares of Alterola Stock prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola Stock.

 

Concurrently with the signing of the Secondary SPA, the Company and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect the Company’s acquisition of Alterola or Alterola’s merger into the Company or a subsidiary of the Company, as the case may be, pursuant to additional terms set forth in the Voting Agreement. Pursuant to the Voting Agreement, the Sellers executed an irrevocable proxy (the “Irrevocable Proxy”) whereby the Sellers granted the Company an irrevocable proxy to vote the Sellers’ Subject Shares (as defined therein) in a manner consistent with the Voting Agreement and pursuant to additional terms set forth in the Irrevocable Proxy.

 

The Alterola Agreement provides that the parties shall use their good faith efforts to enter into a definitive agreement setting forth the binding terms of the transaction, whereby we shall acquire all remaining Alterola Stock in exchange for an additional $6 million together with an aggregate of $40 million of shares of our common stock (the “Alterola Transaction”).

 

On February 9, 2023, we appointed Seamus McAuley, Chief Executive Officer of Alterola, as our Chief Executive Officer, and entered into an executive employment agreement with Mr. McAuley. At that time, Terry Rafih stepped down as Chief Executive Officer, continuing as Executive Chairman of the Board. For more information, see “Named Executive Officer Employment Arrangements”.

 

On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola.

 

Available Information

 

Our principal executive offices are located at 1033 George Hanosh Boulevard Grants, NM 87020, and our telephone number is (833) 658-1799. Our corporate website address is https://brightgreen.us. Information contained on or accessible through our website is not a part of this Annual Report and should not be considered to be part thereof. The public may read and copy any materials that we file with the Securities and Exchange Commission (the “SEC”) electronically through the SEC website (www.sec.gov). The information contained on the SEC’s website is not incorporated by reference into this Annual Report and should not be considered to be part thereof. We also provide access without charge to all of our SEC filings, including copies of this Annual Report, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as reasonably practicable after filing or furnishing, on our website.

 

15
 

 

Human Capital Resources

 

As of December 31, 2022, we had 23 full-time employees. We consider our relationship with our employees to be good. We emphasize several measures and objectives in managing its human capital assets, including, among others, (i) employee safety and wellness, (ii) talent acquisition and retention, (iii) employee engagement, development and training, (iv) diversity and inclusion and (v) compensation. These targeted ideals may include annual bonuses, stock-based compensation awards, a 401(k) plan with employee matching opportunities, healthcare, and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, family care resources, and/or employee assistance programs. We also provide our employees with access to various innovative, flexible, and convenient health and wellness programs. We designed these programs to support employees’ physical and mental health by providing tools and resources to improve or maintain their health status and encourage engagement in healthy behaviors.

 

Item 1A. Risk Factors.

 

Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under “Special Note Regarding Forward-Looking Statements,” you should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report, including our financial statements and related notes included at the end of this Annual Report and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our securities could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

 

Risk Factors Summary

 

Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should carefully consider the full risk factor disclosure outlined in this Annual Report, in addition to the other information herein, including the section of this Annual Report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes.

 

  ● We have a relatively limited history of operations, a history of losses, and our future earnings, if any, and cash flows may be volatile, resulting in uncertainty about our prospects;
  ● We had negative operating cash flow for the year ended December 31, 2022 and December 31, 2021;
  ● We are highly dependent on our management team, certain members of our board of directors and advisors, and the loss of our executive officers, non-executive directors or other key advisors or service providers could harm our ability to implement our strategies, impair our relationships with clients and adversely affect our business, results of operations and growth prospects;
  ● The COVID-19 pandemic could continue to materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations;
  ● Our plan to expand our product offerings and sales channels might not be successful, and implementation of these plans might divert our operational, managerial and administrative resources, which could impact our competitive position;
  ● We are in discussions to consummate arrangements with certain service providers, and if these arrangements do not materialize, or materialize on terms that are not favorable to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations;
  ●

We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of June 30, 2022, as a result of the restatement of our unaudited financial information as of and for the quarter ended June 30, 2022. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. Although our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2022, we may, in the future, identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations;

  ● Cannabis is highly regulated at the federal and state level, and authorizations for the production of cannabis for research is still in the early stages;
  ● A denial of, or significant delay in obtaining, or any interruption of required government authorizations to grow cannabis for federally sanctioned purposes would likely significantly, negatively impact us;
  ● The U.S. wholesale market for cannabis for research is of unknown size and is difficult to forecast;
  ● FDA regulation of cannabis could negatively affect the cannabis industry, which would directly affect our financial condition;
  ● Research in the United States, Canada and other countries on the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids may cause adverse effects on our operations;
  ● The very dynamic nature of the laws and regulations affecting the cannabis market, the federal authorization of cannabis for research, or the state-regulated cannabis industry could materially adversely affect our proposed operations, and we cannot predict the impact that future laws or regulations may have on us;
  ● The uncertainties around funding, construction, and growing an agricultural crop pose risks to our business;
  ● The cannabis industry is subject to the risks inherent in an agricultural business, including environmental factors and the risk of crop failure;
  ● We are subject to environmental regulations and laws, and failure to timely or completely comply with such regulations and laws, or failure to obtain or maintain applicable licenses, may adversely affect our business;
  ● The growth of our business continues to be subject to new and changing federal, state, and local laws and regulations;

 

16
 

 

  ● We are subject to risks, including delays, from our ongoing and future construction projects, which may result from reliance on third parties, delays relating to material delivery and supply chains, and fluctuating material prices, among other factors;
  ● Our planned future sale of cannabis and cannabis products could expose us to significant product liability risks;
  ● We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms;
  ● There is no guarantee that we will be able to continue to raise funds through our EB-5 Program, if and when such program receives requisite regulatory approvals;
  ● We are dependent on our banking relations, and while we currently have a stable banking relationship and operate in compliance with all applicable laws, we could have difficulty accessing or consistently maintaining banking or other financial services due to banks’ risk aversion toward serving even legal parts of the cannabis industry;
  ● While we have entered into a non-binding letter of intent with Alterola Biotech Inc. and have entered into exclusive negotiations for a merger therewith, we cannot assure you that the transactions contemplated by our non-binding letter of intent will be consummated or, that if such transactions are consummated, they will be accretive to stockholder value;
  ● We may engage in future acquisitions or strategic transactions, including the transaction with Alterola, which may require us to seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management;
  ● We are subject to risks related to information technology systems, including cyber-security risks; successful cyber-attacks or technological malfunctions can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential information and reputational risk, all of which would negatively impact our business, financial condition or results of operations;
  ● Our common stock has a limited trading history and an active trading market may not develop or continue to be liquid, and the market price of our shares of common stock may be volatile;
  ● The market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control;
  ● You may be diluted by issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price;
  ● The future exercise of registration rights may adversely affect the market price of our common stock;
  ● If securities or industry analysts do not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock , its trading price and volume could decline;
  ● We are an “emerging growth company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors;
  ● Provisions of our amended and restated certificate of incorporation and bylaws may delay or prevent a take-over that may not be in the best interests of our stockholders;
  ● The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members;
  ● Our failure to meet the continuing listing requirements of Nasdaq could result in a de-listing of our securities;
  ● If we cannot continue to satisfy the rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them;
  ● Your ownership interest will be diluted and our stock price could decline when we issue additional shares of common stock; and
  ● We have issued warrants and may continue to issue additional securities in the future. The exercise of these warrants and the sale of the common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.

 

Risks Related to our Business and Operations - General Risks

 

We have a relatively limited history of operations, a history of losses, and our future earnings, if any, and cash flows may be volatile, resulting in uncertainty about our prospects.

 

Our lack of a significant history and the evolving nature of the market in which we operate make it likely that there are risks inherent to our business that are yet to be recognized by us or others, or not fully appreciated, and that could result in us suffering further losses. As a result of the foregoing, and concerns regarding the economic impact from COVID-19, an investment in our securities necessarily involves uncertainty about the stability of our operating results or results of operations.

 

We had negative operating cash flow for the years ended December 31, 2022 and December 31, 2021.

 

We had negative operating cash flow of $2,265,770 in the year ended December 31, 2022, and a negative operating cash flow of $1,656,575 for the year ended December 31, 2021. To the extent that we have negative operating cash flow in future periods, we may need to allocate a portion of our cash reserves to fund such negative cash flow. We may also be required to raise additional funds through the issuance of equity or debt securities. There can be no assurance that we will be able to generate positive cash flow from our operations, that additional capital or other types of financing will be available when needed or that these financings will be on terms favorable to us.

 

We have not based our financial projections or valuation on actual operations.

 

Our pre-operational stage precludes us from providing financial information based on actual operations. Current financial projections are based on assumptions concerning future operations that we believe are reasonable but may prove incorrect. Because actual conditions will differ from those assumptions, and the differences may be material, we cannot assure you that these projections will prove accurate and caution you against excessive reliance on them in deciding whether to invest in our equity securities. Any increase in our costs or decrease in our revenues could affect your ability to receive a return on your investment.

 

We are highly dependent on our management team, certain members of our board of directors and advisors, and the loss of our executive officers, non-executive directors or other key advisors or service providers could harm our ability to implement our strategies, impair our relationships with clients and adversely affect our business, results of operations and growth prospects.

 

Our success depends, to a large degree, on the skills of our management team and our ability to retain, recruit and motivate key officers and employees. Our active senior executive leadership team has significant experience, and their knowledge and relationships would be difficult to replace. Leadership changes will occur from time to time, and we cannot predict whether significant resignations will occur or whether we will be able to recruit additional qualified personnel. Competition for senior executives and skilled personnel in the horticulture industry is intense, which means the cost of hiring, paying incentives and retaining skilled personnel may continue to increase.

 

We need to continue attracting and retaining key personnel and recruiting qualified individuals to succeed existing key personnel to ensure the continued growth and successful operation of our business. In addition, as a provider of custom-tailored horticulture solutions, we must attract and retain qualified personnel to continue to grow our business, and competition for such personnel can be intense. Our ability to effectively compete for senior executives and other qualified personnel by offering competitive compensation and benefit arrangements may be restricted by cash flow and other operational restraints. The loss of the services of any senior executive or other key personnel, or the inability to recruit and retain qualified personnel in the future, could have a material adverse effect on our business, financial condition or results of operations. In addition, to attract and retain personnel with appropriate skills and knowledge to support our business, we may offer a variety of benefits, which could reduce our earnings or have a material adverse effect on our business, financial condition or results of operations.

 

17
 

 

Our insurance may not adequately cover our operating risk.

 

We have insurance to protect our assets, operations and employees. While we believe our insurance coverage addresses all material risks to which we are exposed and is adequate and customary in our current state of operations, such insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which we are exposed. In addition, no assurance can be given that such insurance will be adequate to cover our liabilities or will be generally available in the future or, if available, that premiums will be commercially justifiable. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if we were to incur such liability at a time when we are not able to obtain liability insurance, our business, results of operations and financial condition could be materially adversely affected.

 

We may have difficulty obtaining insurance at economically viable rates.

 

Our lack of operating history in an emerging area, and our plan to grow cannabis, even legally under all applicable laws, may make it difficult to obtain insurance policies at rates competitive with rates for other crops. Insurance that is otherwise readily available, such as workers’ compensation, general liability, title insurance and directors’ and officers’ insurance, is more difficult for us to find and more expensive because of our involvement in emerging areas as well as our cultivation, processing, and sale of cannabis, albeit legally under both state and federal laws. There are no guarantees that we will be able to find insurance coverage at otherwise competitive, or even economically viable terms.

 

Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results.

 

U.S. GAAP and related pronouncements, implementation guidelines and interpretations with regard to a wide variety of matters that are relevant to our business, such as, but not limited to, revenue recognition, stock-based compensation, trade promotions, and income taxes, are highly complex and involve many subjective assumptions, estimates and judgments by our management. Changes to these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported results.

 

The COVID-19 pandemic could continue to materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations.

 

The outbreak of COVID-19, a novel strain of coronavirus first identified in China, which has spread across the globe including the U.S., has had an adverse impact on our operations and financial condition. Most recently, the response to this coronavirus by federal, state and local governments in the U.S. has resulted in the significant market and business disruptions across many industries and affecting businesses of all sizes. This pandemic has also caused significant stock market volatility and further tightened capital access for most businesses. Given that the COVID-19 pandemic and its disruptions are of unknown duration, they could have an adverse effect on our liquidity and profitability.

 

The ultimate magnitude of COVID-19, including the extent of its impact on our financial and operational results, which could be material, will depend on the length of time that the pandemic continues, its effect on the demand for our products and our supply chain, the effect of governmental regulations imposed in response to the pandemic, as well as uncertainty regarding all of the foregoing. We cannot at this time predict the full impact of the COVID-19 pandemic, but it could have a larger material adverse effect on our business, financial condition, results of operations and cash flows beyond what is discussed within this Annual Report.

 

18
 

 

We could be adversely affected by declines in discretionary consumer spending, consumer confidence and general and regional economic conditions.

 

Our success depends to a significant extent on discretionary consumer spending, which is heavily influenced by general economic conditions and the availability of discretionary income. We believe the cannabis markets are heavily reliant on discretionary consumer spending. The current economic environment as a result of COVID-19, coupled with high volatility and uncertainty as to the future global economic landscape, may have an adverse effect on consumers’ discretionary income and consumer confidence. Future volatile, negative, or uncertain economic conditions and recessionary periods or periods of significant inflation may adversely impact consumer spending on our products and services, which would materially adversely affect our business, financial condition and results of operations. Such effects can be especially pronounced during periods of economic contraction or slow economic growth.

 

Our plan to expand our product offerings and sales channels might not be successful, and implementation of these plans might divert our operational, managerial and administrative resources, which could impact our competitive position.

 

BGC’s success and the planned growth and expansion of the business depends on their products and services achieving greater and broader acceptance, resulting in a larger customer base, and on the expansion of its operations into new markets. However, there can be no assurance that customers will purchase its products and/or services, or that they will be able to continually expand their customer base. Additionally, if they are unable to effectively market or expand their product and/or service offerings, we will be unable to grow and expand our business or implement our business strategy.

 

BGC’s ability to grow its existing brand and develop or identify new growth opportunities depends in part on its ability to appropriately identify, develop and effectively execute strategies and initiatives. Failure to effectively identify, develop and execute strategies and initiatives may lead to increased operating costs without offsetting benefits and could have a material adverse effect on our results of operations. These plans involve various risks discussed elsewhere in these risk factors, including:

 

  ● implementation of these plans may be delayed or may not be successful;
     
  ● if BGC’s expanded product offerings and sales channels fail to maintain and enhance our distinctive brand identity, our brand image may be diminished, and our sales may decrease; and
     
  ● implementation of these plans may divert management’s attention from other aspects of our business and place a strain on our management, operational and financial resources, as well as our information systems.

 

In addition, BGC’s ability to successfully carry out our plans to expand its product offerings may be affected by, among other things, laws and regulations pertaining to cannabis use, economic and competitive conditions, changes in consumer spending patterns and consumer preferences. BGC’s expansion plans could be delayed or abandoned, could cost more than anticipated and could divert resources from other areas of our business, any of which could impact its competitive position and reduce our revenue and profitability.

 

We are in discussions to consummate arrangements with certain service providers, and if these arrangements do not materialize, or materialize on terms that are not favorable to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations

 

We are in discussions to consummate arrangements with certain service providers. Any agreement we plan to enter into with a third party may not materialize, or, may not be on favorable terms, and the expected benefits and growth from these agreements may not materialize as planned. If we fail to enter into agreements with such service providers, or enter into agreements that are not on favorable terms to the Company, it could materially adversely affect our business, financial condition, results of operations, cash flows and day-to-day operations.

 

19
 

 

We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of June 30, 2022, as a result of the restatement of our unaudited financial information as of and for the quarter ended June 30, 2022. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. Although our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2022, we may, in the future, identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations.

 

Under the supervision and with the participation of our management, including our former Interim Chief Executive Officer and Chief Financial Officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material error in our annual or interim financial statements will not be prevented or detected on a timely basis. In Management’s Report on Internal Control over Financial Reporting included in our quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed August 12, 2022, our management previously concluded that we maintained effective internal control over financial reporting as of June 30, 2022. Our management subsequently concluded that a material weakness existed and our internal control over financial reporting was not effective as of June 30, 2022. This determination was made as a result of a recording error of the fair value of shares of common stock we issued for services in June 2022. Such shares have a fair value of $8.00 per share, the price of our common stock at the time of our Direct Listing, but were initially recorded at a fair value of $4.00 per share. With this error being corrected in amendment no. 1 to our quarterly report on Form 10-Q for the period ended June 30, 2022, net loss increased by $6,297,960. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. The Company continues to evaluate and implement procedures as deemed appropriate to enhance our disclosure controls.

 

If we identify new material weaknesses in our internal control over financial reporting, if we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be late with the filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected. As a result of such failures, we could also become subject to investigations by the stock exchange on which our securities are then listed, the SEC, or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from our core business, and would have a material adverse effect on our business, financial condition and results of operations.

 

We are at risk of cyber-attacks or other security breaches that could compromise sensitive business information, undermine our ability to operate effectively and expose us to liability, which could cause our business and reputation to suffer.

 

Increasingly, companies are subject to a wide variety of attacks on their networks on an ongoing basis. In addition to traditional computer “hackers” malicious code (such as viruses and worms), phishing attempts, employee theft or misuse, and denial of service attacks, sophisticated nation-state and nation-state supported actors engage in intrusions and attacks (including advanced persistent threat intrusions) and add to the risks to internal networks, cloud deployed enterprise and customer-facing environments and the information they store and process. Despite significant efforts to create security barriers to such threats, it is virtually impossible for us to entirely mitigate these risks. We, and our third-party software and service providers, may face security threats and attacks from a variety of sources.

 

As part of our business, we store our data, including intellectual property, and certain data about our employees, customers and vendors in our information technology systems. Our security measures may be breached as a result of third-party action, including intentional misconduct by computer hackers, employee error, malfeasance or otherwise. Third parties may attempt to fraudulently induce employees or customers into disclosing sensitive information such as usernames, passwords, or other information to gain access to our customers’ data or our data, including our intellectual property and other confidential business information, or our information technology systems. In addition, given their size and complexity, our information systems could be vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties attempting to gain unauthorized access to our products, systems or confidential information.

 

20
 

 

If a third party gained unauthorized access to our data, including any data regarding our employees, customers or vendors, the security breach could expose us to risks. Such unauthorized access and a failure to effectively recover from breaches could compromise confidential information, disrupt our business, harm our reputation, result in the loss of customer confidence, business and assets (including trade secrets and other intellectual property), result in regulatory proceedings and legal claims, and have a negative impact on our financial results.

 

Risks Related to our Business and Operations - Required DEA Authority To Grow and Process Cannabis and Cannabis Generally

 

Cannabis is highly regulated at the federal and state level, and authorizations for the production of cannabis for research are still in the early stages.

 

Cannabis, other than hemp, is a Schedule I controlled substance under the CSA. Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis all remain violations of federal law that are punishable by imprisonment, substantial fines and forfeiture. While cannabis remains a federally illegal Schedule I drug under the CSA, there is a limited exemption under which cannabis can be grown or manufactured for uses in federally sanctioned research. To become an authorized cannabis supplier or researcher in the United States, one must obtain a registration from the DEA and meet certain requirements imposed by the DEA, which are required by the DEA to comply with federal statutes and international treaty law. The registration process to manufacture controlled substances is codified under 21 U.S.C. § 823. It requires that the Attorney General determine whether registrations are in the public interest. To do so, the Attorney General is directed to consider multiple public interest factors, including “compliance with applicable State and local law.”

 

The University of Mississippi, pursuant to a contractual agreement with National Institute on Drug Abuse (“NIDA”), was the only federally authorized cannabis producer in the United States for years. In the face of unprecedented demand for cannabis manufacture for research necessitating more suppliers, the program at the University of Mississippi has faced significant criticism for its poor quality flower, mold issues, and limited availability of strains with levels of THC and CBD comparable to commercial cannabis products.

 

In recent years, the federal government has acknowledged the need for new suppliers. During his confirmation hearings in 2019, Attorney General Barr testified that he supported authorizing more facilities to cultivate cannabis in the U.S. for research purposes. In January 2020, a senior policy advisor for the DEA, Matthew J. Strait, testified before the House Energy and Commerce Committee regarding the DEA’s progress to date. Mr. Strait acknowledged concerns about the limited supply of research-grade cannabis and the lack of chemical diversity in the plants cultivated in Mississippi. He outlined the DEA’s various steps in the past few years to expand cannabis research and manufacturing capacity, including:

 

  ●

In December 2015, the DEA announced to all existing Schedule I researchers that it was easing the requirements for obtaining a modification of their existing registration for those who wished to conduct research on cannabidiol (CBD).

  ●

In early 2018, the DEA announced that it had developed and implemented an online portal for researchers to safely and securely submit their qualifications, research protocol and institutional approvals for a proposed Schedule I research registration thereby streamlining the acquisition of information necessary to process each application. Presently, the average time it takes for DEA and the FDA to review/approve an application is 52 days.

  ● On the manufacturing side, between 2017 and 2022, the DEA increased the aggregate production quota for cannabis by 575%, from 472 kg in 2017 to 3,200 kg in 2022. The increase has directly supported NIDA’s provision of various strains of cannabis to researchers in the United States.

 

21
 

 

In addition to these efforts, in 2016, the DEA began accepting new research cultivation applications under regulations developed by the Obama administration. However, no decisions were made on those applications, and, in August 2019, the DEA issued a notice to the pending applicants, stating that it would promulgate new regulations to govern the program of growing “marihuana” for scientific and medical research prior to issuing any registrations. During his testimony, Mr. Strait explained that the DEA is “actively taking steps to expand” the number of registered growers, and had recently sent draft regulations to facilitate licensing additional growers to the Office of Management and Budget.

 

Those draft regulations were published in late March 2020. Under the proposed regulations, the DEA will maintain sole ownership of all cannabis produced under the program, requiring growers to notify the DEA of an upcoming harvest up to four months’ in advance, or at a minimum, 15 days before a harvest. The DEA currently has roughly thirty-five outstanding applications for research cannabis cultivation licenses, and the agency said it expects to approve approximately five to thirteen suppliers once the rules are finalized after a public comment period, which has ended. The proposed rule provides that, with a limited exception, applications accepted for filing after the date the final rule becomes effective will not be considered pending until all applications accepted for filing on or before the date the final rule becomes effective have been granted or denied by the Administrator.

 

On December 18, 2020, the DEA finalized new regulations pertaining to applications by entities seeking to become registered with the DEA to grow cannabis as bulk manufacturers for research purposes and provide cannabis to other DEA registered manufacturers. Under these and other applicable regulations, applicants are responsible for demonstrating that they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion. The DEA has registered a limited number of additional bulk manufacturers for the U.S. wholesale market for cannabis for research.

 

On May 14, 2021, the DEA announced that it planned to provide memorandums of agreement to an unspecified and unnamed number of companies to collaborate with the DEA “to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations as well as other applicable legal standards and relevant laws.” The DEA’s final rule on the topic estimated that it would award licenses to between three and fifteen companies. To the extent these memorandums of agreement are finalized, the DEA anticipates issuing DEA registrations to these manufacturers. Each applicant will then be authorized to cultivate cannabis – up to an allotted quota – in support of the more than 575 DEA-licensed researchers across the nation. As individual manufacturers are granted DEA registrations, that information will be made available on DEA’s Diversion Control website.

 

22
 

 

A denial of, or significant delay in obtaining, or any interruption of required government authorizations to grow cannabis for federally sanctioned purposes would likely significantly, negatively impact us.

 

Our business plan depends heavily on receiving the necessary state and federal authorizations to research cannabis and to grow cannabis for federally sanctioned cannabis research. Bright Green may not commence cannabis growing operations until both the State of New Mexico and the federal government, in particular the DEA, have signed off that Bright Green has met its obligations under state law and the MOA and is compliance with all applicable regulations. While New Mexico has granted to Bright Green the necessary licenses to grow cannabis for research, and BGC and the DEA have entered into a MOA for BGC to be one of the entities registered by the DEA to grow cannabis for federally sanctioned purposes, we cannot guarantee that the DEA will ultimately permit BGC to register manufacture cannabis.  The MOA was effective and became binding on May 20, 2021. The DEA’s denial of any authorizations or any delay in granting the authorization or renewal could have a significantly negative impact on our business plans, operations and financial results. 

 

BGC must comply with all terms agreed to in the MOA which include:

 

  ● submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250;
  ● submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189;
  ● collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown;
  ● providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis;
  ● following the DEA’s packaging, labeling, storage and transportation requirements;
  ● distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and
  ● invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Furthermore, unless terminated for cause by the DEA, the MOA is effective for an initial one-year term from its effective date, subject to automatic renewal for up to four additional one-year terms. There is no guarantee, however, that the needed authorizations will be obtained in the first place, or subsequently renewed at the one year or subsequent renewal terms.

 

Changes in the competitive landscape for cannabis for federally sanctioned research could significantly, negatively impact us.

 

The DEA has not made public how many entities received memorandums of agreement. If the DEA awards additional Federal Registrations to grow cannabis for federally sanctioned research it would limit our competitive advantage. This would have a negative impact on our business plans, operations and financial results.

 

The U.S. wholesale market for cannabis for research is of unknown size and is difficult to forecast.

 

BGC plans to operate in a novel market which currently only has seven other participants. The extent to which the DEA will expand the current cannabis research program, and the supply that the DEA will require from bulk manufacturers to furnish researchers with cannabis is unknown and unprecedented. Because this market is new and novel, there are risks to predicting the market size and the resulting revenue BGC will obtain from government contracts to supply cannabis researchers, should the DEA registration be obtained, and any such projections may prove inaccurate.

 

We may not develop as many cannabis products or a crop of the consistency or quality that we expect, which could have a negative adverse effect on our business plan and profitability.

 

Our success depends on our ability to attract and retain research customers, but we face competition in obtaining customers for our cannabis materials and products. There are many factors that could impact our ability to attract and retain customers, including our ability to successfully compete based on price, produce high quality or consistent crops, continually produce desirable and effective products that are superior to others in the market, and the successful implementation of our customer acquisition plan and the continued growth in the aggregate number of potential customers. Competition for customers may result in increasing our costs while also lowering the market prices for our products, and reduce our profitability. If we are not successful in attracting and retaining customers, we may fail to be competitive or achieve profitability or sustain profitability over time.

 

As a result of changing customer preferences, even among research or pharmaceutical customers, many products attain financial success for a limited period of time.

 

23
 

 

Even if we are successful in introducing new products, a failure to gain consumer acceptance or to update products with compelling attributes could cause a decline in our products’ popularity that could reduce revenues and harm our business, operating results and financial condition. Failure to introduce new products or product types and to achieve and sustain market acceptance could result in our being unable to meet consumer preferences and generate revenue, which would have a material adverse effect on our profitability and financial results from operations.

 

FDA regulation of cannabis could negatively affect the cannabis industry, which would directly affect our financial condition.

 

Should the federal government legalize cannabis, it is possible that the FDA would seek to regulate it under the Food, Drug and Cosmetics Act. After the U.S. government removed hemp and its extracts from the CSA as part of the Agriculture Improvement Act of 2018, the FDA Commissioner Scott Gottlieb issued a statement reminding the public of the FDA’s continued authority “to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug and Cosmetic Act and section 351 of the Public Health Service Act.” He also reminded the public that “it’s unlawful under the FDCA to introduce food containing added cannabidiol (“CBD”) or tetrahydrocannabinol (“THC”) into interstate commerce, or to market CBD or THC products, as, or in, dietary supplements, regardless of whether the substances are hemp-derived,” and regardless of whether health claims are made, because CBD and THC entered the FDA testing pipeline as the subject of public substantial clinical investigations for GW Pharmaceuticals’ Sativex (THC and CBD) and Epidiolex (CBD). Gottlieb’s statement added that, prior to introduction into interstate commerce, any cannabis product, whether derived from hemp or otherwise, marketed with a disease claim (e.g., therapeutic benefit, disease prevention, etc.) must first be approved by the FDA for its intended use through one of the drug approval pathways.

 

The FDA has sent numerous warning letters to sellers of CBD products making health claims. The FDA could turn its attention to the cannabis industry at large. In addition to requiring FDA approval of cannabis products marketed as drugs, the FDA could issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of cannabis. It is also possible that the FDA would require that facilities where cannabis is grown register with the FDA and comply with certain federally prescribed regulations. Cannabis facilities are currently regulated by state and local governments. In the event that some or all of these federal enforcement and regulations are imposed, we do not know what the impact would be on our operations, including what costs, requirements and possible prohibitions may be enforced. If we are unable to comply with the regulations or registration as prescribed by the FDA, we may be unable to continue to operate our business in its proposed form or at all. There is no guarantee that cannabinoid products that may not be fully legal now will be able to be legally commercialized in the future or that Bright Green’s products or operations will meet any new FDA regulations or interpretations of the law, which could inhibit Bright Green’s business prospects even in the case that the federal government were to legalize cannabis.

 

Due to the FDA’s position on CBD, and because we are committed to complying with both state and federal laws, any legal restriction on the sale of products that containing extracts of cannabis could limit the legally accessible CBD/legal cannabinoid market for our proposed products.

 

Additionally, the FDA may, in the future, decide to regulate cannabis products, which could significantly accelerate or stall the development and sale of cannabis-based products. Currently, there is uncertainty regarding the FDA’s path forward regarding cannabis. If the FDA were to regulate cannabis, it is possible that it would distinguish between DEA-approved facilities like Bright Green’s, and commercial cannabis retailers selling directly to consumers in state-legal markets. Because Bright Green’s products are not going directly to consumers, and would only reach consumers via a prescription drug that has undergone FDA clinical trials and safety testing, it is likely that the majority of the FDA’s regulation would affect state-legal cannabis operators more so than Bright Green. However, the effect of future FDA regulation on cannabis remains uncertain and could also have an adverse effect on our business operations, operating costs, and performance. Moreover, there is no guarantee that the FDA will find our products safe or effective or grant us the required approvals under the FDCA, which may inhibit our business prospects even in the case that the federal government were to legalize cannabis, and could also create unforeseen costs created by requirements to comply with the FDCA.

 

24
 

 

Research in the United States, Canada and other countries on the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids may cause adverse effects on our operations.

 

Historically stringent regulations related to cannabis have made conducting medical and academic studies challenging. Many statements concerning the potential medical benefits of cannabinoids are based on published articles and reports, and as a result, such statements are subject to the experimental parameters, qualifications and limitations in the studies that have been completed. Future research and clinical trials may draw different or negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical cannabis, which could adversely affect social acceptance of cannabis and the demand for their products.

 

There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention, or other research findings or publicity will be favorable to the cannabis market or any particular cannabis product or will be consistent with earlier publicity. Adverse future scientific research reports, findings and regulatory proceedings that are, or litigation, media attention or other publicity that is, perceived as less favorable than, or that questions, earlier research reports, findings or publicity (whether or not accurate or with merit) could result in a significant reduction in the demand for the cannabis products of a portfolio company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis, or our products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could adversely affect our business. This adverse publicity could arise even if the adverse effects associated with cannabis products resulted from consumers’ failure to use such products legally, appropriately or as directed.

 

The very dynamic nature of the laws and regulations affecting the cannabis market, the federal authorization of cannabis for research, or the state-regulated cannabis industry could materially adversely affect our proposed operations, and we cannot predict the impact that future laws or regulations may have on us.

 

Local, state and federal cannabis laws and regulations have been evolving rapidly and are subject to varied interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan and could negatively impact our business plan or business. We can know neither the nature of any future laws, regulations, interpretations or applications nor the effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. For example, if cannabis is no longer illegal under federal law, and depending on future laws or guidance on cannabis for research, we may experience a significant increase in competition. Accordingly, any change in these laws or regulations, changes in their interpretation, or newly enacted laws or regulations and any failure by us to comply with these laws or regulations could require changes to certain of our business practices, negatively impact our operations, cash flow or financial condition, impose additional costs on us or otherwise adversely affect our business.

 

Operating in a highly regulated business requires significant resources.

 

We intend to operate in a highly regulated business. As a result, we expect a significant amount of our management’s time and external resources to be used to comply with the laws, regulations and guidelines that impact our business, and changes thereto, and such compliance may place a significant burden on our management and other resources.

 

Additionally, we may be subject to a variety of laws, regulations and guidelines in each of the jurisdictions in which we distribute cannabis, which may differ among these various jurisdictions. Complying with multiple regulatory regimes will require additional resources and may our ability to expand into certain jurisdictions. For example, even if cannabis were to become legal under U.S. federal law, companies operating in the cannabis industry would have to comply with all applicable state and local laws, which may vary greatly between jurisdictions, increasing costs for companies that operate in multiple jurisdictions.

 

25
 

 

The uncertainties around funding, construction, and growing an agricultural crop pose risks to our business.

 

Our planned operations are contingent on completion of raising significant additional funding for the construction of certain facilities in Grants, New Mexico. We need significant additional capital to build out the properties, and the timing and terms of obtaining that capital are uncertain. It is also possible that we may not be able to raise the capital required for our construction plans.

 

Delays in obtaining the capital, onerous terms for the capital, or a failure to raise the significant capital required could have a material, negative impact on business or plans of operations. Furthermore, we will be an agricultural supplier and will be subject to agricultural risks related to issues such as climate change, natural disasters or pests. In particular, there could be difficulties with the first crop or harvest in any new facility.

 

The cannabis industry is subject to the risks inherent in an agricultural business, including environmental factors and the risk of crop failure.

 

The growing of cannabis is an agricultural process. As such, a portfolio company with operations in the cannabis industry is subject to the risks inherent in the agricultural business, including risks of crop failure presented by weather, climate change, water scarcity, fires, insects, plant diseases and similar agricultural risks. Although some cannabis production is conducted indoors under climate-controlled conditions, cannabis continues to be grown outdoors, and in our case, in greenhouses using natural light, which is susceptible to climate changes, and there can be no assurance that artificial or natural elements, such as insects and plant diseases, will not entirely interrupt production activities or have an adverse effect on the production of cannabis and, accordingly, the operations of a portfolio company, which could have an adverse effect on our business, financial condition and results of operations.

 

We may be vulnerable to rising energy costs, and an increase or volatility in energy prices may adversely affect our business and results of operations.

 

Cannabis growing operations consume considerable energy, which makes us vulnerable to rising energy costs and/or the availability of stable energy sources. Accordingly, rising or volatile energy costs or the inability to access stable energy sources may have a material adverse effect on our business, financial condition and results of operations.

 

We are subject to environmental regulations and laws, and failure to timely or completely comply with such regulations and laws, or failure to obtain or maintain applicable licenses, may adversely affect our business.

 

Cultivation and production activities may be subject to licensing requirements relating to environment regulation. Environmental legislation and regulations are evolving in such a manner that may result in stricter standards and enforcement, larger fines and liability and potentially increased capital expenditures and operating costs. The application of environmental laws to our business may cause us to increase the costs of our cultivation, production or scientific activities. Unanticipated licensing delays can result in significant delays and expenses related to compliance with new environmental regulations, and cost overruns in our business and could affect our financial condition and results of operations. There can be no assurance that these delays will not occur.

 

The growth of our business continues to be subject to new and changing federal, state, and local laws and regulations.

 

Continued development of the cannabis industry is dependent upon further legalization of cannabis at the state level, and a number of factors could slow or halt progress in this area, even where there is public support for legislative action. Any delay or halt in the passing or implementation of legislation legalizing cannabis use, or its cultivation, manufacturing, processing, transportation, distribution, storage and/or sale, or the re-criminalization or restriction of cannabis at the state level, could negatively impact our business, even though we are primarily regulated by the DEA. Additionally, changes in applicable federal, state, and local regulations, including zoning restrictions, environmental requirements, FDA compliance, security requirements, or permitting requirements and fees, could restrict the products and services we may offer or impose additional compliance costs on us. Violations of applicable laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. We cannot predict the nature of any future laws, regulations, interpretations or applications, including local, state, federal, or environmental, and it is possible that regulations may be enacted in the future that will be materially adverse to our business or which would have materially significant costs of compliance which could negatively impact our business.

 

26
 

 

We are subject to risks, including delays, from our ongoing and future construction projects, which may result from reliance on third parties, delays relating to material delivery and supply chains, and fluctuating material prices, among other factors.

 

We are subject to several risks in connection with the construction of our projects, including the availability and performance of engineers and contractors, suppliers and consultants, the availability of funding, and the receipt of required governmental approvals, licenses and permits, and the projected timeline for construction, which could change due to delays. Any delay in the performance of any one or more of the contractors, suppliers, consultants or other persons on which we are dependent in connection with our construction activities, a delay in or failure to receive the required governmental approvals, licenses and permits in a timely manner or on reasonable terms, or a delay in or failure in connection with the completion and successful operation of the operational elements in connection with construction could delay or prevent the construction of the additional phases of the facilities as planned. There can be no assurance that current or future construction plans implemented by us will be successfully completed on time, within budget and without design defect, that the necessary personnel and equipment will be available in a timely manner or on reasonable terms to complete construction projects successfully, that we will be able to obtain all necessary governmental approvals, licenses and permits, or that the completion of the construction, the start-up costs and the ongoing operating costs will not be significantly higher than anticipated by us. Any of the foregoing factors could adversely impact our operations and financial condition.

 

The costs to procure such materials and services to build new facilities may fluctuate widely based on the impact of numerous factors beyond our control including, international, economic and political trends, foreign currency fluctuations, expectations of inflation, global or regional consumptive patterns, speculative activities and increased or improved production and distribution methods.

 

Since early 2020, the COVID-19 pandemic has impacted global economic activity, and the governments of many countries, states, cities and other geographic regions have previously taken or continue to take preventative or protective actions, which have caused disruptions in global supply chains such as closures or other restrictions on the conduct of business operations of manufacturers, suppliers and vendors. Such preventative or proactive actions may be reinstated or expanded upon in the future. The recovery from COVID-19 also may have risks in that increased economic activity globally or regionally may result in high demand for, and constrained access to, materials and services we require to construct and commission our facilities, which may lead to increased costs or delays that could materially and adversely affect our business.

 

Global demand on shipping and transport services may cause us to experience delays in the future, which could impact our ability to obtain materials or build our facilities in a timely manner. These factors could otherwise disrupt our operations and could negatively impact our business, financial condition and results of operations.

 

Logistical problems, unexpected costs, and delays in facility construction, whether or not caused by the COVID-19 pandemic, which we cannot control, can cause prolonged disruption to or increased costs of third-party transportation services used to ship materials, which could negatively affect our facility building schedule, and more generally our business, financial condition, results of operations and prospects. If we experience significant unexpected delays in construction, we may have to delay or limit our production depending on the timing and extent of the delays, which could harm our business, financial condition and results of operation.

 

27
 

 

Product recalls could adversely affect our business.

 

Our products could become subject to recall or return for various reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of our products are recalled due to an alleged product defect, regulatory requirements or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Recall of products could lead to adverse publicity, decreased demand for our products and could have significant reputational and brand damage. Although we have detailed procedures in place for testing finished products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by health authorities or regulatory agencies where the Company operates or products are sold, requiring further management attention and potential legal fees and other expenses.

 

Our planned future sale of cannabis and cannabis products could expose us to significant product liability risks.

 

We may be subject to various product liability claims, including, among others, that our products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against us could result in increased costs, could adversely affect our reputation with our clients and consumers generally, and could have a material adverse effect on our business, financial condition and results of operations. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our potential products.

 

A significant failure or deterioration in our quality control systems could have a material adverse effect on our business and operating results.

 

The quality and safety of our products are critical to the success of our business and operations. As such, it is imperative that our (and our service providers’) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training programs and adherence by employees to quality control guidelines. Although we strive to ensure that all of our service providers have implemented and adhere to high-quality control systems, any significant failure or deterioration of such quality control systems could have a material adverse effect on our business and operating results.

 

28
 

 

We are subject to liability arising from any fraudulent or illegal activity by our employees, contractors and consultants.

 

We are exposed to the risk that our employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless, or negligent conduct or disclosure of unauthorized activities to us that violate (i) government regulations, (ii) manufacturing standards, (iii) federal, state and provincial healthcare fraud and abuse laws and regulations, or (iv) laws that require the true, complete and accurate reporting of financial information or data. It is not always possible for us to identify and deter misconduct by our employees and other third parties, and the precautions taken by us to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any actions are brought against us, including by former employees, independent contractors or consultants, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment of our operations, any of which would have an adverse effect on our business, financial condition and results from operations.

 

We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms.

 

Designing and constructing cultivation, processing and distribution facilities and cultivating and producing cannabis is expensive. Changing circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, we may incur costs for the design and construction of cultivation, processing and dispensary facilities that greatly exceed our current budget for such projects. Alternatively, we may identify opportunities to acquire additional cannabis licenses that we believe would be beneficial to us. The acquisition of such licenses, and the cost of acquiring the related cultivation, processing or distribution facilities or, if not in existence or completed, the design and construction of such facilities may require substantial capital. In such events, we may need to raise additional capital to fund the completion of any such projects.

 

Furthermore, the cannabis industry is in its early stages and it is likely that we and our competitors will seek to introduce new products in the future which may include new genetic formulations. In attempting to keep pace with any new market developments, we will need to expend significant amounts of capital to successfully develop and generate revenues from new products, including new genetic formulations. We may also be required to obtain additional regulatory approvals from applicable authorities based on the jurisdictions in which we plan to distribute our products, which may take significant time. We may not be successful in developing effective and safe new products, bringing such products to market in time to be effectively commercialized or obtaining any required regulatory approvals, which together with capital expenditures made in the course of such product development and regulatory approval processes, may have a material adverse effect on our business, financial condition and results of operations.

 

We may need to raise additional funds in the future to support our operations. If we are required to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, and we may be required to:

 

  ● significantly delay, scale back or discontinue the design and construction of any cultivation, processing and dispensary facilities for which we are awarded licenses or
  ● relinquish any cultivation, processing and dispensary licenses that we are awarded, or sell any cultivation, processing or distribution facilities that we are designing and constructing.

 

If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from executing upon our business plan. This would have a material adverse effect on our business, financial condition and results of operations.

 

There is no guarantee that we will be able to continue to raise funds through our EB-5 Program, if and when such program receives requisite regulatory approvals.

 

On February 1, 2023, we initiated our EB-5 Program, whereby we may issue up to an aggregate of 12,609,152 shares of common stock to accredited or institutional investors, at a price of $39.99 per share. As of the date of this Annual Report, we have issued an aggregate of 44,010 shares and may issue up to a further 12,565,142 shares of common stock under our EB-5 Program. There is no guarantee that we will raise sufficient funds under the EB-5 Program to avoid the need for parallel fundraising activities. If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from executing upon our business plan. This would have a material adverse effect on our business, financial condition and results of operations. See “Item 1.A. Risk Factors – We will need to raise substantial additional funds in the future, which funds may not be available or, if available, may not be available on acceptable terms”, “Item 1.A. Risk Factors – Although we have received executed subscription agreements from investors to purchase shares of common stock under our EB-5 Program, such investors may never receive the requisite approvals to participate in our EB-5 Program”, and “Item 1. Business – Bright Green EB-5 Program” for more information.

 

29
 

 

Although we have received executed subscription agreements from investors to purchase shares of common stock under our EB-5 Program, such investors may never receive the requisite approvals to participate in our EB-5 Program.

 

Although we have received executed subscription agreements from 37 investors to purchase 814,185 shares of common stock for $32.6 million, such investors may never receive the requisite approvals to participate in our EB-5 Program. Failure by these investors to receive the requisite approvals to participate in our EB-5 Program may negatively affect us. The potential financial returns to us under the aforesaid executed subscription agreements depends in large part on the investors receiving the requisite approvals to participate in such program, and if these investors fail to receive the requisite approvals, the funding of our EB-5 Program could be delayed, hindered or may not occur and our business and prospects could be materially and adversely affected.

 

We are dependent on our banking relations, and while we currently have a stable banking relationship and operate in compliance with all applicable laws, we could have difficulty accessing or consistently maintaining banking or other financial services due to banks’ risk aversion toward serving even legal parts of the cannabis industry.

 

We are dependent on the banking industry to support the financial functions of our company. Our business operating functions including payroll for our employees and other expenses and transactions which are reliant on traditional banking. Additionally, we anticipate that our clients will pay us via wire transfer to our bank accounts, or via checks that we deposit into our banks. We require access to banking services for both us and our clients to receive payments in a timely manner. Lastly, to the extent we rely on any lines of credit, these could be affected by our relationships with financial institutions and could be jeopardized if we lose access to a bank account.

 

Important components of our offerings depend on client accounts and relationships, which in turn depend on banking functions. Most federal and federally-insured state banks currently do not serve businesses that grow and sell cannabis products under state laws on the stated ground that growing and selling cannabis is illegal under federal law, even though the Treasury Department’s Financial Crimes Enforcement Network (“FinCEN”), issued guidelines to banks in February 2014 that clarified how financial institutions can provide services to cannabis-related businesses, consistent with financial institutions’ obligations under the Bank Secrecy Act. The continued uncertainty surrounding financial transactions related to federally-illegal cannabis activities and the subsequent risks this uncertainty presents to financial institutions may result in their discontinuing services to the cannabis industry or limit their ability to provide services to the cannabis industry or even federally-legal cannabis businesses like ours, because of the misperception that we are a cannabis business like federally illegal ones are. While we are not transacting in any way with non-federally legal cannabis, it is possible that banks could view us as a risk because of our association with cannabis or a misunderstanding of our legal status.

 

While our business is federally legal and complies with the CSA, it is possible we could still face banking difficulties. Banks have and may continue to consider us to be part of the cannabis industry that is subject to banking restrictions. If we were to lose any of our banking relationships or fail to secure additional banking relationships in the future, we could experience difficulty and incur increased costs in the administration of our business, paying our employees, accepting payments from clients, each of which may adversely affect our reputation or results of operations. Additionally, the closure of many or one of our bank accounts due to a bank’s reluctance to provide services to a cannabis business, even though we are operating legally under U.S. law, would require significant management attention from us and could materially adversely affect our business and operations.

 

While we have entered into a non-binding letter of intent with Alterola and have entered into exclusive negotiations for a merger therewith, we cannot assure you that the transactions contemplated by our non-binding letter of intent will be consummated or, that if such transactions are consummated, they will be accretive to stockholder value.

 

On August 25, 2022, we entered into the Alterola Agreement with Alterola pursuant to which we agreed to explore a merger transaction with Alterola. Pursuant to the Alterola Agreement, the Company agreed to acquire the Initial Shares, subject to customary due diligence and applicable regulatory approvals. Additionally, pursuant to the Alterola Agreement, we received the Alterola Option to acquire all remaining issued and outstanding shares of Alterola Stock, subject to customary due diligence, and regulatory, stockholder and other necessary approvals. The Alterola Agreement provides that the parties shall use their good faith efforts to enter into a definitive agreement setting forth the binding terms of the Alterola Transaction, whereby we shall acquire all remaining Alterola Stock in exchange for an additional $6 million together with an aggregate of $40 million of shares of our common stock.

 

30
 

 

In accordance with the Alterola Agreement, on October 3, 2022, we entered into the Secondary SPA with the Sellers and Alterola providing for the purchase by Bright Green of the Initial Shares from the Sellers.

 

The Sellers in aggregate sold 201,761,982 shares of Alterola Stock to Bright Green for a purchase price of $3,999,999 pursuant to the payment schedule set forth in the Secondary SPA. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Alterola Stock pursuant to a loan agreement.

 

The Sellers held 67% of the total outstanding shares of Alterola Stock prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola Stock.

 

Concurrently with the signing of the Secondary SPA, the Company and the Sellers entered into the Voting Agreement whereby the Sellers agree to vote in favor of the adoption of an agreement to effect the Company’s acquisition of Alterola or Alterola’s merger into the Company or a subsidiary of the Company, as the case may be, pursuant to additional terms set forth in the Voting Agreement. Pursuant to the Voting Agreement, the Sellers executed the Irrevocable Proxy whereby the Sellers granted the Company an irrevocable proxy to vote the Sellers’ Subject Shares (as defined therein) in a manner consistent with the Voting Agreement and pursuant to additional terms set forth in the Irrevocable Proxy.

 

The Alterola Agreement provides that the parties shall use their good faith efforts to enter into a definitive agreement setting forth the binding terms of the Alterola Transaction, whereby we shall acquire all remaining Alterola Stock in exchange for an additional $6 million together with an aggregate of $40 million of shares of our common stock. However, the Alterola Agreement did not include material terms related to any proposed acquisitive transaction with Alterola and there is no guarantee that we will agree to terms or definitive documentation with Alterola in order to effect the proposed merger transaction. Further, even if we are able to agree to terms with Alterola for a merger transaction, there is no guarantee that the terms will be favorable to and approved by our stockholders, that the transaction will be completed in the time frame or in the manner currently anticipated, or that we will recognize the anticipated benefits of the transaction.

 

On April 4, 2023, we announced our intention to exercise the Alterola Option.

 

We may engage in future acquisitions or strategic transactions, including the transaction with Alterola, which may require us to seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management.

 

As described herein, we have recently entered into a non-binding letter of intent to merge the Company with Alterola which enables us to conduct due diligence and negotiate the terms of a definitive merger agreement. In the event we engage in an acquisition or strategic transaction, we may need to acquire additional financing (particularly, if the acquired entity is not cash flow positive or does not have significant cash on hand). Obtaining financing through the issuance or sale of additional equity and/or debt securities, if possible, may not be at favorable terms and may result in additional dilution to our current stockholders. Additionally, any such transaction may require us to incur non-recurring or other charges, may increase our near and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, an acquisition or strategic transaction may entail numerous operational and financial risks, including the risks outlined above and additionally:

 

  ● exposure to unknown liabilities;
  ● disruption of our business and diversion of our management’s time and attention in order to develop acquired products or technologies;
  ● higher than expected acquisition and integration costs;
  ● write-downs of assets or goodwill or impairment charges;

 

31
 

 

  ● increased amortization expenses;
  ● difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
  ● impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and
  ● inability to retain key employees of any acquired businesses.

 

Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

 

Risks Related to our Business and Operations - Intellectual Property

 

We may be forced to litigate to defend our intellectual property rights, or to defend against claims by third parties against us relating to intellectual property rights.

 

We may be forced to litigate to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of other parties’ proprietary rights. Any such litigation could be very costly and could distract our management from focusing on operating our business. The existence and/or outcome of any such litigation could harm our business.

 

We are subject to risks related to information technology systems, including cyber-security risks; successful cyber-attacks or technological malfunctions can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential information and reputational risk, all of which would negatively impact our business, financial condition or results of operations.

 

Our use of technology is critical to our continued operations. We are susceptible to operational, financial and information security risks resulting from cyber-attacks or technological malfunctions. Successful cyber-attacks or technological malfunctions affecting us or our service providers can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential or proprietary information and reputational risk. As cybersecurity threats continue to evolve, we may be required to use additional resources to continue to modify or enhance protective measures or to investigate security vulnerabilities, which could have a material adverse effect on our business, financial condition or results of operations.

 

We are reliant on our intellectual property; failure to protect our intellectual property could negatively affect our business, financial condition or results of operations.

 

Our success will depend in part on our ability to use and develop new extraction technologies, know-how and new strains of cannabis. We may be vulnerable to competitors who develop competing technology, whether independently or as a result of acquiring access to the proprietary products and trade secrets of acquired businesses. In addition, effective future patent, copyright and trade secret protection may be unavailable or limited in the U.S. due to federal illegality or in foreign countries and may be unenforceable under the laws of some jurisdictions. Failure to adequately maintain and enhance protection over our proprietary techniques and processes, as well as over our unregistered intellectual property, including policies, procedures and training manuals, could have a material adverse effect on our business, financial condition or results of operations.

 

32
 

 

Risks Related to Ownership of Our Common Stock

 

Our common stock has a limited trading history and an active trading market may not develop or continue to be liquid, and the market price of our shares of common stock may be volatile.

 

Our common stock is listed and traded on Nasdaq. Prior to the listing on Nasdaq, there had not been a public market for our common stock, and an active market for our common stock may not develop or be sustained, which could depress the market price of our securities and could affect the ability of our stockholders to sell our common stock at favorable prices. In the absence of an active public trading market, investors may not be able to liquidate their investments in our shares of common stock. An inactive market may also impair our ability to raise capital by selling our common stock or equity-linked securities, our ability to motivate our employees through equity incentive awards and our ability to acquire other companies, products or technologies by using our common stock or equity-linked securities consideration. Further, the market price of our common stock has been and may continue to be, volatile. Between May 17, 2022, the date our common stock began trading on Nasdaq, and April 14, 2023, the market price of our common stock ranged from a high of $58.00 on May 18, 2022 to a low of $0.35 on December 28, 2022.

 

The market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control.

 

The market price of our common stock has fluctuated, and may continue to fluctuate, widely, due to many factors, some of which may be beyond our control. These factors include, without limitation:

 

  ● “short squeezes”;
  ● comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media;
  ● an increase or decrease in the short interest in our common stock ;
  ● actual or anticipated fluctuations in our financial and operating results;
  ● risks and uncertainties associated with events and macroeconomics events such as the ongoing COVID-19 pandemic, fluctuations in U.S. interest rates and rapid inflation; and
  ● overall general market fluctuations.

 

Publicly traded companies’ stock prices in general, and our stock price in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies and our company. For example, on May 18, 2022 and December 28, 2022, the closing price of our common stock was $48.08 and $0.35, respectively, and the daily trading volume on these days was approximately 3,221,100 and 273,900 shares, respectively. These broad market fluctuations may adversely affect the trading price of our common stock. In particular, a proportion of our common stock has been, and may continue to be, traded by short sellers which may put pressure on the supply and demand for our common stock, further influencing volatility in the market price. Additionally, these and other external factors have caused, and may continue to cause, the market price and demand of our common stock to fluctuate, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.

 

A “short squeeze” due to a sudden increase in demand for shares of our common stock could lead to extreme price volatility in shares of our common stock.

 

Investors may purchase shares of our common stock to hedge existing exposure or to speculate on the price of our common stock. Speculation of the price of our common stock may lead to long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase on the open market, investors with short exposure may have to pay a premium to repurchase shares of our common stock for delivery to lenders of our common stock. Those repurchases may in turn, dramatically increase the price of our common stock until additional shares of our common stock are available for trading or borrowing. This is often referred to as a “short squeeze.” A proportion of our common stock has been, and may continue to be, traded by short sellers which may increase the likelihood that our common stock will be the target of a short squeeze. A short squeeze could lead to volatile price movements in shares of our common stock that are unrelated or disproportionate to our operating performance and, once investors purchase the shares of our common stock necessary to cover their short positions, the price of our common stock may rapidly decline. Investors that purchase shares of our common stock during a short squeeze may lose a significant portion of their investment.

 

33
 

 

You may be diluted by issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price.

 

Our certificate of incorporation, as amended and restated, authorizes us to issue up to 500,000,000 shares of common stock and up to 10,000,000 shares of preferred stock. Additionally, our amended and restated certificate of incorporation which authorizes us to issue shares of common stock and options, rights, warrants and appreciation rights relating to our common stock for the consideration and on the terms and conditions established by our Board of Directors (the “Board”), in its sole discretion. We could issue a significant number of shares of common stock in the future in connection with investments or acquisitions. Any of these issuances could dilute our existing stockholders, and such dilution could be significant. Moreover, such dilution could have a material adverse effect on the market price for the shares of our common stock.

 

The future issuance of shares of preferred stock with voting rights may adversely affect the voting power of the holders of shares of our common stock, either by diluting the voting power of our common stock if the preferred stock votes together with the common stock as a single class, or by giving the holders of any such preferred stock the right to block an action on which they have a separate class vote, even if the action were approved by the holders of our shares of our common stock.

 

The future issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common stock less attractive. For example, investors in the common stock may not wish to purchase common stock at a price above the conversion price of a series of convertible preferred stock because the holders of the preferred stock would effectively be entitled to purchase common stock at the lower conversion price, causing economic dilution to the holders of common stock.

 

On December 12, 2022, our stockholders approved the Bright Green Corporation 2022 Omnibus Equity Compensation Plan (the “Plan”). An aggregate of 13,547,384 shares of common stock are reserved for issuance under the Plan, and awards under the Plan may come in the form of options (including non-qualified options and incentive stock options), SARs, restricted shares, performance shares, deferred stock, restricted stock units, dividend equivalents, bonus shares or other stock-based awards.

 

The future exercise of registration rights may adversely affect the market price of our common stock.

 

Certain of our stockholders have registration rights for restricted securities. In addition, certain registration rights holders can request underwritten offerings to sell their securities. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.

 

We do not anticipate paying any cash dividends on our common stock in the foreseeable future.

 

We currently intend to retain our future earnings, if any, for the foreseeable future, to fund the development and growth of our business. We do not intend to pay any dividends to holders of our common stock in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board taking into account various factors, including our business, operating results and financial condition, current and anticipated cash needs, plans for expansion, any legal or contractual limitations on our ability to pay dividends under our loan agreements or otherwise. As a result, if our Board does not declare and pay dividends, the capital appreciation in the price of our common stock, if any, will be your only source of gain on an investment in our common stock, and you may have to sell some or all of your common stock to generate cash flow from your investment.

 

If securities or industry analysts do not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock, its trading price and volume could decline.

 

We expect the trading market for our common stock to be influenced by the research and reports that industry or securities analysts publish about us, our business or our industry. As a new public company, we do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock may be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline and our common stock to be less liquid. Moreover, if one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, or if our results of operations do not meet their expectations, our stock price could decline.

 

34
 

 

We are an “emerging growth company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors.

 

For so long as we remain an “emerging growth company” as defined in the JOBS Act, we may take advantage of certain exemptions from various requirements that are applicable to public companies that are not “emerging growth companies,” including not being required to comply with the independent auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, being required to provide fewer years of audited financial statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may lose our emerging growth company status and become subject to the SEC’s internal control over financial reporting management and auditor attestation requirements. If we are unable to certify the effectiveness of our internal controls, or if our internal controls have a material weakness, we could be subject to regulatory scrutiny and a loss of confidence by stockholders, which could harm our business and adversely affect the market price of our common stock.

 

We will cease to be an “emerging growth company” upon the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (ii) the date we qualify as a large accelerated filer, with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year following the fifth anniversary of becoming a public company. As an emerging growth company, we may choose to take advantage of some but not all of these reduced reporting burdens. Accordingly, the information we provide to our stockholders may be different than the information you receive from other public companies in which you hold stock. In addition, the JOBS Act also provides that an “emerging growth company” can take advantage of an extended transition period for complying with new or revised accounting standards.

 

We have elected to take advantage of this extended transition period under the JOBS Act. As a result, our operating results and financial statements may not be comparable to the operating results and financial statements of other companies who have adopted the new or revised accounting standards. It is possible that some investors will find our common stock less attractive as a result, which may result in a less active trading market for our common stock and higher volatility in our stock price.

 

We are a “smaller reporting company,” and our election to comply with the reduced disclosure requirements as a public company may make our common stock less attractive to investors.

 

For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies, such as providing only two years of audited financing statements. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter.

 

If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. It is possible that some investors will find our common stock less attractive as a result, which may result in a less active trading market for our common stock and higher volatility in our stock price.

 

35
 

 

Provisions of our amended and restated certificate of incorporation and bylaws may delay or prevent a take-over that may not be in the best interests of our stockholders.

 

Provisions of our amended and restated certificate of incorporation and bylaws may be deemed to have anti-takeover effects, which include when and by whom special meetings of our stockholders may be called, and may delay, defer or prevent a takeover attempt.

 

In addition, our amended and restated certificate of incorporation authorizes the issuance of shares of preferred stock which will have such rights and preferences determined from time to time by our Board. Our Board may, without stockholder approval, issue additional preferred shares with dividends, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of our common stock.

 

The choice of forum provision in our amended and restated bylaws, could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or colleagues.

 

Our amended and restated bylaws, provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for any derivative action or proceeding brought on behalf of us, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, or any action asserting a claim governed by the internal affairs doctrine, shall be a state or federal court located within the state of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. The choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other colleagues, which may discourage such lawsuits against us and our directors, officers and other colleagues. Alternatively, if a court were to find such choice of forum provisions to be inapplicable or unenforceable in an action, including but not limited to claims brought in connection with the Securities Act of 1934, as amended (the “Securities Act”), or Exchange Act, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Investors are unable to waive compliance with U.S. federal securities laws and the rules and regulations thereunder.

 

The forum selection provision is intended to apply “to the fullest extent permitted by applicable law,” subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, the exclusive forum provision will not apply to actions brought under the Securities Act, or the rules and regulations thereunder.

 

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. As such, stockholders of the Company seeking to bring a claim regarding the internal affairs of the Company may be subject to increased costs associated with litigating in Delaware as opposed to their home state or other forum, precluded from bringing such a claim in a forum they otherwise consider to be more favorable, and discouraged from bringing such claims as a result of the foregoing or other factors related to forum selection. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.

 

36
 

 

The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.

 

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations. Compliance with these rules and regulations involves significant legal and financial compliance costs, may make some activities more difficult, time-consuming or costly and may increase demand on our systems and resources, particularly after we are no longer an “emerging growth company,” as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants, which will increase our costs and expenses.

 

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as regulatory and governing bodies provide new guidance. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us, and our business may be adversely affected.

 

However, for as long as we remain an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We would cease to be an “emerging growth company” upon the earliest of: (i) the last day of the fiscal year following the fifth anniversary the last day of the fiscal year ending after the fifth anniversary of the listing of our common stock on Nasdaq; (ii) the first fiscal year after our annual gross revenues are $1.235 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) as of the end of any fiscal year in which the market value of the common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year.

 

As a result of disclosure of information in this Annual Report and in filings required of a public company, our business and financial condition are highly visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be adversely affected, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business and operating results.

 

We are subject to additional regulatory burdens as a public company.

 

We are required to operate, maintain and oversee financial management control systems to manage our obligations as a public company listed on Nasdaq and registered with the SEC. These areas include corporate governance, corporate controls, disclosure controls and procedures and financial reporting and accounting systems. We expended significant resources to improve these systems in preparation for becoming a public company, and continue to review and improve these systems, but we cannot assure holders of our common stock that these and other measures we might take will be sufficient to allow us to satisfy our obligations as a public company. In addition, compliance with reporting and other requirements applicable to public companies listed on Nasdaq create additional costs for us and require management’s time and attention. We cannot predict the amount of the additional costs that we might incur, the timing of such costs or the impact that management’s attention to these matters will have on our business.

 

37
 

 

Our failure to meet the continuing listing requirements of Nasdaq could result in a de-listing of our securities.

 

On November 14, 2022, we received a written notification (the “Notice Letter”) from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until May 15, 2023 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of the Initial Compliance Period, we may apply for an additional compliance period as provided for in the Notice Letter.

 

If we fail to satisfy the continuing listing requirements of such as minimum closing bid price requirements, as discussed above, the corporate governance, or stockholders’ equity or minimum closing bid price requirements, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders’ ability to sell or purchase our common stock. In the event of a delisting, we would likely take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

We may be exposed to currency fluctuations.

 

Although our revenues and expenses are expected to be predominantly denominated in U.S. dollars, we may be exposed to currency exchange fluctuations. Recent events in the global financial markets have been coupled with increased volatility in the currency markets. Fluctuations in the exchange rate between the U.S. dollar and the currency of other regions in which we may operate or have customers may have a material adverse effect on our business, financial condition and operating results. We may, in the future, establish a program to hedge a portion of our foreign currency exposure with the objective of minimizing the impact of adverse foreign currency exchange movements. However, even if we develop a hedging program, there can be no assurance that it will effectively mitigate currency risks.

 

Shares eligible for future sale may have adverse effects on our share price.

 

Sales of substantial amounts of shares or the perception that such sales could occur may adversely affect the prevailing market price for our shares. We may issue additional shares in subsequent public offerings or private placements to make new investments or for other purposes. Therefore, it may not be possible for existing shareholders to participate in such future share issuances, which may dilute the existing shareholders’ interests in us.

 

If we cannot continue to satisfy the rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

 

Even though our common stock is listed on Nasdaq, we cannot assure you that our common stock will continue to be listed on Nasdaq.

 

We are required to comply with certain rules of Nasdaq, including those regarding minimum shareholders’ equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. We may not be able to continue to satisfy these requirements and applicable rules. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be subject to delisting.

 

38
 

 

If Nasdaq delists our securities from trading, we could face significant consequences, including:

 

  ● a limited availability for market quotations for our securities;
     
  ● reduced liquidity with respect to our securities;
     
  ● a determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock ;
     
  ● limited amount of news and analyst coverage; and
     
  ● a decreased ability to issue additional securities or obtain additional financing in the future.

 

Investment in our common stock is speculative and involves a high degree of risk. You may lose your entire investment.

 

There is no guarantee that the common stock will earn any positive return in the short term or long term. A holding of our common stock is speculative and involves a high degree of risk and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment. A holding of our common stock is appropriate only for holders who have the capacity to absorb a loss of some or all of their holdings.

 

Your ownership interest will be diluted and our stock price could decline when we issue additional shares of common stock.

 

We expect to issue from time to time in the future additional shares of common stock or securities convertible into, or exercisable or exchangeable for, shares of common stock in connection with possible financings, acquisitions, equity incentives for employees or otherwise. Any such issuance could result in substantial dilution to existing shareholders and cause the trading price of the common stock to decline.

 

Under our EB-5 Program, we may issue up to an aggregate of 12,609,152 shares of common stock. As of April 14, 2023, we have issued an aggregate of 44,010 shares of common stock pursuant to our EB-5 Program and may issue up to an additional 12,565,142 shares. For more information, see “Item 1.A. Risk Factors – “Although we have received executed subscription agreements from investors to purchase shares of common stock under our EB-5 Program, such investors may never receive the requisite approvals to participate in our EB-5 Program”,

 

We have issued warrants and may continue to issue additional securities in the future. The exercise of these warrants and the sale of the common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.

 

As of December 31, 2022, we have issued and have outstanding warrants to purchase 9,523,810 shares of common stock at an exercise price of $1.05 per share, subject to adjustment as described therein. Because the market for our common stock may be thinly traded, the sales and/or the perception that those sales may occur, could adversely affect the market price of our common stock. Furthermore, the mere existence of a significant number of shares of common stock issuable upon exercise of our outstanding securities may be perceived by the market as having a potential dilutive effect, which could lead to a decrease in the price of our common stock.

 

Item 1B. Unresolved Staff Comments.

 

Not Applicable.

 

39
 

 

Item 2. Properties.

 

The following table set forth the Company’s owned and leased physical properties as of December 31, 2022, which include corporate offices, cultivation and production facilities (operating and under construction). In addition to the currently owned and leased property, the Company holds two options, each for the purchase of 300 acres of land in Grants, New Mexico.

 

Property Type   Owned/Leased   County   State
Agricultural Property – 40 acres   Owned   Cibola   New Mexico
Agricultural Property – 70 acres   Owned   Cibola   New Mexico
Office   Leased   Broward   Florida

 

As of December 31, 2022, we notified the land owners of our intention to exercise the two options and are in process of negotiating final terms of acquisition. 

 

Corporate Headquarters

 

Our principal executive offices are located at 1033 George Hanosh Boulevard Grants, NM 87020, and our telephone number is (833) 658-1799. The Company believes that its existing facilities and other available properties will be sufficient for its needs for the foreseeable future.

 

Item 3. Legal Proceedings

 

From time to time, we may be involved in legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Other than as set forth below, we are not presently a party to any litigation the outcome of which, if determined adversely to us, would in our estimation, have a material adverse effect on our business, operating results, cash flows or financial condition.

 

  ● Bright Green Corporation v. John Fikany, D-1333-CV-202000231, State of New Mexico, County of Cibola, Thirteenth Judicial District. On October 23, 2020, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfil agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against Lynn Stockwell, founder and a director of the Company, and Ms. Stockwell’s husband, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.
     
  ● Bright Green Corporation v. Jerry Capussi, D-1333-CV-202000252, State of New Mexico, County of Cibola, Thirteenth Judicial District. On November 16, 2020, the Company and defendant, a former consultant of Sunnyland Farms Inc, an entity unrelated to the Company, each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and we are preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

40
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock is listed on Nasdaq under the symbol “BGXX”. On April 14, 2023, the closing price of our common stock was $1.55 per share.

 

Holders of Our common stock

 

As of April 14, 2023, we had 95 holders of record of our common stock. Certain shares are held in “street” name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

 

Dividend Policy

 

Since our inception, we have not paid any dividends on our common stock, and we currently expect that, for the foreseeable future, all earnings, if any, will be retained for use in the development and operation of our business. In the future, our Board may decide, at its discretion, whether dividends may be declared and paid to holders of our common stock.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

 

Recent Sales of Unregistered Securities

 

All sales of unregistered securities by us during the year ended December 31, 2022 have been included previously in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

We did not purchase any of our registered equity securities during the period covered by this Annual Report.

 

Item 6. [Reserved].

 

Not Applicable.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the accompanying notes included in Part II, Item 8 of this Annual Report. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set forth in the section titled “Risk Factors,” our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors.” Please also refer to the section titled “Special Note Regarding Forward Looking Statements.”

 

41
 

 

Overview

 

We are a first-mover in the U.S. federally-authorized cannabis space. We are one of a few companies who have received conditional approval based on already agreed terms from the DEA to produce federally legal cannabis and have entered into the MOA with the DEA which permits us to proceed towards a Federal Registration for the Bulk Manufacturing of cannabis under DEA Document Control Number W20078135E.

 

Unlike state-licensed cannabis companies who engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, subject to the milestones and requirements set forth herein, we are conditionally authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations. We plan to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

 

In addition to research and pharmaceutical supply sales, Bright Green will be able, and has received the DEA’s express permission, to sell certain cannabinoids, such as CBN (cannabinol) and CBG (cannabigerol) as hemp isolates or extracts, and plans to sell CBN and CBG hemp products to consumers where such products are fully legal under all applicable laws. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the 2018 Farm Bill, which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis sales conducted under a Federal Registration for the Bulk Manufacturing of cannabis, if and when we receive such registration

 

Because cannabis is still a Schedule I Controlled Substance in the U.S., it has been historically under-researched. Though the majority of Americans now live in states where cannabis is legal, the full potential of the cannabis plant for medicinal use remains understudied due to limited access to federally-approved cannabis. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, we received conditional approval from the DEA, based on already agreed upon terms set forth in the MOA. Final approval from the DEA is contingent on, among other things, completed construction of manufacturing and production facilities and systems. Completion of construction is subject to the risk factors described herein and also requires successful fundraising.

 

Final registration under the MOA is anticipated in the second quarter of 2023, and is contingent upon completion of construction and a successful inspection by the DEA of BGC’s facilities. Additionally,  BGC must comply with the terms agreed upon pursuant to the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Following final approval from the DEA, we will be permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. There is no guarantee that we will receive final approval from the DEA. Upon receipt of the Federal Registration for the Bulk Manufacturing of cannabis, our activities will be legal under federal law, which sets BGC apart from most other U.S. cannabis companies, if and when we receive such approval.

 

We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe position us as a future industry leader in the production of cannabis.

 

42
 

 

Recent Developments

 

Key Factors Affecting Our Results of Operations and Future Performance

 

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part I, Item 1A of this Annual Report.

 

Results of Operations

 

Year Ended December 31, 2022, Compared to Year Ended December 31, 2021

 

Revenue:

 

We are a start-up company and have not generated any revenues for the twelve months ended December 31, 2022 and 2021. We can provide no assurance that we will generate sufficient revenues from our intended business operations to sustain a viable business operation. In order to generate revenues, we must first receive receipt of final registration from the DEA as described herein and begin operations.

 

Operating Expenses:

 

We incurred operating expenses in the amount of $27,313,922 for the twelve months ended December 31, 2022, as compared with $2,490,499 for the same period ended 2021. Our operating expenses for all periods consisted entirely of general and administrative expenses and depreciation. The detail by major category within general and administrative expenses for the twelve months ended December 31, 2022 and 2021 is reflected in the table below.

 

   For the year ended 
   2022   2021 
         
Stock-based compensation  $18,833,781   $360,000 
Professional fees   6,260,289    888,926 
Officer salaries   696,614    - 
Travel   232,794    68,374 
Other expenses   203,554    254,301 
Insurance   145,993    44,914 
Licenses   87,304    15,935 
Property taxes   58,054    68,766 
Office salaries   52,358    - 
Land option   38,500    37,500 
Total general and administrative expenses  $26,609,241   $1,738,716 
Depreciation   704,681    751,783 
Total operating expenses  $27,313,922   $2,490,499 

 

43
 

 

The increase of $24,870,525 in our general and administrative expenses for the year ended December 31, 2022 as compared to December 31, 2021 was primarily a result of increased spending on share based compensation to service providers and executives and professional fees associated with the Direct Listing.

 

We expect our general and administrative expenses to increase in future quarters as we continue with our reporting obligations with the SEC and the increased expenses associated with increased operational activity, which is expected for the balance of the year.

 

Liquidity and Capital Resources

 

As of December 31, 2022, the Company had cash of $414,574 compared to $1,282,565 as of December 31, 2021. The decrease of $867,991 in cash was mainly by the use of funds for the construction in progress, deposits for equipment, and the costs associated with the Company’s SEC filings. This decrease was partly offset by cash received from the sales of common stock of $12,186,733. Since its inception, the Company has incurred net losses and funded its operations primarily through the issuance of equities, an advance from a director, and since December 2022, a $3,579,990 draw on a line of credit provided by a director of the Company. As of December 31, 2022 and 2021, the Company had a total stockholders’ equity of $11,578,836 and $8,220,399, respectively.

 

The Company is in its initial stages to start building facilities to grow, research and distribute medical plants. The Company has incurred recurring losses from operations, and as at December 31, 2022 and 2021, had an accumulated deficit of $34,075,821 and $6,413,744, respectively, and a negative working capital of $7,030,929 and positive working capital of $1,282,829, respectively. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the financial statements were authorized to be issued. The Company’s continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan. During the twelve months ended December 31, 2022, the Company raised $12,186,733 through common stock issuances. The Company has also secured a $15,000,000 line of credit from a related party entity and has drawn $5,191,057 and paid down $1,611,067, leaving available $11.3 million to draw from that credit facility. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the event that the Company is not able to raise capital from investors or credit facilities in a timely manner, the Company will explore available options, including but not limited to, an equity backed loan against the property. In the absence of additional appropriate financing, the Company may have to modify its plan or slow down the pace of development and commercialization.

 

Sources of Liquidity

 

During the twelve months ended December 31, 2022, the Company raised $12,186,733 through common stock issuances. The Company has also secured a $15,000,000 line of credit from a related party entity and has drawn $5,191,057 and paid down $1,611,067, leaving available $11.3 million to draw from that credit facility.

 

Cash Flows

 

Operating Activities

 

   For the years ended 
   December 31, 2022   December 31, 2021 
       
Net cash used in operating activities   (2,265,770)   (1,656,575)

 

Investing Activities

 

   For the years ended 
   December 31, 2022   December 31, 2021 
         
Net cash used in investing activities   (14,368,944)   (302,717)

 

Financing Activities

 

   For the years ended 
   December 31, 2022   December 31, 2021 
       
Net cash provided by financing activities   15,766,723    3,139,594 

 

Contractual Obligations and Commitments

 

The Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be cancelled with minimal fees, non-cancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

44
 

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about the Company’s significant accounting policies, refer to Note 3 “Summary of Significant Accounting Policies,” in the Company’s financial statements included in this Annual Report on Form 10-K. During the year ended December 31, 2022, no material changes were made to the Company’s significant accounting policies.

 

Recently Issued Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3 to the Company’s financial statements, Standards, Amendments, and Interpretations Adopted.

 

Impact of the COVID-19 Pandemic

 

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus, or COVID-19, as a pandemic, which continues to spread throughout the U.S. and worldwide. As with many companies around the world, our day-to-day operations were disrupted with the imposition of work from home policies and requirements for physical distancing for any personnel present in our offices and laboratories. The pandemic has also disrupted our activities as shelter-in-place orders, quarantines, supply chain disruptions, travel restrictions and other public health safety measures have impacted our ability to interact with our existing and potential partners for our activities. However, the COVID-19 pandemic did not materially impact our business, operating results, or financial condition. There is significant uncertainty as to the trajectory of the pandemic and its impacts on our business in the future. We could be materially and adversely affected by the risks, or the public perception of the risks, related to the COVID-19 pandemic or similar public health crises. Such crises could adversely impact our ability to conduct on-site laboratory activities, expand our laboratory facilities, secure critical supplies such as reagents, laboratory tools or immunized animals required for discovery research activities, and hire and retain key personnel. The ultimate extent of the impact of any epidemic, pandemic, outbreak, or other public health crisis on our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic, outbreak, or other public health crisis and actions taken to contain or prevent the further spread, among others. Accordingly, we cannot predict the extent to which our business, financial condition and results of operations will be affected. We remain focused on maintaining our operations, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from the COVID-19 pandemic.

 

45
 

 

JOBS Act Accounting Election

 

We qualify as an “emerging growth company” as defined in the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are not otherwise applicable to public companies. These provisions include, but are not limited to:

 

  ● being permitted to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this Annual Report;
  ● not being required to comply with the auditor attestation requirements on the effectiveness of our internal controls over financial reporting;
  ● not being required to comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis);
  ● reduced disclosure obligations regarding executive compensation arrangements; and
  ● exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

We may use these provisions until the last day of our fiscal year in which the fifth anniversary of the completion of our initial public offering occurred. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenue exceeds $1.235 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

 

We have elected to take advantage of certain of the reduced disclosure obligations in this Annual Report and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our shareholders may be different than the information you receive from other public companies in which you hold stock.

 

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, until those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section 7(a)(2)(B) of the Securities Act upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which we will adopt the recently issued accounting standard.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

Our financial statements, together with the report of our independent registered public accounting firm, appear beginning on page F-1 of this Annual Report for the years ended December 31, 2022 and 2021.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

Not Applicable.

 

46
 

 

Item 9A. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of our management, including our former Interim Chief Executive Officer and Chief Financial Officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material error in our annual or interim financial statements will not be prevented or detected on a timely basis. In Management’s Report on Internal Control over Financial Reporting included in our quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed August 12, 2022, our management previously concluded that we maintained effective internal control over financial reporting as of June 30, 2022. Our management subsequently concluded that a material weakness existed and our internal control over financial reporting was not effective as of June 30, 2022. This determination was made as a result of a recording error of the fair value of shares of common stock we issued for services in June 2022. Such shares have a fair value of $8.00 per share, the price of our common stock at the time of our Direct Listing, but were initially recorded at a fair value of $4.00 per share. With this error being corrected in amendment no. 1 to our quarterly report on Form 10-Q for the period ended June 30, 2022, net loss increased by $6,297,960. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. The Company continues to evaluate and implement procedures as deemed appropriate to enhance our disclosure controls.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of the year ended December 31, 2022.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management including our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets: (ii) provide reasonable assurance (a) transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting policies (b) our receipts and expenditures are being made only in accordance with authorizations of our management and directors: and (c) regarding the prevention or timely detection of the unauthorized acquisition use or disposition of assets that could have a material effect on our financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

 

This Annual Report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of the company’s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.

 

Changes in Internal Control Over Financial Reporting

 

As described above, we implemented certain remediation efforts as a result of the error identified in our financial statements for the quarter ended June 30, 2022, and the corresponding material weakness identified by management in such period. Except as described above, there were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 

Not Applicable.

 

47
 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Directors and Executive Officers

 

The following persons are serving as our executive officers and directors:

 

Directors and Executive Officers   Age   Position/Title
Seamus McAuley   47   Chief Executive Officer
Terry Rafih   66   Executive Chairman
Saleem Elmasri   37   Chief Financial Officer
Dr Alfie Morgan   71   Director
Lynn Stockwell   65   Director
Dean Valore   50   Director
Robert Arnone   56   Director

 

Family Relationships

 

There are no family relationships among any of our directors or executive officers.

 

Executive Officers

 

Seamus McAuley has been BGC’s Chief Executive Officer since February 2023. From June 2021 to February 2023, Mr. McAuley was the Chief Executive Officer of Alterola Biotech Inc., a UK based pharmaceutical company developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs) and targeting European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products. Mr. McAuley has been the Chief Executive Officer of Opes Medical Holdings Ltd. (“OPES”) since founding the company in July 2019. OPES is a consultancy offering strategic executive services for the development of new and innovative medical technologies and in- vitro diagnostics, accessing funding sources and commercial launch of products. Before founding OPES, Mr. McAuley held several senior level sales and commercialization positions. From September 2018 to July 2019, Mr. McAuley was the European Corporate Development Manager for Diploma PLC, an international group of businesses supplying specialized technical products and services to the life sciences sector, where he was responsible for identifying, targeting, assessing and closing company acquisitions in strategically identified geographic zones and market sectors. Prior to that, from July 2011 to July 2019, Mr. McAuley was Sales and Commercial Director (UK & Ireland) for Technopath Distribution Ltd., an international manufacturer and distributor of clinical diagnostic products, where he more than doubled sales. Mr. McAuley earned diplomas in counselling and nursing from the University of Ulster.

 

Terry Rafih has been the Executive Chairman of BGC’s Board since October 2019, and previously served as BGC’s Chief Executive Officer from September 2022 to February 2023 and as BGC’s Interim Chief Executive Officer from June 2022 to September 2022. Since January 1989, Mr. Rafih has been the Owner and Chief Executive Officer of Rafih Automotive Group, one of Canada’s largest networks of auto dealerships. Mr. Rafih has decades of business experience and has managed mergers and acquisitions representing several billion dollars in aggregate value. Mr. Rafih received a B.S. in business administration from the University of Windsor. Mr. Rafih brings over 30 years of executive leadership experience to the Board. Mr. Rafih’s insights are critical to Board discussions.

 

Saleem Elmasri has been Chief Financial Officer since March 2022. Mr. Elmasri has been working at Titan Advisory Services LLC as Managing Partner since September 2020. Titan Advisory Services LLC is a boutique advisory firm focused on providing collaborative and customized financial operations and CFO services to early stage companies. Mr. Elmasri was Managing Director at DLA LLC, a professional services firm providing clients internal audit, accounting advisory, and corporate finance services, from June 2019 to April 2021 (ended full time employment September 2020 and became a consultant to DLA through April 2021). Prior to that, Mr. Elmasri worked as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm, from March 2018 to June 2019, and worked as Senior Manager for PricewaterhouseCoopers LLP, a Big-4 Accounting and Global Professional Services firm, from September 2007 to March 2018. Mr. Elmasri is a CPA and seasoned business professional who has a passion for delivering meaningful and measurable value to clients through practical solutions. Mr. Elmasri has over 15 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers and worked on several of the firm’s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, Mr. Elmasri transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting advisory. Mr. Elmasri has B.S. degrees in Accounting and Finance from Rutgers University.

 

Non-Employee Directors

 

Biographical information for Terry Rafih, our Executive Chairman of the Board, is set forth above in “Item 10. Directors, Executive Officers and Corporate Governance - Executive Officers”.

 

Dr. Alfie Morgan has been a Director of BGC’s Board since 2020. Dr. Morgan has been an Emeritus Professor of Business Administration at the University of Windsor in Canada since September 2016. From 1969 to 2003, he served as a professor with the University of Windsor, retiring as full-time member of faculty. He is the author/co-author of numerous publications and a book covering topics in the areas of strategic management, strategic planning, entrepreneurship, new venture formation, and corporate strategy and corporate best practices. He has served as a Director of the Windsor Regional Chamber of Commerce since 2003, and served as a Director of the Better Business Bureau of Southwest Ontario from 2018 to 2020. He previously maintained a management consulting practice specializing in strategic planning, and new venture formation. Dr. Morgan holds a B.Com from Cairo University, an M.B.A. from Boston University, and a Ph.D. from American University. Dr. Morgan brings decades of management, research and leadership experience to the Board.

 

Lynn Stockwell is the founder of Bright Green Corporation and has been a Director of BGC’s Board since its inception. From 2015 to 2020, Ms. Stockwell was a Managing Member of Bright Green Innovations, LLC, a concept for a federally legal emerging cannabis company, where Ms. Stockwell was responsible for managing the company’s industry, business and medical research relationships. Ms. Stockwell has served as a director of a hospital and held senior leadership positions in connection with fund raising events to promote the use of natural additives as an alternative to opioids. Ms. Stockwell is a sponsor of biomedical research and clinical trials and a member of AHP, the Association for Healthcare Philanthropy, with an interest in plant-based bio-identical hormone replacement. Ms. Stockwell is intimately familiar with BGC’s business and operations and brings significant knowledge of BGC’s business and the healthcare industry to the Board.

 

Dean M. Valore has been a Director of BGC’s Board since 2020 and Lead Independent Director since July 2022. Mr. Valore is managing partner of Valore & Gordillo L.L.P., a law firm based in Cleveland, Ohio, which he co-founded in January 2012. Since January 2021, Mr. Valore has also acted as Magistrate with the South Euclid Municipal Court in Ohio. Mr. Valore has been an adjunct professor of law, focusing on federal procedure, with the Cleveland-Marshall College of Law at Cleveland State University since January 2011. Before entering private practice, Mr. Valore was a United States Attorney. Mr. Valore is an expert in matters related to federal corporate compliance and acts as legal counsel to several medical-grade cannabis and cannabis-related companies. Mr. Valore received his J.D. from Cleveland State University - Cleveland-Marshall College of Law and his B.S. in finance from Miami University. Mr. Valore brings decades of corporate governance and federal regulatory and legal experience to the Board.

 

48
 

 

Robert Arnone has been a member of BGC’s Board since July 2021. Since 2006, Mr. Arnone has been co-owner and Chief Executive Officer of Levaero Aviation, the exclusive Canadian dealer for Pilatus Aircraft, and a globally recognized leading aircraft brokerage (“Levaero”). Mr. Arnone joined Levaero in 1999 and held various leadership positions before acquiring the company in 2006. Under his leadership, Levaero has expanded significantly and regularly records annual sales in excess of $75 million. Mr. Arnone holds a B.A. from Lakehead University and is a Certified Public Accountant.

 

Corporate Governance

 

Our business and affairs are managed under the direction of our Board. The number of directors will be fixed by our Board, subject to the terms of our amended and restated certificate of incorporation and bylaws, which include a requirement that the number of directors be fixed exclusively by a resolution adopted by directors constituting a majority of the total number of authorized directors, whether or not there exist any vacancies in previously authorized directorships. Our Board currently consists of five (5) directors.

 

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable our Board to satisfy its oversight responsibilities effectively in light of our business and structure, the Board focuses primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business.

 

Corporate Governance Profile

 

Our corporate governance is structured in a manner we believe closely aligns our interests with those of our stockholders. Notable features of our corporate governance structure include the following:

 

  ● Our Board is not classified, with each of our directors subject to re-election annually;
  ● A majority of our directors satisfy the Nasdaq listing standards for independence;
  ● Our Board leadership consists of a Lead Independent Director, a Chairman of the Board, and independent committee chairs.
  ● Generally, all matters to be voted on by stockholders will be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all stockholders present in person or represented by proxy, voting together as a single class;
  ● We comply with the requirements of the Nasdaq marketplace rules, including marketplace rules regarding composition of our Board committees;
  ● By virtue of the position, the Lead Independent Director is a member of the audit committee, the compensation committee and the nominating and corporate governance committee; and
  ● We do not have a stockholder rights plan.

 

Our directors stay informed about our business by attending meetings of our Board and its committees and through supplemental reports and communications. Our independent directors meet regularly in executive sessions without the presence of our corporate officers or non-independent directors.

 

Role of the Board in Risk Oversight

 

The Board actively manages the Company’s risk oversight process and receives periodic reports from management on areas of material risk to the Company, including operational, financial, legal, and regulatory risks. The Board committees and the lead independent director assist the Board in fulfilling its oversight responsibilities in certain areas of risk. The audit committee assists the Board with its oversight of the Company’s major financial risk exposures. The compensation committee assists the Board with its oversight of risks arising from the Company’s compensation policies and programs. The nominating and corporate governance committee assists the Board with its oversight of risks associated with board organization, board independence, and corporate governance. While each committee is responsible for evaluating certain risks and overseeing the management of those risks, the entire Board is regularly informed about the risks by committee chairs and the lead independent director.

 

49
 

 

Director Independence

 

The Nasdaq marketplace rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominations committees be independent, or, if a listed company has no nominations committee, that director nominees be selected or recommended for the board’s selection by independent directors constituting a majority of the board’s independent directors. The Nasdaq marketplace rules further require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act.

 

Our Board has affirmatively determined that each of Dr. Alfie Morgan, Dean Valore and Robert Arnone qualify as an independent director, as defined under the applicable corporate governance standards of Nasdaq. These rules require that our audit committee be composed of at least three (3) members, one of whom must be independent on the date of listing on Nasdaq, a majority of whom must be independent within 90 days of the effective date of the registration statement containing the prospectus for our Direct Listing, and all of whom must be independent within one year of the effective date of the registration statement containing the prospectus for our Direct Listing.

 

Board Leadership

 

Terry Rafih is the Executive Chairman of the Board. In addition, Mr. Valore, Lead Independent Director, is a member of the audit committee, corporate governance and nominating committee, and compensation committee.

 

Board Meetings

 

The Board holds periodic meetings, and ad hoc meetings if and when necessary. Directors are expected to attend Board meetings, meetings of stockholders and meetings of the committees on which they serve, with the understanding that on occasion a director may be unable to attend a meeting.

 

During 2022, our Board held 2 meetings, and each director attended 100% of the aggregate of (i) the total number of meetings of our board of directors held during the period for which he or she has been a director and (ii) the total number of meetings held by all committees of our board of directors on which he or she served during the periods that he or she served.

 

Board Committees

 

In April 2022, the Board established three standing committees, the audit committee, the compensation committee and the corporate governance and nominating committee, to assist the Board with the performance of its responsibilities. The initial composition of these committees was set by the Board at that time, in its discretion. Going forward, the Board will designate the members of these committees and the committee chairs based on the recommendation of the corporate governance and nominating committee. The Board has adopted written charters for each of these committees, which are available on the investor relations section of our website at https://brightgreen.us. Copies will also be available in print to any stockholder upon written request.

 

50
 

 

Audit Committee

 

The Board formally established an audit committee in April 2022. The audit committee is composed of three (3) independent directors, Robert Arnone, Dr. Alfie Morgan, and Dean Valore, Lead Independent Director. Mr. Arnone serves as chair of the audit committee. The committee’s primary duties are to:

 

  ● review and discuss with management and our independent auditor our annual and quarterly financial statements and related disclosures, including disclosure under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the results of the independent auditor’s audit or review, as the case may be;
  ● review our financial reporting processes and internal control over financial reporting systems and the performance, generally, of our internal audit function;
  ● oversee the audit and other services of our independent registered public accounting firm and be directly responsible for the appointment, independence, qualifications, compensation and oversight of the independent registered public accounting firm, which reports directly to the audit committee;
  ● provide an open means of communication among our independent registered public accounting firm, management, our internal auditing function and our Board;
  ● review any disagreements between our management and the independent registered public accounting firm regarding our financial reporting;
  ● prepare the audit committee report for inclusion in our proxy statement for our annual stockholder meetings;
  ● establish procedures for complaints received regarding our accounting, internal accounting control and auditing matters; and
  ● approve all audit and permissible non-audit services conducted by our independent registered public accounting firm.

 

The Board has determined that each member of the audit committee is independent of management and free of any relationships that, in the opinion of the Board, would interfere with the exercise of independent judgment and are independent, as that term is defined under the enhanced independence standards for audit committee members in the Exchange Act and the rules promulgated thereunder.

 

The Board has determined that Robert Arnone is an “audit committee financial expert,” as that term is defined in the rules promulgated by the SEC pursuant to the Sarbanes-Oxley Act of 2012. The Board has further determined that each member of the audit committee is financially literate and that at least one member of the committee has accounting or related financial management expertise, as such terms are interpreted by the Board in its business judgment.

 

Compensation Committee

 

The Board formally established a compensation committee in April 2022. The compensation committee is composed of three (3) independent directors (as defined under the general independence standards of the Nasdaq listing standards and our corporate governance guidelines): Dean Valore, Dr. Alfie Morgan, and Robert Arnone, each a “non-employee director” (within the meaning of Rule 16b-3 of the Exchange Act). Mr. Valore serves as chair of the compensation committee. The committee’s primary duties are to:

 

  ● approve corporate goals and objectives relevant to executive officer compensation and evaluate executive officer performance in light of those goals and objectives;
  ● determine and approve executive officer compensation, including base salary and incentive awards;
  ● make recommendations to the Board regarding compensation plans; and
  ● administer any stock plan, equity incentive plan, inducement plan or other compensation plan adopted for the benefit of our employees and/or directors.

 

The compensation committee determines and approve all elements of executive officer compensation. It also provides recommendations to the Board with respect to non-employee director compensation. The compensation committee may not delegate its authority to any other person, other than to a subcommittee.

 

51
 

 

Compensation Committee Interlocks and Insider Participation

 

No person who served as a member of the compensation committee during the fiscal year ended December 31, 2022 was a current or former officer or employee of the Company or engaged in certain transactions with the Company required to be disclosed by regulations of the SEC. Additionally, there were no compensation committee “interlocks” during the fiscal year ended December 31, 2022, which generally means that no executive officer of the Company served as a director or member of the compensation committee of another entity, one of whose executive officers served as a director or member of the compensation committee of the Company.

 

Nominating and Corporate Governance Committee

 

Our Board formally established a nominating and corporate governance committee in April 2022. The nominating and corporate governance committee is composed of three (3) independent directors (as defined under the general independence standards of the Nasdaq listing standards and our corporate governance guidelines): Dean Valore, Dr. Alfie Morgan and Robert Arnone, each a “non-employee director” (within the meaning of Rule 16b-3 of the Exchange Act). Mr. Valore, Lead Independent Director, serves as chair of the committee. The committee’s primary duties are to:

 

  ● recruit new directors, consider director nominees recommended by stockholders and others and recommend nominees for election as directors;
  ● review the size and composition of our Board and committees;
  ● oversee the evaluation of the Board;
  ● recommend actions to increase the Board’s effectiveness; and
  ● develop, recommend and oversee our corporate governance principles, including our code of business conduct and ethics and our corporate governance guidelines.

 

The nominating and corporate governance committee will consider several qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the board of directors. The nominating and corporate governance committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating and corporate governance committee does not distinguish among nominees recommended by stockholders and other persons.

 

We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders.

 

52
 

 

Director Nominations

 

The process of recommending director nominees for selection by the Board is undertaken by the nominating and corporate governance committee (see above).

 

The board of directors will also consider director candidates recommended for nomination by our stockholders during such times as they are seeking proposed nominees to stand for election at the next annual meeting of stockholders (or, if applicable, a special meeting of stockholders). Our stockholders that wish to nominate a director for election to our board of directors should follow the procedures set forth in our bylaws.

 

Section 16 Reporting Compliance

 

Section 16(a) of the Exchange Act requires certain of our officers and our directors, and persons who own more than 10 percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Officers, directors, and greater than 10 percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

 

Based solely on our review of copies of such forms received by us, we believe that during the year ended December 31, 2022, all filing requirements applicable to all of our officers, directors, and greater than 10% beneficial stockholders were timely complied with.

 

Code of Ethics

 

We adopted a written code of business ethics and conduct (the “Code of Conduct”) that applies to all of our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer. The objective of the Code of Conduct is to provide guidelines for maintaining our and our subsidiaries integrity, reputation, honesty, objectivity and impartiality. The Code of Conduct addresses conflicts of interest, protection of our assets, confidentiality, fair dealing with stockholders, competitors and employees, insider trading, compliance with laws and reporting any illegal or unethical behavior. As part of the Code of Conduct, any person subject to the Code of Conduct is required to avoid or fully disclose interests or relationships that are harmful or detrimental to our best interests or that may give rise to real, potential or the appearance of conflicts of interest. Our Board has ultimate responsibility for the stewardship of the Code of Conduct, and it monitors compliance through our nominating and corporate governance committee. Directors, officers and employees are required to annually certify that they have not violated the Code of Conduct. Our Code of Conduct reflects the foregoing principles. The full text of our Code Conduct is be published on our website.

 

We intend to disclose any amendments to or waivers of certain provisions of our Code of Conduct in a Current Report on Form 8-K.

 

Item 11. Executive Compensation.

 

The following is a discussion and analysis of compensation arrangements of the Company’s named executive officers. This discussion may contain forward-looking statements that are based on the Company’s current plans, considerations, expectations and determinations regarding future compensation programs. The actual compensation programs that the Company adopts may differ materially from the currently planned programs that are summarized in this discussion. As an “emerging growth company” as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.

 

53
 

 

Summary Executive Compensation Table

 

The following table sets forth information regarding the compensation awarded to or earned by our named executive officers for the fiscal years ended December 31, 2022 and 2021.

 

Name and Principal Position  Year  Salary
($)		   Option Awards
(1)($)		   Non-Equity Incentive Plan Compensation
($)		   All Other Compensation
($)		   Total
($)		 
Terry Rafih, Executive Chairman, Former Chief Executive Officer(2)  2022   200,000    -    -    4,255,313    4,455,313 
   2021   -    -   -    10,000    10,000 
                             
Saleem Elmasri, Chief Financial Officer  2022   218,669    -    -    2,000,000    2,218,669 
   2021   -    -    -    -    - 
                             
Edward Robinson, Former Chief Executive Officer(3)  2022   180,250    -    -    -    180,250 
   2021   -    -    -    -    - 

 

  (1) Represents the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating the amounts in this column may be found in the notes to our audited financial statements for the year ended December 31, 2022 set forth in this Annual Report. These amounts do not represent the actual amounts paid to or realized by the executives during the fiscal years presented.
  (2) Mr. Rafih resigned as Chief Executive Officer in February 2023. Seamus McAuley was appointed as his replacement in February 2023.
  (3) Mr. Robinson resigned as Chief Executive Officer in June 2022. Terry Rafih was appointed as his replacement in June 2022.

 

Outstanding Equity Awards at Fiscal 2022 Year-End

 

The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2022.

 

   Option Awards   Stock Awards 
Name  Number of Securities Underlying Unexercised Options (#) Exercisable   Number of Securities Underlying Unexercised Options (#) Unexercisable   Option Exercise Price ($)  

Option

Expiration

Date

   Number of Shares or Units of Stock That Have Not Vested (#) Exercisable   Market Value of Shares or Units of Stock That Have Not Vested ($) 
Terry Rafih, Executive Chairman, Former Chief Executive Officer(1)   0    0    0    0    6,037,500   $2,834,606 
Saleem Elmasri, Chief Financial Officer   0    0    0    0    0    0 

Edward Robinson,

Former Chief Executive Officer(2)

   0    0    0    0    0    0 

 

(1) Mr. Rafih resigned as Chief Executive Officer in February 2023. Seamus McAuley was appointed as his replacement in February 2023.
(2) Mr. Robinson resigned as Chief Executive Officer in June 2022. Terry Rafih was appointed as his replacement in June 2022.

 

54
 

 

Named Executive Officer Employment Arrangements

 

Below are descriptions of the current employment agreements with our named executive officers and Seamus McAuley, our current Chief Executive Officer.

 

Seamus McAuley

 

On February 15, 2023, effective as of February 9, 2023, the Company entered into an Executive Employment Agreement with Mr. McAuley (the “McAuley Agreement”) to serve as the Company’s Chief Executive Officer. The McAuley Agreement provides Mr. McAuley an annual base salary of $300,000, reimbursement for certain expenses, and eligibility to participate in the Company’s benefit plans and executive compensation programs generally. Additionally, upon the achievement of specific milestones, as described in Exhibit A to the McAuley Agreement, Mr. McAuley shall be eligible to receive awards to purchase up to an aggregate of 5,000,000 shares of the Company’s common stock. Each award is subject to and conditioned upon the approval of the Board, which approval shall be granted as each milestone is met. The McAuley Agreement subjects Mr. McAuley to standard restrictive covenants for agreements of its type, including non-competition, non-solicitation, and invention assignment provisions.

 

The McAuley Agreement is terminable by either Mr. McAuley or the Company on three months’ notice in writing. The Company reserves the right to pay Mr. McAuley in lieu of all or any part of his notice entitlement at the Company’s absolute discretion which will be calculated based on his basic salary. Where the Company pays in lieu of notice, the termination date of his employment will be the date on which notice is served (and not the date on which payment is made).

 

Terry Rafih

 

On September 22, 2022, and effective as of September 1, 2022, the Company entered into an Executive Employment Agreement with Mr. Terry Rafih (the “Rafih Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors and Chief Executive Officer. The Rafih Agreement provides Mr. Rafih an annual base salary of $600,000, which shall initially be deferred until March 15, 2023, and eligibility to participate in the Company’s benefit plans and executive compensation programs generally. Additionally, Mr. Rafih is eligible to receive an annual cash bonus of up to 150% of his base salary, provided that certain performance objectives are met (as set and determined by the Board), and an annual bonus equal to 1.5% of the net revenue generated by the Company for each of the Company’s fiscal years ending 2022, 2023, and 2024. The Rafih Agreement subjects Mr. Rafih to standard restrictive covenants, including non-competition, non-solicitation, and invention assignment provisions.

 

If Mr. Rafih’s employment is terminated by the Company without “Cause” (as defined in the Rafih Agreement) (other than for death or disability) or is terminated by Mr. Rafih for “Good Reason” (as defined in the Rafih Agreement) or the term of his employment is not renewed, Mr. Rafih will be entitled to receive (i) Accrued Obligations (as defined below); (ii) a lump sum payment equal to two (2) times the sum of (a) Mr. Rafih’s base salary then in effect and (b) two (2) times the maximum cash bonus then in effect for the current year; (iii) any earned but unpaid revenue bonus with respect to any completed fiscal year immediately preceding the termination date; (iv) any revenue bonus Mr. Rafih would have earned for the full year in which such termination occurred, prorated as set forth in the Rafih Agreement (v) all rights to which Mr. Rafih is entitled under each equity award as determined in accordance with the terms of the equity plans, programs, or award agreement under which any such equity has been granted, subject to the terms and conditions of the Rafih Agreement; and (vi) reimbursement of the COBRA premiums paid for continuation of coverage for Mr. Rafih, and his eligible dependents, until the earlier of (a) thirty-six (36) month period from the date of termination or (b) the date upon which Mr. Rafih and/or Mr. Rafih’s eligible dependents are no longer eligible for COBRA continuation coverage.

 

If Mr. Rafih’s employment is terminated for “Cause” (as defined in the Rafih Agreement) or is terminated by Mr. Rafih without “Good Reason” (as defined in the Rafih Agreement), Mr. Rafih will be entitled to receive (i) accrued but unpaid base salary for services rendered through the date of termination and accrued but unused vacation; (ii) reimbursement for unreimbursed business expenses properly incurred by Mr. Rafih; (iii) amounts which Mr. Rafih has earned and are owed to him pursuant to the terms of any written agreements, compensation and/or equity plans or programs of the Company or any of its affiliates as of the termination date, including, but not limited to any awards granted pursuant to any such plans or programs (such amounts subject to the terms and rights of those agreements and plans, all of which may differ based on the events of termination, and based on any discretion of the Board or the Company to accelerate vesting); (iv) amounts to which Mr. Rafih is legally entitled pursuant to any employee benefit plans of the Company or any of its affiliates as of the termination date (including, but not limited to, life insurance proceeds upon death and/or disability insurance proceeds upon disability); and (v) any indemnification rights Mr. Rafih has in connection with his service as an officer and/or director of the Company and/or its affiliates as of the termination date, whether pursuant to the Company’s governing documents or otherwise ((i)-(v) collectively, the “Accrued Obligations”).

 

Saleem Elmasri

 

On February 28, 2022, we entered into a Consulting Agreement (the “Elmasri Agreement”) with Saleem Elmasri, our Chief Financial Officer, to provide services to the Company prior to, and following, the registration of the Company’s securities under the Exchange Act. Mr. Elmasri was appointed Chief Financial Officer in March 2022. The Elmasri Agreement provides for the following compensation and benefits to Mr. Elmasri.

 

  ● A monthly cash fee not to exceed $30,720, subject to increase as set forth in the Elmasri Agreement.
  ● An initial term of two years.
  ● Eligibility to participate in any equity compensation plan adopted by the Company
  ● Issuance of 500,000 shares of the Company’s common stock

 

Edward Robinson

 

On April 1, 2022, we entered into an Employment Agreement (the “Robinson Agreement”) with Edward Robinson, our former Chief Executive Officer. The Robinson Agreement provided for the following compensation and benefits to Mr. Robinson:

 

●An annual base salary of $540,000 paid in monthly instalments (as adjusted from time to time in the discretion of the Board and Compensation Committee). Notwithstanding the foregoing, during the fiscal year ended December 31, 2022, Mr. Robinson was to receive monthly payments in the amount of $6,750 with an aggregate of $344,250 in deferred compensation due and payable on or before December 15, 2022. Mr. Robinson was paid an aggregate of $180,250 in the year ended December 31, 2022.
●An annual bonus of up to 100% of annual base salary.
●Reimbursement of travel and other expenses incurred by Mr. Robinson in connection with his service as Chief Executive Officer.
●Upon termination by the Company without “cause” or resignation by Mr. Robinson for “good reason,” each as defined in the Robinson Agreement, Mr. Robinson was entitled to the accrued benefits due to the executive as set forth in the Robinson Agreement.

 

On June 27, 2022, Mr. Robinson resigned as the Company’s Chief Executive Officer.

 

55
 

 

Summary Director Compensation Table

 

The following table sets forth information regarding the compensation awarded to, earned by or paid to our directors for the fiscal year ended December 31, 2022.

 

Name 

Fees Earned

or Paid in Cash

($)

  

Option Awards (1)

($)

  

Stock Awards (1)

($)

  

Total

($)

 
Lynn Stockwell   0    0    0    0 
Dr. Alfie Morgan   0    0    0    0 
Dean Valore   0    0    0    0 
Robert Arnone   0    0    0    0 
Terry Rafih   0    0    0    0 

 

(1) Represents the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating the amounts in this column may be found in the notes to our audited financial statements for the year ended December 31, 2022 set forth in this Annual Report. These amounts do not represent the actual amounts paid to or realized by the executives during the fiscal years presented.

 

Bright Green Corporation 2022 Omnibus Equity Incentive Plan

 

The Plan was adopted and become effective upon obtaining shareholder approval on December 12, 2022.

 

Summary of the Plan

 

The following paragraphs provide a summary of the principal features of the Plan and its operation.

 

13,547,384 of shares of common stock will be available for delivery pursuant to Awards granted under the Plan. The Plan covers the grant of awards to the Company’s employees (including officers), non-employee consultants and non-employee directors and those of the Company’s affiliates. In addition, the Plan permits the grant of awards (other than incentive stock options) to individuals who are expected to become an employee to, non-employee consultant or non-employee director of the Company or any of its affiliates within a reasonable period of time after the grant of an award. Any award granted to any individual who is expected to become an employee, non-employee consultant or non-employee director will be automatically terminated and cancelled without consideration if the individual does not begin performing services for the Company or any of its affiliate within twelve (12) months after the grant date. For purposes of the Plan, the Company’s affiliates include any corporation, partnership, limited liability company, joint venture or other entity, with respect to which we, directly or indirectly, own either (i) stock of a corporation possessing more than fifty percent (50%) of the total combined voting power of all classes of stock entitled to vote, or more than fifty percent (50%) of the total value of all shares of all classes of stock of such corporation, or (ii) an aggregate of more than fifty percent (50%) of the profits interest or capital interest of any non-corporate entity.

 

The compensation committee of the Board administers the Plan. The compensation committee may delegate any or all of its administrative authority to the Company’s Chief Executive Officer or to a management committee except with respect to awards to executive officers who are subject to Section 16 of the Exchange Act. In addition, the full Board must serve as the committee with respect to any awards to the Company’s non-employee directors.

 

The stock delivered to settle awards made under the Plan may be authorized and unissued shares or treasury shares, including shares repurchased by the Company for purposes of the Plan. If any shares subject to any award granted under the Plan (other than a substitute award as described below) is forfeited or otherwise terminated without delivery of all or a portion of such shares, including on payment in shares on exercise of a stock appreciation right (or if such shares are returned to the Company due to a forfeiture restriction under such award), the shares subject to such awards will again be available for issuance under the Plan. Any shares that are withheld or applied as payment (either actually or by attestation) for shares issued upon exercise of an award or for the withholding or payment of taxes due upon exercise of the award will not be treated as having been delivered under the Plan and will, at the discretion of the Company, be available for grant under the Plan.

 

56
 

 

If a dividend or other distribution (whether in cash, shares of common stock or other property), recapitalization, forward or reverse stock split, subdivision, consolidation or reduction of capital, reorganization, merger, consolidation, scheme of arrangement, split-up, spin-off or combination involving the Company or repurchase or exchange of our shares or other securities, or other rights to purchase shares of the Company’s securities or other similar transaction or event affects the common stock such that the committee determines that an adjustment is appropriate in order to prevent dilution or enlargement of the benefits (or potential benefits) provided to grantees under the Plan, the committee will make an equitable change or adjustment as it deems appropriate in the number and kind of securities subject to awards (whether or not then outstanding) and the related exercise price relating to an award in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan.

 

Other than in the case of substitute awards, (i) a non-employee director who is a lead independent director or a director chair or a newly-appointed director may not be granted awards for cash or shares that together with any awards granted outside of the Plan have a fair market value (determined as of the date of grant) in excess of $2,000,000 in a single calendar year and (ii) any other non-employee director may not be granted awards for cash or shares that together with any awards granted outside of the Plan have a fair market value (determined as of the date of grant) in excess of $1,000,000 in a single calendar year.

 

Types of Awards

 

The Plan permits the granting of any or all of the following types of awards to all grantees:

 

  ● stock options, including incentive stock options (“ISOs”);
     
  ● stock appreciation rights (“SARs”);
     
  ● restricted shares;
     
  ● deferred stock and restricted stock units;
     
  ● performance units and performance shares;
     
  ● dividend equivalents;
     
  ● bonus shares; and
     
  ● other stock-based awards.

 

Generally, awards under the Plan are granted for no consideration other than prior and future services. Awards granted under the Plan may, in the discretion of the committee, be granted alone or in addition to, in tandem with or in substitution for, any other award under the Plan or other plan of ours; provided, however, that if SARs are granted in tandem with ISOs, the SARs and ISOs must have the same grant date and term and the exercise price of the SARs may not be less than the exercise price of the ISOs. The material terms of each award will be set forth in a written award agreement between the grantee and us.

 

57
 

 

Stock Options and SARs

 

The committee is authorized to grant SARs and stock options (including ISOs except that an ISO may only be granted to an employee of the Company or one of its subsidiary corporations). A stock option allows a grantee to purchase a specified number of shares of the common stock at a predetermined price per share (the “exercise price”) during a fixed period measured from the date of grant. A SAR entitles the grantee to receive the excess of the fair market value of a specified number of shares on the date of exercise over a predetermined exercise price per share. The exercise price of an option or a SAR will be determined by the committee and set forth in the applicable award agreement but (other than in the case of substitute awards) the exercise price may not be less than the fair market value of a share of common stock on the grant date. The term of each option or SAR is determined by the committee and set forth in the applicable award agreement, except that the term may not exceed 10 years. Options may be exercised by payment of the purchase price through one or more of the following means: payment in cash (including personal check or wire transfer), by delivering shares of the common stock previously owned by the grantee, or with the approval of the committee, by delivery of shares of common stock acquired upon the exercise of such option or by delivering restricted shares. The committee may also permit a grantee to pay the exercise price of an option through the sale of shares acquired upon exercise of the option through a broker-dealer to whom the grantee has delivered irrevocable instructions to deliver sales proceeds sufficient to pay the purchase price and any applicable tax withholding amounts to the Company.

 

Restricted Shares

 

The committee may award restricted shares consisting of shares of common stock which remain subject to a risk of forfeiture and may not be disposed of by grantees until certain restrictions established by the committee lapse. The vesting conditions may be service-based (i.e., requiring continuous service for a specified period) or performance-based (i.e., requiring achievement of certain specified performance objectives) or both. A grantee receiving restricted shares will have all of the rights of a stockholder, including the right to vote the shares and the right to receive any dividends, except as otherwise provided in the applicable award agreement. Upon termination of the grantee’s affiliation with the Company during the restriction period (or, if applicable, upon the failure to satisfy the specified performance objectives during the restriction period), the restricted shares will be forfeited as provided in the applicable award agreement. Stock dividends and deferred cash dividends issued with respect to restricted shares will be subject to the same restrictions and other terms as apply to the restricted shares with respect to which such dividends are issued.

 

Deferred Stock and Restricted Stock Units

 

The committee may also grant deferred stock awards and/or restricted stock unit awards. A deferred stock award is the grant of a right to receive a specified number of shares of common stock at the end of specified deferral periods or upon the occurrence of a specified event, which satisfies the requirements of Section 409A of the Code. A restricted stock unit award is the grant of a right to receive a specified number of shares of common stock upon lapse of a specified forfeiture condition (such as completion of a specified period of service or achievement of certain specified performance objectives). If the service condition and/or specified performance objectives are not satisfied during the restriction period, the award will lapse without the issuance of the shares underlying such award.

 

Restricted stock units and deferred stock awards carry no voting or other rights associated with stock ownership until the shares underlying the award are delivered in settlement of the award. Unless otherwise determined by the Committee, a grantee will have the rights to receive dividend equivalents in respect of deferred stock and/or restricted stock units, which dividend equivalents will be deemed reinvested in additional shares of deferred stock or restricted stock units, as applicable, and which will remain subject to the same forfeiture conditions applicable to the deferred stock or restricted stock units to which such dividend equivalents relate.

 

Performance Units

 

The committee may grant performance units, which entitle a grantee to cash or shares conditioned upon the fulfillment of certain performance conditions and other restrictions as specified by the committee and reflected in the applicable award agreement. The initial value of a performance unit will be determined by the committee at the time of grant. The committee will determine the terms and conditions of such awards, including performance and other restrictions placed on these awards, which will be reflected in the applicable award agreement.

 

58
 

 

Performance Shares

 

The committee may grant performance shares, which entitle a grantee to a certain number of shares of common stock, conditioned upon the fulfillment of certain performance conditions and other restrictions as specified by the committee and reflected in the applicable award agreement. The committee will determine the terms and conditions of such awards, including performance and other restrictions placed on these awards, which will be reflected in the applicable award agreement.

 

Bonus Shares

 

The committee may grant fully vested shares of common stock as bonus shares in recognition of past performance or as an inducement to become an employee, non-employee consultant or director on such terms and conditions as specified in the applicable award agreement.

 

Dividend Equivalents

 

The committee is authorized to grant dividend equivalents, which provide a grantee the right to receive payment equal to the dividends paid on a specified number of shares of common stock. Dividend equivalents may be paid directly to grantees or may be deferred for later delivery under the Plan. No dividend equivalents may be granted with respect to options or SARs. If deferred such dividend equivalents may be credited with interest or may be deemed to be invested in shares of common stock or in other property. Any dividend equivalents granted in conjunction with any award that is subject to forfeiture conditions will remain subject to the same forfeiture conditions applicable to the award to which such dividend equivalents relate.

 

Other Stock-Based Awards

 

The Plan authorizes the committee to grant awards that are valued in whole or in part by reference to or otherwise based on the Company’s securities. The committee determines the terms and conditions of such awards, including whether awards are paid in shares or cash.

 

Merger, Consolidation or Similar Corporate Transaction

 

If there is a merger or consolidation of the Company with or into another corporation or a sale of substantially all of the Company’s stock, or, collectively, a Corporate Transaction, and the outstanding awards are not assumed by surviving company (or its parent company) or replaced with economically equivalent awards granted by the surviving company (or its parent company), the committee will cancel any outstanding awards that are not vested and non-forfeitable as of the consummation of such Corporate Transaction (unless the committee accelerates the vesting of any such awards) and with respect to any vested and non-forfeitable awards, the committee may either (i) allow all grantees to exercise options and SARs within a reasonable period prior to the consummation of the Corporate Transaction and cancel any outstanding options or SARs that remain unexercised upon consummation of the Corporate Transaction, or (ii) cancel any or all of such outstanding awards (including options and SARs) in exchange for a payment (in cash, or in securities or other property) in an amount equal to the amount that the grantee would have received (net of the exercise price with respect to any options or SARs) if the vested awards were settled or distributed or such vested options and SARs were exercised immediately prior to the consummation of the Corporate Transaction. If an exercise price of the option or SAR exceeds the fair market value of common stock and the option or SAR is not assumed or replaced by the surviving company (or its parent company), such options and SARs will be cancelled without any payment to the grantee.

 

59
 

 

Further Amendments to the Plan

 

The Plan may be amended, altered, suspended, discontinued or terminated by the Board without further stockholder approval, unless such approval of an amendment or alteration is required by law or regulation or under the rules of any stock exchange or automated quotation system on which the common stock is then listed or quoted. Thus, stockholder approval will not necessarily be required for amendments which might increase the cost of the Plan or broaden eligibility. Stockholder approval will not be deemed to be required under laws or regulations that condition favorable treatment of grantees on such approval, although the Board may, in its discretion, seek stockholder approval in any circumstance in which it deems such approval advisable.

 

The terms of any outstanding option or stock appreciation right may not be amended: (i) to reduce the exercise price of such option or stock appreciation right, or (ii) cancel any outstanding option or stock appreciation right in exchange for other options or stock appreciation rights with an exercise price that is less than the exercise price of the cancelled option or stock appreciation right or for any cash payment (or shares having a fair market value) in an amount that exceeds the excess of the fair market value of the shares underlying such cancelled option or stock appreciation right over the aggregate exercise price of such option or stock appreciation right or for any other award, or (iii) take any other action with respect to an option or stock appreciation right that would be treated as a repricing under the rules and regulations on the principal securities exchange on which the shares are traded, in each case without stockholder approval. The foregoing restrictions will not apply (i) unless the Company has a class of stock that is registered under Section 12 of the Exchange Act or (ii) to any adjustment allowed under the provisions of the Plan relating to adjustments for changes in capitalization, corporate transactions, or a liquidation or dissolution.

 

In addition, subject to the terms of the Plan, no amendment or termination of the Plan may materially and adversely affect the right of a grantee without the consent of the grantee under any award granted under the Plan.

 

Unless earlier terminated by the Board, the Plan will terminate when no shares remain reserved and available for issuance or, if earlier, on the tenth anniversary of the most recent effective date of the Plan.

 

Federal Income Tax Consequences

 

The following discussion summarizes the certain Federal income tax consequences of the Plan based on current provisions of the Code, which are subject to change. This summary is not intended to be exhaustive and does not address all matters which may be relevant to a particular grantee based on his or her specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Code Section 409A or golden parachute excise taxes under Code Section 4999), or other tax laws other than federal income tax law. The following is not intended or written to be used, and cannot be used, for the purposes of avoiding taxpayer penalties. Because individual circumstances may vary, the Company advises all grantees to consult their own tax advisors concerning the tax implications of awards granted under the Plan.

 

Options. A recipient of a stock option will not have taxable income upon the grant of the stock option. For stock options that are not incentive stock options, the grantee will recognize ordinary income upon exercise in an amount equal to the value of any cash received, plus the difference between the fair market value of the freely transferable and non-forfeitable shares received by the grantee on the date of exercise and the exercise price. The grantee’s tax basis in such shares will be the fair market value of such shares on the date the option is exercised. Any gain or loss recognized upon any later disposition of the shares generally will be a long-term or short-term capital gain or loss.

 

The acquisition of shares upon exercise of an incentive stock option will not result in any taxable income to the grantee, except, possibly, for purposes of the alternative minimum tax. The gain or loss recognized by the grantee on a later sale or other disposition of such shares will either be long-term capital gain or loss or ordinary income, depending upon whether the grantee holds the shares for the legally-required period (currently two years from the date of grant and one year from the date of exercise). If the shares are not held for the legally-required period, the grantee will recognize ordinary income equal to the lesser of (i) the difference between the fair market value of the shares on the date of exercise and the exercise price, or (ii) the difference between the sales price and the exercise price. If the grantee holds the shares for the legally required holding period, the grantee’s tax basis in such shares will be the exercise price paid for the shares.

 

60
 

 

Generally, a company can claim a federal income tax deduction equal to the amount recognized as ordinary income by a grantee in connection with the exercise of a stock option, but not relating to a grantee’s capital gains. Accordingly, the Company will not be entitled to any tax deduction with respect to an incentive stock option if the grantee holds the shares for the legally-required period.

 

Restricted Shares. Unless a grantee makes the election described below, a grant of restricted shares will not result in taxable income to the grantee or a deduction for the Company in the year of grant. The value of such restricted shares will be taxable to a grantee as ordinary income in the year in which the restrictions lapse. Alternatively, a grantee may elect to treat as income in the year of grant the fair market value of the restricted stock on the date of grant, provided the grantee makes the election within 30 days after the date of such grant. If such an election were made, the grantee would not be allowed to deduct at a later date the amount included as taxable income if the grantee should forfeit the shares of restricted stock. The amount of ordinary income recognized by a grantee is deductible by the Company in the year such income is recognized by the grantee, provided such amount constitutes reasonable compensation to the grantee. If the election described above is not made, then prior to the lapse of restrictions, dividends paid on the shares subject to such restrictions will be taxable to the grantee as additional compensation in the year received, and the Company will be allowed a corresponding deduction.

 

Other Awards. Generally, when a grantee receives payment in settlement of any other award granted under the Plan, the amount of cash and the fair market value of the shares received will be ordinary income to such grantee, and the Company will be allowed a corresponding deduction for federal income tax purposes.

 

Generally, when a grantee receives payment with respect to dividend equivalents, the amount of cash and the fair market value of any shares or other property received will be ordinary income to such grantee. The Company will be entitled to a federal income tax deduction in an amount equal to the amount the grantee includes in income.

 

If the grantee is an employee or former employee, the amount the grantee recognizes as ordinary income in connection with an award (other than an incentive stock option) is subject to tax withholding.

 

Limitations on Deductions. Code Section 162(m) as amended by the Tax Cuts and Jobs Act, limits the Federal income tax deductibility of compensation paid to any covered employee to $1 million per fiscal year. A “covered employee” is any individual who (i) is the Company’s principal executive officer or principal financial officer at any time during the then current fiscal year, (ii) is one of the three highest paid named executive officers (other than the principal executive officer or principal financial officer) during the then current fiscal year or (iii) was a covered employee in any prior fiscal year beginning after December 31, 2016.

 

Deferred Compensation. Under Section 409A of the Code. Any award that is deemed to be a deferral arrangement (excluding certain exempted short-term deferrals) will be subject to Code Section 409A. Generally, Code Section 409A imposes accelerated inclusion in income and tax penalties on the recipient of deferred compensation that does not satisfy the requirements of Code Section 409A. Options and restricted shares granted under the Amended and Restated Omnibus Plan will typically be exempt from Code Section 409A. Other awards may result in the deferral of compensation. Awards under the Plan that may result in the deferral of compensation are intended to be structured to meet applicable requirements under Code Section 409A. Certain grantee elections and the timing of distributions relating to such awards must also meet requirements under Code Section 409A in order for income taxation to be deferred and tax penalties avoided by the grantee upon vesting of the award.

 

Indemnification Agreements

 

We have entered into indemnification agreements with each of our directors and executive officers. For more information, see “Item 13. Certain Relationships and Related Transactions, and Director Independence - Indemnification Agreements.”

 

61
 

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth information regarding the beneficial ownership of our common stock as of April 14, 2023, by:

 

  ● each person known to be the beneficial owner of more than 5% of our outstanding common stock;
  ● each of our executive officers and directors; and
  ● all of our executive officers and directors as a group.

 

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60 days. Shares subject to options that are currently exercisable or exercisable within 60 days are considered outstanding and beneficially owned by the person holding such options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the Company believes that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of the directors and executive officers of the Company is c/o Bright Green Corporation., 1033 George Hanosh Boulevard Grants, NM 87020.

 

62
 

 

Name and address of Beneficial Owner 

Shares Beneficially

Owned(1)

  

Percentage of Shares Beneficially

Owned(1)

 
5% Stockholders:          
E. Mailloux Enterprises, Inc. and related parties(2)   20,200,000    11.66%
           
Named Executive Officers and Directors          
Seamus McAuley, CEO   -    * 
Terry Rafih, Executive Chairman   24,842,500    14.25%
Saleem Elmasri, CFO   500,000    * 
Lynn Stockwell, Director   69,111,470    39.63%
Dr. Alfie Morgan, Director   5,000    *%
Dean Valore, Director   5,000    *%
Robert Arnone, Director   105,000(3)   *%     
Directors and Executive Officers as a Group (7 persons)(4)   100,273,970(4)   57.5%(4)

 

* Less than 1%.

 

(1) Based on 174,423,810 shares of common stock outstanding as of April 14, 2023. Any shares of common stock not outstanding which are issuable upon the exercise or conversion of other securities held by a person within the next 60 days are considered to be outstanding when computing such person’s ownership percentage of common stock but are not when computing anyone else’s ownership percentage.

 

(2) This information is solely based on the Company’s review of filings made on Schedule 13G with the SEC, relating to beneficial ownership of 20,200,000 shares of common stock as of June 3, 2022. The address of E. Mailloux Enterprises, Inc. (“MEI”) is 3129 Marentette Ave., Unit 2 Windsor ON N8X 4G1, Canada. Ernie Mailloux has voting and dispositive power with respect to the shares of common stock held by MEI. Consists of 12,700,000 shares of common stock held by MEI, 7,500,000 shares of common stock held by Cheryl Mailloux, wife of Mr. Mailloux. Mr. Mailloux may be deemed to have voting and dispositive power over shares of common stock held by Mrs. Mailloux.

 

(3) Includes 100,000 shares held by Aerigo Solutions Inc. Mr. Arnone has sole voting and dispositive power over the shares of common stock held by Aerigo Solutions Inc.

 

(4) Includes 100,000 shares beneficially owned by Douglas Bates, who resigned as Chief Financial Officer in March 2022 and 5,605,000 shares beneficially owned by Edward Robinson, who resigned as Chief Executive Officer in June 2022 and as a director on July 1, 2022.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

The following includes a summary of transactions since January 1, 2022 to which we have been a party, in which the amount involved in the transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive Compensation.”

 

June 2022 Shareholder Line of Credit

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Company’s Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The June Note provides that the Company may borrow up to $5.0 million, including an initial loan in the amount of $3.0 million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Lender has committed to fund to the Company $3.0 million under the June Note by June 30, 2022. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2.0 million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds form Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum.

 

63
 

 

On November 14, 2022, the Company and LDS Capital LLC amended the June Note to increase the line of credit from $5.0 million to $15.0 million.

 

As of December 31, 2022, the Company had drawn down approximately $3.6 million under this June Note, and thus has a drawing capacity of $11.3 million when taking into consideration accrued interest.

 

Arrangement with Alterola

 

See “Item 1. Business – Arrangement with Alterola.”

 

Indemnification Agreements

 

We have entered into agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person’s status as a member of our board of directors to the maximum extent allowed under Delaware law.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Company pursuant to provisions of the State of Delaware, the Company has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in that Act and is, therefore, unenforceable.

 

Policies and Procedures for Transactions with Related Parties

 

The Company has adopted a related party transaction policy that set forth its procedures for the identification, review, consideration and approval or ratification of related person transactions. A related person includes directors, executive officers, beneficial owners of 5% or more of any class of the Company’s voting securities, immediate family members of any of the foregoing persons, and any entities in which any of the foregoing is an executive officer or is an owner of 5% or more ownership interest. Under the related party transaction policy, if a transaction involving an amount in excess of $120,000 has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, information regarding the related person transaction must be reviewed and approved by the Company’s audit committee.

In considering related person transactions, the Company’s audit committee will take into account the relevant available facts and circumstances including, but not limited to:

 

● the related person’s interest in the related person transaction;

● the approximate dollar value of the amount involved in the related person transaction;

● the approximate dollar value of the amount of the related person’s interest in the transaction without regard to the amount of any profit or loss;

● whether the transaction was undertaken in the ordinary course of business of the Company;

 

64
 

 

● whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to the Company than terms that could have been reached with an unrelated third party;

● the purpose of, and the potential benefits to the Company of, the transaction; and

● any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.

 

The related party transaction policy requires that, in determining whether to approve, ratify or reject a related person transaction, the audit committee must review all relevant information available to it about such transaction, and that it may approve or ratify the related person transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, the best interests of the Company.

 

Item 14. Principal Accounting Fees and Services.

 

The Company’s independent registered public accounting firm for the fiscal years ended December 31, 2022 and 2021 is SRCO, C.P.A., Professional Corporation (“SRCO”), Amherst, NY, 6722.

 

The following table represents aggregate fees billed to the Company for the fiscal years ended December 31, 2022 and 2021 by SRCO.

 

(US Dollars)  2022   2021 
Audit fees  $76,000   $55,000 
Audit-related fees  $23,000   $0 
Tax fees  $0   $0 
All other fees  $0   $0 
Total  $99,000   $55,000 

 

Audit fees for the fiscal years ended December 31, 2022 and 2021 rendered by SRCO relate to professional services rendered for the audits of our financial statements, quarterly reviews, and review of documents filed with the SEC.

 

Pre-Approval Policies and Procedures

 

The audit committee has adopted a policy that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The policy generally provides that we will not engage SRCO to render any audit, audit-related, tax or permissible non-audit service unless the service is explicitly approved by the audit committee. Any service to be provided by SRCO requires specific pre-approval by the audit committee or by a designated member of the audit committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For pre-approval the audit committee will consider whether such services are consistent with the SEC’s rules on auditor independence.

 

65
 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(1) For a list of the financial statements included herein, see Index to the Financial Statements on page F-1 of this Annual Report, incorporated into this Item by reference.

 

(2) Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the financial statements or the notes thereto.

 

(3) Exhibits:

 

Exhibit   Description
2.1   Agreement and Plan of Merger between Bright Green Corporation and Bright Green Grown Innovation LLC dated May 28, 2019, filed as Exhibit 2.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
2.2   Agreement and Plan of Merger between Bright Green Corporation and Grants Greenhouse Growers Inc. dated as of October 30, 2020, filed as Exhibit 2.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
2.3   Agreement and Plan of Merger between Bright Green Corporation and Naseeb Inc. dated as of November 10, 2020, filed as Exhibit 2.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.1   Certificate of Incorporation of the registrant, filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.2   Amended and Restated Certificate of Incorporation of the registrant, filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022.
3.3   Bylaws of the registrant, filed as Exhibit 3.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
3.4   Amended and Restated Bylaws of the registrant, filed as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022.
3.5   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Bright Green Corporation, filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 16, 2022.
4.1   Form of Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 13, 2022.
4.2*   Description of Registrant’s Securities
10.1   Memorandum of Agreement between Bright Green Corporation and the Department of Justice, Drug Enforcement 7 Administration, filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
10.2   Line of Credit Note, dated June 4, 2022, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on June 7, 2022
10.3   Executive Employment Agreement with Edward Robinson, filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
10.4   Consulting Agreement with Saleem Elmasri, filed as Exhibit 10.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
10.5#   Securities Purchase Agreement dated September 7, 2022, by and between the Company and the purchasers thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022
10.6   Registration Rights Agreement dated September 12, 2022, by and between the Company and the purchasers thereto, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022
10.7   Placement Agent Agreement dated September 12, 2022 by and between the Company and EF Hutton, division of Benchmark Investments, LLC, filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on September 13, 2022

 

66
 

 

10.8¥   Executive Employment Agreement, dated September 22, 2022, by and between Bright Green Corporation. and Terry Rafih filed, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 28, 2022.
10.9   Secondary Stock Purchase Agreement and Release dated October 3, 2022, by and among Bright Green Corporation, Alterola Biotech, Inc. and the Sellers (as defined therein), filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2022.
10.10   Amendment and Restated Line of Credit Note, dated November 14, 2022, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 14, 2022.
10.11¥   Bright Green Corporation 2022 Omnibus Equity Compensation Plan, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 16, 2022.
10.12¥   Executive Employment Agreement, dated as of February 9, 2023, by and between Bright Green Corporation. and Seamus McAuley, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 15, 2023.
21.1   List of subsidiaries of the registrant, filed as Exhibit 21.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on May 4, 2022
23.1*   Consent of SRCO, C.P.A., Professional Corporation
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

**Furnished herewith.

#Certain schedules and exhibits have been omitted pursuant to Item 601(A)(5) of Regulation S-K. The Company will furnish supplementally copies of omitted schedules and exhibits to the SEC or its staff upon its request.

¥ Indicates a management contract or compensatory plan, contract or arrangement.

 

 

 

Item 16. Form 10-K Summary

 

None.

 

67
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BRIGHT GREEN CORPORATION
     
Date: April 17, 2023    
                               
  By: /s/ Seamus McAuley
  Name: Seamus McAuley
  Title: Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

Name   Title   Date
         

/s/ Seamus McAuley

   Chief Executive Officer,   April 17, 2023
Seamus McAuley, Chief Executive Officer,   (Principal Executive Officer)    
         
/s/ Saleem Elmasri   Chief Financial Officer   April 17, 2023
Saleem Elmasri, Chief Financial Officer   (Principal Financial Officer)    
         
/s/ Terry Rafih   Executive Chairman   April 17, 2023
Terry Rafih, Executive Chairman        
         
/s/ Alfie Morgan   Director   April 17, 2023
Dr. Alfie Morgan, Director        
         
/s/ Lynn Stockwell   Director   April 17, 2023
Lynn Stockwell, Director        
         
/s/ Dean Valore   Director   April 17, 2023
Dean Valore, Director        
         
/s/ Robert Arnone   Director   April 17, 2023
Robert Arnone, Director        

 

68
 

 

INDEX TO FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm F-2
Balance Sheets as of December 31, 2022 and 2021 F-3
Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021 F-4
Statements of Changes in Stockholders’ Equity for the years ended December 31, 2022 and 2021 F-5
Statements of Cash Flows for the years ended December 31, 2022 and 2021 F-6
Notes to Financial Statements F-7

 

F-1

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of Bright Green Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Bright Green Corporation (the “Company”) as of December 31, 2022 and 2021 and the related statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2022 and 2021 and the results of its operations and its cash flows for the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Material Uncertainty Related to Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to this matter are also described in Note 2. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the United States Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

We have served as the Company’s auditor since 2021

Amherst, NY

April 17, 2023

/s/ SRCO, C.P.A., Professional Corporation

 

SRCO, C.P.A., Professional Corporation (6722)

CERTIFIED PUBLIC ACCOUNTANTS

 

F-2

 

 

BRIGHT GREEN CORPORATION

Balance Sheets

As at December 31, 2022 and 2021

(Expressed in United States Dollars)

 

   December 31, 2022   December 31, 2021 
ASSETS        
Current assets          
Cash  $414,574   $1,282,565 
Prepaid expenses and other assets   77,847    168,226 
Total current assets   492,421    1,450,791 
           
Deposits (Note 5 and 10)   1,157,587    - 
Equity method investment (Note 6)   3,990,960    - 
Property, plant, and equipment (Note 8)   17,146,325    7,328,764 
Intangible assets (Note 9)   1,000    1,000 
           
Total assets  $22,788,293   $8,780,555 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $5,033,831   $149,935 
Accrued liabilities (Note 14)   447,325    18,027 
Due to others (Note 6)   1,650,000    - 
Due to related party (Note 14)   392,194    - 
Total current liabilities   7,523,350    167,962 
           
Long-term liabilities          
Due to related party (Note 14)   -    392,194 
Related party line of credit note (Note 11)   3,686,107    - 
Total long-term liabilities   3,686,107    392,194 
           
Total liabilities   11,209,457    560,156 
           
STOCKHOLDERS’ EQUITY          
Common stock; $.0001 par value; 500,000,000 stock authorized; 173,304,800 and 157,544,500 stock issued and outstanding at December 31, 2022 and December 31, 2021, respectively (Note 12)   17,329    15,754 
           
Additional paid-in capital (Note 12)   45,637,328    14,618,389 
Accumulated deficit   (34,075,821)   (6,413,744)
Total stockholders’ equity   11,578,836    8,220,399 
           
Total liabilities and stockholders’ equity  $22,788,293   $8,780,555 
Going Concern (Note 2)          
Commitments (Note 10)          
Contingencies (Note 15)          
Subsequent events (Note 16)          

 

The accompanying notes are an integral part of the financial statements 

 

F-3

 

 

BRIGHT GREEN CORPORATION

Statements of Operations and Comprehensive Loss

For the Years Ended December 31, 2022 and 2021

(Expressed in United States Dollars)

 

   2022   2021 
   Years Ended 
   2022   2021 
         
Revenue  $-   $- 
           
Expenses          
           
General and administrative expenses   26,609,241    1,738,716 
Depreciation   704,681    751,783 
Total operating expenses   27,313,922    2,490,499 
           
Loss from Operations   (27,313,922)   (2,490,499)
           
Other Expense          
Change in Fair Value of Voting Agreement Derivative   213,000    - 
Total Other Expense   213,000    - 
           
Loss before income taxes and equity in net losses of affiliate   (27,526,922)   (2,490,499)
           
Income tax expense   -    - 
Loss before equity in net losses of affiliate  $(27,526,922)  $(2,490,499)
           
Equity in net losses of affiliate   (135,155)   - 
Net loss and comprehensive loss   (27,662,077)  $(2,490,499)
           
Weighted average common shares outstanding - basic and diluted   162,058,082    156,800,164 
           
Net loss per common share - basic and diluted  $(0.17)  $(0.02)

 

The accompanying notes are an integral part of the financial statements 

 

F-4

 

 

BRIGHT GREEN CORPORATION

Statements of Changes in Stockholders’ Equity

For the Years Ended December 31, 2022 and 2021

(Expressed in United States Dollars)

 

 

   Shares   Amount   issued   capital   deficit   equity 
   Common Stock   Common Stock to be   Additional paid-in   Accumulated   Total 
   Shares   Amount   issued   capital   deficit   equity 
                         
Balance at December 31, 2020   156,046,000   $15,605   $138,000   $10,990,538   $(3,923,245)  $7,220,898 
                               
Common stock issued for services (Note 12)   125,000    12    -    359,988    -    360,000 
Common stock issued for cash (Note 12)   1,373,500    137    (138,000)   3,267,863    -    3,130,000 
Net loss   -    -    -    -    (2,490,499)   (2,490,499)
                               
Balance, December 31, 2021   157,544,500   $15,754   $-   $14,618,389   $(6,413,744)  $8,220,399 
                               
Common stock issued for cash (Note 12)   312,500    31    -    3,049,969    -    3,050,000 
Common stock and warrants issued for cash in private placement, net of issuance costs of $863,267 (Note 12)   9,523,810    952    -    9,135,781    -    9,136,733 
Common stock issued for services (Note 12)   6,036,990    603    -    18,850,629    -    18,851,232 
Common stock cancelled that was issued for services (Note 12)   (113,000)   (11)   -    (17,440)   -    (17,451)
Net loss   -    -    -    -    

(27,662,077

)   

(27,662,077

)
                               
Balance, December 31, 2022   173,304,800   $17,329   $-   $45,637,328   $(34,075,821)  $

11,578,836

 

 

The accompanying notes are an integral part of the financial statements 

 

F-5

 

 

BRIGHT GREEN CORPORATION

Statements of Cash Flows

For the Years Ended December 31, 2022 and 2021

(Expressed in United States Dollars)

 

 

   2022   2021 
   Years Ended 
   2022   2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
           
Net loss  $(27,662,077)  $(2,490,499)
           
Adjustments to reconcile net cash used in operating activities:          
Change in fair value of voting agreement derivative   213,000    - 
Equity in net losses of affiliate   135,155    - 
Depreciation   704,681    751,783 
Stock-based compensation   18,833,781    360,000 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   90,379    (149,153)
Accounts payable   4,883,896    (30,403)
Accrued liabilities   429,298    (98,303)
Accrued interest   106,117    - 
Net cash used in operating activities   (2,265,770)   (1,656,575)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
    -    - 
Deposits   (1,157,587)   - 
Purchase of equity method investment   (2,689,115)   - 
Purchase of property, plant, and equipment   (10,522,242)   (302,717)
Net cash used in investing activities   (14,368,944)   (302,717)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
    -    - 
Proceeds from related party   -    122,514 
Payments to related party   -    (112,920)
Proceeds from related party line of credit   5,191,057    - 
Payments to related party line of credit   (1,611,067)   - 
Proceeds from issuance of common stock   3,050,000    3,130,000 
Proceeds from issuance of common stock and warrants,          
issued in private placement, net of issuance costs   9,136,733    - 
Net cash provided by financing activities   15,766,723    3,139,594 
           
NET (DECREASE) INCREASE IN CASH   (867,991)   1,180,302 
CASH, BEGINNING OF YEAR   1,282,565    102,263 
CASH, END OF YEAR  $414,574   $1,282,565 
           
CASH PAID FOR          
Interest  $-   $- 
Taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES          
Due to others for purchase of Common stock in Alterola Biotech, Inc.  $1,650,000   $- 

 

The accompanying notes are an integral part of the financial statements 

 

F-6

 

 

BRIGHT GREEN CORPORATION

Notes to the Financial Statements

For the Years Ended December 31, 2022 and 2021

(Expressed in United States Dollars)

 

1. Description of Business and Organization

 

Bright Green Corporation (Company) was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company is located in Grants, New Mexico. The Company holds the land, greenhouse and patents required in the growth, production, and research of medicinal plants.

 

On May 28, 2019, the Company entered into a merger agreement with Bright Green Grow Innovation, LLC (“BGGI”) (Note 7).

 

On October 30, 2020, Grants Greenhouse Growers, Inc. (GGGI), a New Mexico corporation, merged with the Company (Note 7).

 

On November 10, 2020, Naseeb, Inc. (Naseeb), a New Mexico corporation, merged with the Company (Note 7).

 

On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

 

On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

 

The Company is a start-up company at December 31, 2022 and has no revenue.

 

The Company’s operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company’s operations and ability to finance its operations.

 

2. Going Concern and Basis of Presentation

 

The financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). US GAAP contemplates continuation of the Company as a going concern. For the fiscal years ended December 31, 2022 and 2021, the Company had no revenues from product sales and incurred a net loss of $27,662,077 and $2,490,499, respectively. Net cash used in operations for years ended 2022 and 2021 was $2,265,770 and $1,656,575, respectively. As of December 31, 2022, the Company had a working capital deficit and accumulated deficit of $7,030,929 and $34,075,821, respectively.

 

F-7

 

 

The Company is in its initial stages to start building facilities to grow, research and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the financial statements were authorized to be issued. The Company’s continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

 

In 2022, the Company raised $12,186,733 through common stock issuances. The Company also secured a $15,000,000 line of credit from a related party, has drawn $5,191,057 and paid down $1,611,067, leaving available $11.3 million to draw from that credit facility (Note 11). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

 

In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to, general economic conditions, competition, and regulatory matters. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates.

 

These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Capital Program announced on February 1, 2023 (Note 16). However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects, or that the Company will be able to successfully execute its operating plan.

 

The financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be cancelled with minimal fees, non-cancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

This disclosure is intended to inform users of the financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

 

F-8

 

 

3. Summary of Significant Accounting Policies

 

  A. Basis of Measurement

 

The financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is re-tired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

Building and improvement - declining balance method   10 year life
Furniture and fixtures - straight-line method   3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 7) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

F-9

 

 

3. Summary of Significant Accounting Policies (continued)

 

  E. Fair Value of Financial Instruments

  

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  ● Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;
     
  ●  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  ●  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of our cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2022 and 2021 due to their short-term nature.

 

The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):

 

   December 31, 2022 
Balance on December 31, 2021  $- 
Voting Agreement derivative asset   213,000 
Change in fair value   (213,000)
Balance on December 31, 2022  $- 

 

  F. Investments under the equity method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $78,193 and $68,571 for the years ended December 31, 2022 and 2021, respectively.

 

F-10

 

 

3. Summary of Significant Accounting Policies (continued)

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

F-11

 

 

3. Summary of Significant Accounting Policies (continued)

 

  K. Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of

 

F-12

 

 

3. Summary of Significant Accounting Policies (continued)

 

  M. Warrants (continued)

 

the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

F-13

 

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  2) Leases (continued)

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).

 

4. Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $187,821 in excess of the FDIC insured limit at December 31, 2022.

 

5. Deposits

 

Deposits are comprised of one down payment for a construction of equipment contract for which the Company has not yet taken title and one down payment for a construction contract for which the work has not started (Note 10).

 

F-14

 

 

6. Equity Method Investment in Alterola

 

On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

 

The Secondary SPA provides that, as of the date thereof, the authorized shares of Alterola consist of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares are issued and outstanding. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to Bright Green for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. As of December 31, 2022, the Company has a liability to the Sellers of $1,650,000 due on April 28, 2023. The liability is not interest bearing and not secured. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement.

 

The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola.

 

Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement. The agreement will terminate upon the earlier of eight months from the date of the agreement or written notice by Bright Green.

 

Concurrently with the execution of the Voting Agreement, each Stockholder agrees to deliver to Bright Green an Irrevocable Proxy (“Proxy”). The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock.

 

The Company accounted for the transaction under the equity method and recoded the carrying value of the Company’s investment in Alterola common shares at cost, including transaction costs incurred to obtain the equity method investment of $339,115 in equity method investment in the balance sheet.

 

The following table provides summarized balance sheet information for Alterola as of December 31, 2022:

 

Schedule of Financial Statement Information

   December 31, 2022   December 31, 2021 
Current Assets  $192,011   $90,705 
Non-Current Assets   12,018,147    12,000,000 
Current Liabilities   1,822,696    1,217,811 
Non-Current Liabilities   151,255    169,038 
Equity   10,236,237    10,703,856 

 

The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022:

 

   December 31, 2022   

December 31, 2021

  
Total revenues  $-    $ -  
Net loss  $4,980,510    $ 3,460,815  

 

Our ownership percentage of 25% of Alterola allows us to have significant influence over the operations and decision making at Alterola. Accordingly, the investment is accounted for as an equity method investment. Our share of net loss from our investment in Alterola was $135,155 for the period from October 3, 2022 through the year ended December 31, 2022.

 

On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola (Note 16).

 

Voting Agreement

 

The Voting Agreement was initially measured at fair value utilizing the Black-Scholes-option-pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

 

As of December 31, 2022, the value of the option was impaired to nil to reflect the likelihood that the option would be exercised according to the terms set forth and prior to expiry.

 

7. Merger Transactions

 

  A. Bright Green Grow Innovations, LLC Merger

 

On May 28, 2019, the Company entered into a merger agreement with BGGI. Pursuant to the merger agreement, BGGI transferred to the Company two parcels of land and a greenhouse building having a total net carrying value of $9,128,851 in exchange for shares of the Company (Note 8). The land transfer consisted of a 70-acre lot with a greenhouse at 1033 George Hanosh Blvd., Grants, New Mexico 87020 and a 40-acre lot in the City of Grants, New Mexico. The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions

 

F-15

 

 

7. Merger Transactions (continued)

 

  A. Bright Green Grow Innovations, LLC Merger (continued)

 

of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical carrying values of BGGI.

 

  B. Grants Greenhouse Growers, Inc. Merger

 

On October 30, 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. (“GGG”) (the “GGG Merger Agreement”). Pursuant to the GGG Merger Agreement, GGG was merged into the Company in exchange for 1,000,000 shares of the Company. GGG had no assets or liabilities, other than the following options agreements:

 

  - A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
     
  - A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

 

The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. The asset acquisition was accounted for at the fair value of the options agreement of $103,837 determined using the Black Scholes Model and management had assessed the value of these options to be impaired due to uncertainty surrounding their recoverability.

 

  C. Naseeb, Inc. Merger

 

On November 10, 2020, the Company entered into a merger agreement with Naseeb, Inc. (“Naseeb”) and the sole shareholder of Naseeb, who is also a shareholder and Chairman of the Company. Pursuant to the Naseeb merger agreement, Naseeb was merged into the Company in exchange for 10,000,000 shares of the Company. Naseeb

 

F-16

 

 

7. Merger Transactions (continued)

 

  C. Naseeb, Inc. Merger (continued)

 

transferred to the Company their assistance that was used by the Company towards obtaining the following licenses and patents to the Company:

 

  - New Mexico Hemp License: Industrial Hemp is an agricultural plant that uses all the byproducts of the plant such as seeds and twigs in the production of hemp seed, hemp fiber, and other eco-friendly products.
     
  - New Mexico Board of Pharmacy Schedule 1 Bulk Manufacturers License: Securing the license was required as part of the application and consideration for a federal license. Additionally, being licensed as a Schedule 1 Bulk Manufacturer allows the Company to develop and distribute Schedule 1 drugs; an authorization precedent to the ability to grow, extract and distribute other cannabidiols, such as CBG and CBN. Moreover, with this license, the Company is exempt from the restrictions generally applicable to the cannabis industry, such as plant count and per plant taxes.
     
  - Federal Medical Marijuana License: The Company has a formal agreement with the Drug Enforcement Administration for the construction and operation of a federally licensed agricultural center to grow and distribute marijuana, or its chemical constituents, supplying legitimate researchers in the United States.
     
  - Patents: The patents held by the Company provide innovative medical therapies to a wide range of conditions. These patents can be sold, licensed, or directly marketed as clinical trials are conducted and approved by the FDA.

 

The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical cost of Naseeb of $1,000 (Note 9).

 

8. Property, Plant, and Equipment

 

The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

 

F-17

 

 

8. Property, Plant, and Equipment (continued)

 

Property, plant, and equipment at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Furniture and fixtures  $88,690    - 
Land   260,000    260,000 
Construction in progress   10,736,269    302,717 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   19,968,810    9,446,568 
Accumulated depreciation   (2,822,485)   (2,117,804)
Net property, plant, and equipment  $17,146,325    7,328,764 

 

The amount of interest costs capitalized and included in construction in progress totaled $106,117 and $nil at December 31, 2022 and 2021, respectively (Note 11).

 

9. Intangible Assets

 

Intangible assets at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Licenses (Note 7)  $1,000    1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000    1,000 

 

10. Commitments

 

During 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022 (Note 5). The remaining balance of $1,109,642 is due upon delivery. The Company also entered into and paid in full a construction contract for $47,944 as of December 31, 2022 (Note 5). The construction to be performed under this contract will occur in 2023.

 

11.Related Party Line of Credit Note

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The Note provides that the Company may borrow up to $5.0 million, including an initial loan in the amount of $3.0 million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2.0 million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds form Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest

 

F-18

 

 

11. Related Party Line of Credit Note (continued)

 

on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10 million.

 

As of December 31, 2022, the Lender has funded the Company $5,191,057 with the Company paying back $1,611,067 of those funds. As of December 31, 2022, there was accrued interest of $106,117. The funds have been used for the construction in progress and interest expense of $106,117 has been capitalized (Note 8).

 

The note was drawn on for $392,194 to pay off the Due to Related Party and was paid down $880,000, subsequent to year end (Note 16). On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company (Note 16).

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note, leaving available $11.5 million to draw from that credit facility.

 

12.Stockholders’ Equity

 

The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of December 31, 2022 and 2021, there were 173,304,800 and 157,544,500, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

 

During the twelve months ended December 31, 2022, the Company issued the following:

 

  - 12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;
     
  - 500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of (the “$4.00 Round”), to the Chief Financial Officer of the Company, in April 2022;
     
  - 5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share, were cancelled in April 2022;
     
  - 300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022;
     
  - 1,574,490 shares of common stock for services rendered in connection with the Direct Listing to the Company’s advisor, or its permitted designees, contemporaneous with the Direct Listing and consistent with the direct listing price of $8.00 per share in June 2022;
     
  - 108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were cancelled in June 2022;

 

F-19

 

 

12. Stockholders’ Equity (continued)

 

  - 9,523,810 shares of Common Stock and warrants to purchase up to an aggregate of 9,523,810 shares of Common Stock, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and
     
  -

3,962,500 shares of common stock for services rendered, with (i) 3,000,000 shares issued at a fair value of $1.25 per share, (ii) 87,500 shares at a fair value of $1.08 per share, and (iii) 875,000 shares at a fair value of $0.4695 per share, to the former Chief Executive Officer of the Company, in December 2022.

 

On September 7, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with investors. The combined purchase price of one Share and accompanying Warrant was $1.05. Subject to certain ownership limitations, the Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock (the “Exercise Price”), subject to adjustments as provided under the terms of the Warrants. The Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction related fees and expenses payable by the Company. On February 1, 2023, 200,000 of the Warrants were redeemed for $210,000 (Note 16).

 

In connection with the September Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September Private Placement went effective on September 21, 2022.

 

Transaction costs incurred related to the September Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

 

September Warrants

 

The measurement of fair value was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $1.65, exercise price of $1.05, term of five years, volatility of 174.3%, risk-free rate of 3.41%, probability of dilutive issuance of 15%, estimated timing of dilutive issuance of four and a half months, and expected time to conversion of five years). The grant date fair value of these Warrants were estimated to be $4,489,662 on September 12, 2022 of the gross proceeds and is reflected within additional paid-in capital as of December 31, 2022.

 

During the twelve months ended December 31, 2021, the Company issued the following:

 

  - 1,019,000 shares of common stock at a purchase price of $2.00 per share, for gross cash proceed of $2,038,000 to thirty accredited investors between January 2021 and October 2021, with (i) 184,000 shares issued in January 2021, which includes the 69,000 shares issued for cash proceeds of $138,000 received as of December 31, 2020, (ii) 100,000 shares issued in March 2021, (iii) 335,000 shares issued in May 2021, (iv) 250,000 shares issued in June 2021, and (v) 100,000 shares issued in September 2021 and 50,000 shares issued in October 2021 (the “$2.00 Round”);

 

F-20

 

 

12. Stockholders’ Equity (continued)

 

  - 188,000 shares of common stock at a purchase price of $3.00 per share, for gross cash proceeds of $564,000 to one hundred eighty-eight accredited investors in September and October 2021 with (i) 154,000 shares in September 2021, and (ii) 34,000 shares issued in October 2021 (the “$3.00 Round”);
     
  - 166,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $666,000, to 12 accredited investors in October and December 2021, with (i) 29,000 shares in October 2021, and (ii) 137,500 shares issued in December 2021 (the “$4.00 Round”);
     
  - 25,000 shares of common stock for services rendered, at a fair value of $2.00 per share determined using the per share purchase price of the $2.00 Round, to five consultants, with (i) 10,000 shares issued in January 2021 and (ii) 15,000 shares issued in May 2021;
     
  - 40,000 shares of common stock for services rendered, at a fair value of $2.00 per share determined using the per share purchase price of (the “$2.00 Round”), to three directors of the Company, with (i) 10,000 shares issued in January 2021 and (ii) 30,000 shares issued in February 2021;
     
  - 10,000 shares of common stock for services rendered, at fair value at $3.00 per share determined using the per share purchase price of (the “$3.00 Round”), to two directors of the Company, in September 2021; and
     
  - 50,000 shares of common stock for services rendered, at fair value at $4.00 per share determined using the per share purchase price of (the “$4.00 Round”), to three consultants in November 2021.

  

13. Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2022 and 2021, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.

 

F-21

 

 

13. Income Taxes (continued)

 

The current and deferred income tax expenses for the years ended December 31, 2022 and 2021, were $nil. The provision for income taxes differs from that computed at a combined corporate tax rate of approximately 25.8% (2021 – 25.8%) as follows:

 

   2022   2021 
         
Loss before income taxes  $(27,662,077)  $(2,490,499)
           
The (benefit) provision for income taxes for 2022 and 2021 consists of the following:          
           
Current:          
Federal   -    - 
State   -    - 
Total current (benefit) provision   -    - 
           
Deferred:          
Federal   (5,727,839)   (515,114)
State   (1,309,220)   (117,740)
Total current (benefit) provision  $(7,037,059)  $(632,854)
Valuation allowance   7,037,059    632,854 
Total (benefit) provision  $-   $- 

 

The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

 

   2022   2021 
Other   728,201    546,393 
Net operating loss carry over   7,294,146    438,894 
Total deferred tax assets   8,022,347    985,287 
Less: valuation allowance   (8,022,347)   (985,287)
Deferred tax assets, net of valuation allowance  $-   $- 

 

As of December 31, 2022 and 2021, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2022 and 2021, the Company has approximately $28,271,882 and $1,701,141 respectively, of Federal net operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely and the state loss carryforward expires in 2039. The benefit from the non-capital loss carry-forward balance has not been recorded in the financial statements.

 

The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense.

 

14. Related Party Transactions

 

Other than the transactions disclosed elsewhere in the financial statements, the following are the other significant related party transactions and balances:

 

At December 31, 2022 and 2021, the due to related party balance totaled $392,194 and $392,194, respectively. The balance represents advances from the majority shareholder for payment of Company expenses. The amount is unsecured, non-interest bearing with no terms of repayment. The shareholder has agreed in writing that no payment will be required by the Company to the lender prior to January 31, 2023. On February 1, 2023, this loan was paid in full with a draw on the line of credit (Note 16).

 

F-22

 

 

14. Related Party Transactions (continued)

 

Included in common stock issued for services during the year ended December 31, 2022, were 3,962,500 shares of common stock issued to the former Chief Executive Officer of the Company (Note 12).

 

Included in common stock issued for services during the year ended December 31, 2022, were 500,000 shares of common stock issued to the Chief Financial Officer of the Company (Note 12).

 

Included in common stock issued for services during the year ended December 31, 2021, were 50,000 shares of common stock issued to the five directors of the Company (Note 12).

 

At December 31, 2022, $400,000 was due to the Company’s former interim Chief Executive Officer, who also is a shareholder. The amount, which includes $300,000 in accrued bonus is included in accrued liabilities in the Balance Sheet. The accrued bonus is expected to be paid in the first quarter of 2024 and is subject to Board of Director approvals.

 

At December 31, 2022, $65,856 was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.

 

At December 31, 2022, $60,000 was due to the Company’s former Chief Executive Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.

 

At December 31, 2022, the outstanding balance on the line of credit of $3,686,107 was due to a Lender, whose managing member is a member of the Board (Note 11). The amount is included in the related party line of credit note in the Balance Sheet.

 

The related party line of credit note was drawn on to pay in full, the related party loan balance of $392,194, and was paid down $880,000 subsequent to year end (Note 16).

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note (Note 16).

 

15. Contingencies

 

In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the financial statements.

 

F-23

 

 

15. Contingencies (continued)

 

Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.

 

Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

16. Subsequent Events

 

The Company’s management has evaluated the subsequent events up to April 17, 2023. The date the financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events:

 

As of December 31, 2022, we notified the land owners of our intention to exercise the two Real Estate Option Agreements and are in process of negotiating final terms of acquisition. The acquisition has yet to be completed.

 

On January 31, 2023, LDS Capital LLC assigned the related party line of credit note to its sole member, an individual, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company.

 

On February 1, 2023, the related party line of credit note was used to pay in full, the related party loan balance of $392,194.

 

On February 1, 2023, the Company initiated their EB-5 Program, whereby they may issue up to an aggregate of 12,609,152 shares of common stock to accredited or institutional investors, at a price of $39.99 per share.

 

On February 1, 2023, 200,000 of the September Warrants were redeemed for $210,000.

 

On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 pursuant to the EB-5 Program.

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note, leaving available $11.5 million to draw from that credit facility.

 

On March 27, 2023, we received an additional $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 pursuant to the EB-5 Program.

 

On March 31, 2023, the Company issued 875,000 shares to the former Chief Executive Officer, Terry Rafih, pursuant to his employment agreement.

 

On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola. 

 

F-24

 EX-4.2 2 ex4-2.htm

 

Exhibit 4.2

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”)

 

The following summary of the material terms of Bright Green Corporation’s (“we,” “our,” “us” or the “Company”) securities is not intended to be a complete summary of the rights and preferences of such securities. The descriptions below are qualified by reference to the actual text of our certificate of incorporation, as amended and restated (the “Certificate of Incorporation”), and our bylaws, as amended and restated (the “Bylaws”). We urge you to read our Certificate of Incorporation in its entirety for a complete description of the rights and preferences of our securities.

 

General

 

Our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of which 174,423,810 are issued and outstanding as of April, 10, 2023, and 10,000,000 shares of preferred stock, $0.0001 par value per share, of which none are issued or outstanding, as of the date hereof.

 

Common Stock

 

As of April 14, 2023, there were 174,423,810 shares of our Common Stock outstanding held by approximately 95 stockholders of record. Our Certificate of Incorporation provides that:

 

  ● holders of Common Stock will have voting rights for the election of our directors and all other matters requiring stockholder action, except with respect to amendments to our certificate of incorporation that alter or change the powers, preferences, rights or other terms of any outstanding preferred stock if the holders of such affected series of preferred stock are entitled to vote on such an amendment;
  ● holders of Common Stock will be entitled to one vote per share on matters to be voted on by stockholders and also will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors (the “Board”) in its discretion out of funds legally available therefor;
  ● the payment of dividends, if any, on the Common Stock will be subject to the prior payment of dividends on any outstanding preferred stock;
  ● upon our liquidation or dissolution, the holders of Common Stock will be entitled to receive pro rata all assets remaining available for distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock outstanding at that time; and
  ● our stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the Common Stock.

 

Certain Anti-takeover Provisions of Delaware Law, our Certificate of Incorporation and Bylaws

 

As a Delaware corporation, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally has an anti-takeover effect for transactions not approved in advance by our Board. This may discourage takeover attempts that might result in payment of a premium over the market price for the shares of Common Stock held by stockholders. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that such stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of our voting stock.

 

Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

 

  ● before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; or

 

 
 

 

  ● upon consummation of the transaction which resulted in the stockholder becoming an interested outstanding, shares owned by:
     
  ● persons who are directors and also officers, and
     
  ● employee stock plans, in some instances; or
     
  ● at or after the time the stockholder became interested, the business combination was approved by the board of directors are authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

 

Exclusive Forum

 

Our Bylaws provide, and Certificate of Incorporation provides, that unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine, shall be a state or federal court located within the state of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the above forum exclusivity provisions. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

 

The forum selection provision is intended to apply “to the fullest extent permitted by applicable law,” subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, the exclusive forum provision will not apply to actions brought under the Securities Act, or the rules and regulations thereunder.

 

Special meeting of stockholders

 

Our Bylaws further provide that special meetings of our stockholders may be called by the chairman of the Board, the Board, president of the Company, or by the Board upon written request by the holders of a majority of the voting authority of the Company.

 

Requirements for Advance Notification of Director Nominations and Stockholder Proposals

 

Our Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder’s notice needs to be delivered to the secretary at our principal executive offices not later than the close of business on the day nor earlier than the close of business on the day prior to the first anniversary of the date on which we first mailed our proxy materials for the preceding year’s annual meeting of stockholders; provided, however, if no proxy materials were mailed by us in connection with the preceding year’s annual meeting, or if the date of the annual meeting is advanced more than days prior to or delayed by more than days after the anniversary of the preceding year’s annual meeting, a stockholder’s notice shall be timely if delivered to our principal executive offices not later than the 90th day prior to the scheduled date of the annual meeting of stockholders or the day following the day on which public announcement of the date of our annual meeting of stockholders is first made or sent by us. Our Bylaws specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

 

 
 

 

Authorized but unissued shares

 

Our Certificate of Incorporation provides that authorized but unissued shares of Common Stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

 

Removal of directors

 

Our Bylaws provide that a member of our Board may be removed from service as a director, with or without cause, only by the affirmative vote of the holders of a majority of the shares of voting stock then outstanding and entitled to vote in an election of directors.

 

Limitation of Liability and Indemnification of Directors and Officers

 

Our Bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law.

 

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.

 

Listing

 

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BGXX.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our Common Stock is Vstock Transfer, LLC. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, NY 11598. The transfer agent and registrar can be contacted by phone at: (212) 828-8436.

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

SRCO, C.P.A., Professional Corporation

Certified Public Accountants

14 Wynngate Lane

Amherst, NY 14221

U.S. A

 

Tel: 416 428 1391 & 416 671 7292

Fax: 905 882 9580

Email: info@srco.ca

www.srco.ca

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use of our report dated April 17, 2023 relating to the financial statements of Bright Green Corporation as of December 31, 2022 and 2021, and for the years then ended, which report is included in this Annual Report on Form 10-K. Our report relating to those financial statements includes an emphasis of matter paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern.

 

/s/ SRCO, C.P.A., Professional Corporation

 

Amherst, NY

April 17, 2023

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Seamus McAuley, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Bright Green Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023 By: /s/ Seamus McAuley
    Seamus McAuley
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Saleem Elmasri, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Bright Green Corporation;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023 By: /s/ Saleem Elmasri
   

Saleem Elmasri

Chief Financial Officer

    (Principal Financial and Accounting Officer)

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Bright Green Corporation (the “Company”) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 17, 2023 By: /s/ Seamus McAuley
    Seamus McAuley
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 EX-32.2 7 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Bright Green Corporation (the “Company”) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 17, 2023 By: /s/ Saleem Elmasri
    Saleem Elmasri
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 GRAPHIC 8 form10-k_001.jpg begin 644 form10-k_001.jpg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audit_001.jpg GRAPHIC begin 644 audit_001.jpg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end EX-101.SCH 10 bgxx-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business and Organization link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Deposits link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Merger Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Line of Credit Note link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes (continued) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Merger Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Income Taxes (continued) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Description of Business and Organization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Going Concern and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Estimated Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Changes in the Fair Value of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Concentration of Credit Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Financial Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Merger Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Property, Plant, and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Related Party Line of Credit Note (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Income Taxes (continued) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 bgxx-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 bgxx-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 13 bgxx-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Common Stock To Be Issued [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Credit Facility [Axis] Secured Debt [Member] Long-Lived Tangible Asset [Axis] Building [Member] Furniture and Fixtures [Member] Unsecured Line of Credit [Member] Investment, Name [Axis] Alterola Biotech Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Voting Agreement [Member] Consolidated Entities [Axis] Bright Green Grow Innovations LLC [Member] Merger Agreement [Member] Green House [Member] Geographical [Axis] NEW MEXICO GGG Merger Agreement [Member] Grants Greehouse Growers, Inc. [Member] Real Estate Property Ownership [Axis] Real Estate Option Agreement One [Member] Real Estate Option Agreement Two [Member] Real estate option agreement [Member] Valuation Approach and Technique [Axis] Black Scholes Model [Member] Legal Entity [Axis] Naseeb Inc. [Member] Venlo Style Green House [Member] Lender Name [Axis] LDS Capital LLC [Member] Variable Rate [Axis] Prime Rate [Member] Line of Credit [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Title of Individual [Axis] One Accredited Investor [Member] Sale of Stock [Axis] Private Placement [Member] Directors [Member] Two Accredited Investor [Member] Six Consultants [Member] Consultants [Member] Warrant [Member] Chief Executive Officer [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Securitues Purchase Agreement [Member] Twenty Eight Accredited [Member] Thirty Accredited [Member] Award Date [Axis] January 2021 [Member] December2020 [Member] March 2021 [Member] May 2021 [Member] June 2021 [Member] September 2021 [Member] October 2021 [Member] One Hundred Eighty Eight Accredited [Member] September and October 2021 [Member] Twelve Accredited [Member] October and December 2021 [Member] December 2021 [Member] Five Consultants [Member] Three Directors [Member] February 2021 [Member] Two Directors [Member] Three Consultants [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Chief Financial Officer [Member] Five Directors [Member] Balance Sheet Location [Axis] Accrued Liabilities [Member] Accounts Payable [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Location Auditor Name Auditor Firm ID Statement of Financial Position [Abstract] ASSETS Current assets Cash Prepaid expenses and other assets Total current assets Deposits (Note 5 and 10) Equity method investment (Note 6) Property, plant, and equipment (Note 8) Intangible assets (Note 9) Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued liabilities (Note 14) Due to others (Note 6) Due to related party (Note 14) Total current liabilities Long-term liabilities Due to related party (Note 14) Related party line of credit note (Note 11) Total long-term liabilities Total liabilities STOCKHOLDERS’ EQUITY Common stock; $.0001 par value; 500,000,000 stock authorized; 173,304,800 and 157,544,500 stock issued and outstanding at December 31, 2022 and December 31, 2021, respectively (Note 12) Additional paid-in capital (Note 12) Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Expenses General and administrative expenses Depreciation Total operating expenses Loss from Operations Other Expense Change in Fair Value of Voting Agreement Derivative Total Other Expense Loss before income taxes and equity in net losses of affiliate Income tax expense Loss before equity in net losses of affiliate Equity in net losses of affiliate Net loss and comprehensive loss Weighted average common shares outstanding - basic and diluted Net loss per common share - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued for services (Note 12) Common stock issued for services,shares Common stock issued for cash (Note 12) Common stock issued for cash, shares Net loss Common stock and warrants issued for cash in private placement, net of issuance costs of $863,267 (Note 12) Common stock and warrants issued for cash in private placement, shares Common stock cancelled that was issued for services (Note 12) Common stock cancelled that was issued for services (Note 11), shares Balance Balance, shares Statement of Stockholders' Equity [Abstract] Net of issuance cost Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net cash used in operating activities: Change in fair value of voting agreement derivative Equity in net losses of affiliate Stock-based compensation Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued liabilities Accrued interest Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Deposits Purchase of equity method investment Purchase of property, plant, and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from related party Payments to related party Proceeds from related party line of credit Payments to related party line of credit Proceeds from issuance of common stock Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH CASH, BEGINNING OF YEAR CASH, END OF YEAR CASH PAID FOR Interest Taxes SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES Due to others for purchase of Common stock in Alterola Biotech, Inc. Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business and Organization Going Concern and Basis of Presentation Accounting Policies [Abstract] Summary of Significant Accounting Policies Risks and Uncertainties [Abstract] Concentration of Credit Risk Banking and Thrift Disclosure [Text Block] Deposits Investments, All Other Investments [Abstract] Merger Transactions Property, Plant and Equipment [Abstract] Property, Plant, and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Commitments and Contingencies Disclosure [Abstract] Commitments Related Party Line Of Credit Note Related Party Line of Credit Note Equity [Abstract] Stockholders’ Equity Income Tax Disclosure [Abstract] Income Taxes (continued) Related Party Transactions [Abstract] Related Party Transactions Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Measurement Property, Plant, and Equipment Long-lived Assets Intangible Assets Investments under the equity method Advertising Costs Income Taxes Basic and Diluted Earnings (Loss) per share Segment Reporting Use of Estimates Stock-based Compensation Warrants Standards, Amendments, and Interpretations Adopted Summary of Estimated Useful Life Schedule of Changes in the Fair Value of Financial Assets The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: Schedule of Property Plant and Equipment Schedule of Intangible Assets Schedule of Income Tax Provision Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards Date of incorporation Revenue Line of Credit Facility [Table] Line of Credit Facility [Line Items] Net income loss Net cash provided by used in operating activities working capital Retained earnings accumulated deficit Proceeds from Issuance or Sale of Equity Long-Term Line of Credit Proceeds from Long-Term Lines of Credit Repayments of Other Debt Line of Credit Facility, Remaining Borrowing Capacity Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful life Beginning balance, assets fair value Voting Agreement derivative asset Change in fair value Ending balance, assets fair value Advertising cost Income tax examination, description Cash FDIC insured amount Excess of FDIC insured limit Current Assets Non-Current Assets Current Liabilities Non-Current Liabilities Equity Total revenues Common Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Common Stock, Shares, Outstanding Stock Issued During Period, Shares, New Issues Shares Issued, Price Per Share Liability to the Sellers Debt instrument, stated percentage Equity method investment, description Stock Carrying value Ownership percentage Equity method investments Dividend rate Rist free rate Expected term Volatility rate Share based payment, description Sale of stock Area of land Number of shares issued, shares Payments for rent Price per acre Fair Value of Assets Acquired Exchange of shares Asset acquisition consideration transferred amount Furniture and fixtures Land Construction in progress Building and improvement Property, plant, and equipment gross Accumulated depreciation Net property, plant, and equipment Interest costs capitalized Licenses (Note 7) Accumulated amortization Net intangible assets Payments for purchase Deposits Deposits Construction of contract paid Line of credit facility, maximum borrowing amount Borrowing capacity Interest rate stated percentage Lender committed funds Repayments of other debt Accrued interest Due to related party Line of credit paid Drew from related party line of credit Credit facility Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock, shares authorized Preferred stock, par value Issuance of shares Issued price per share Number of shares issed for services Stock Issued During Period, Value, Issued for Services Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Exercise price Warrants redeemed Warrants redeemed integration related costs Legal fees Escrow deposit Share price Warrant exercise price Warrant term Volatility rate Risk-free rate Dilutive issuance rate Warrants estimate value Issuance of value Shares issued for cash proceeds Loss before income taxes Current: Federal State Total current (benefit) provision Deferred: Federal State Total current (benefit) provision Valuation allowance Total (benefit) provision Other Net operating loss carry over Total deferred tax assets Less: valuation allowance Deferred tax assets, net of valuation allowance Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Current and deferred income tax expenses Tax rate Operating loss carryforwards Due to related party Issuance of service shares Accrued payroll Accrued liabilities Long-term line of credit Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Contingency, taken by defendant description Subsequent Event [Table] Subsequent Event [Line Items] Due to related parties Shares issued Warrants Line of credit current borrowing capacity Shares issued Price per share Investments Officer advance current. Due to others current. Common stock issued value Common Stock To Be Issued [Member] Stock to be issued during period value issued for services. Stock to be issued during period shares issued for services Stock cancelled during period value issued for services Stock cancelled during period shares issued for services Common stock and warrants issued value for cash in private placements Common stock and warrants issued shares for cash in private placements Increase decrease in officer advance. Payments for acquire property deposits Proceeds from issuance of common stock and warrants. New Accounting Pronouncements Adopted Policy [Policy Text Block] Working capital deficit. Working capital. Property plant and equipment estimated useful life [Table Text Block]. Stock on cash. Enterprise value cash. Bright Green Grow Innovations LLC [Member]. Merger Agreement [Member]. Green House [Member]. GGG Merger Agreement [Member]. Grants Greehouse Growers, Inc. [Member] Real Estate Option Agreement One [Member] Purchase price option of land Real Estate Option Agreement Two [Member] Real estate option agreement [Member]. Black Scholes Model [Member]. Naseeb Inc. [Member] Venlo Style Green House [Member]. Investment ownership percentage. Unsecured Line of Credit [Member] LDS Capital LLC [Member] Related Party Line Of Credit [Text Block] One Accredited Investor [Member] Directors [Member] Two Accredited Investor [Member] Six Consultants [Member] Consultants [Member] Share based compensation arrangement by share based payment award fair value assumptions expected dissuance rate. Twenty Eight Accredited [Member] January 2021 [Member] Shares Issued New Issue. December2020 [Member] March 2021 [Member] May 2021 [Member] June 2021 [Member] Eighty Eight Accredited [Member] One Hundred Eighty Eight Accredited [Member] September 2021 [Member] October 2021 [Member] Two Directors [Member] Three Directors [Member] Three Consultants [Member] Five Consultants [Member] February 2021 [Member] Twelve Accredited [Member] December 2021 [Member] Chied Executive Officer [Member]. Five Directors [Member] Thirty Accredited [Member] Securitues Purchase Agreement [Member] September and October 2021 [Member] October and December 2021 [Member] Officer Advance [Member] Executive Employment Agreement [Member] Income loss from continuing operations including portion attributable to noncontrolling interest equity in net losses of affiliate. Equity in net losses of affiliate. Alterola Biotech Inc [Member] Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Payments for acquire property deposit. Achievement of Research Development and Commercial Milestone [Member] Schedule of federal and state tax effects of temporary difference and carryforwards [Table Text Block] Measurement Input Dilutive Issuance [Member] Fair value of warrants. Valuation allowance of income tax provision. Voting Agreement [Member] Assets Due to Related Parties, Noncurrent Liabilities Liabilities and Equity Operating Expenses Other Expenses Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding EquityInNetLossesOfAffiliate Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Interest Receivable, Net Net Cash Provided by (Used in) Operating Activities PaymentsForAcquirePropertyDeposits Payments to Acquire Equity Method Investments Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] WorkingCapital Assets, Fair Value Disclosure Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment PaymentsForAcquirePropertyDeposit Payments for Deposits Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) ValuationAllowancesOfIncomeTaxExpenseBenefit Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Accrued Liabilities Class of Warrant or Right, Outstanding EX-101.PRE 14 bgxx-20221231_pre.xml XBRL PRESENTATION FILE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Apr. 14, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41395    
Entity Registrant Name BRIGHT GREEN CORPORATION    
Entity Central Index Key 0001886799    
Entity Tax Identification Number 83-4600841    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1033 George Hanosh Boulevard    
Entity Address, City or Town Grants    
Entity Address, State or Province NM    
Entity Address, Postal Zip Code 87020    
City Area Code (833)    
Local Phone Number 658-1799    
Title of 12(b) Security Common stock, $0.0001 par value per share    
Trading Symbol BGXX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 141,818,084
Entity Common Stock, Shares Outstanding   174,423,810  
ICFR Auditor Attestation Flag false    
Auditor Location Amherst, NY    
Auditor Name SRCO, C.P.A., Professional Corporation    
Auditor Firm ID 6722    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets    
Cash $ 414,574 $ 1,282,565
Prepaid expenses and other assets 77,847 168,226
Total current assets 492,421 1,450,791
Deposits (Note 5 and 10) 1,157,587
Equity method investment (Note 6) 3,990,960
Property, plant, and equipment (Note 8) 17,146,325 7,328,764
Intangible assets (Note 9) 1,000 1,000
Total assets 22,788,293 8,780,555
Current liabilities    
Accounts payable 5,033,831 149,935
Accrued liabilities (Note 14) 447,325 18,027
Due to others (Note 6) 1,650,000
Due to related party (Note 14) 392,194
Total current liabilities 7,523,350 167,962
Long-term liabilities    
Due to related party (Note 14) 392,194
Related party line of credit note (Note 11) 3,686,107
Total long-term liabilities 3,686,107 392,194
Total liabilities 11,209,457 560,156
STOCKHOLDERS’ EQUITY    
Common stock; $.0001 par value; 500,000,000 stock authorized; 173,304,800 and 157,544,500 stock issued and outstanding at December 31, 2022 and December 31, 2021, respectively (Note 12) 17,329 15,754
Additional paid-in capital (Note 12) 45,637,328 14,618,389
Accumulated deficit (34,075,821) (6,413,744)
Total stockholders’ equity 11,578,836 8,220,399
Total liabilities and stockholders’ equity $ 22,788,293 $ 8,780,555
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Oct. 03, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]      
Common stock, par value $ 0.0001 $ 0.001 $ 0.0001
Common stock, shares authorized 500,000,000 2,000,000,000 500,000,000
Common stock, shares issued 173,304,800   157,544,500
Common stock, shares outstanding 173,304,800 807,047,948 157,544,500
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenue
Expenses    
General and administrative expenses 26,609,241 1,738,716
Depreciation 704,681 751,783
Total operating expenses 27,313,922 2,490,499
Loss from Operations (27,313,922) (2,490,499)
Other Expense    
Change in Fair Value of Voting Agreement Derivative 213,000
Total Other Expense 213,000
Loss before income taxes and equity in net losses of affiliate (27,526,922) (2,490,499)
Income tax expense
Loss before equity in net losses of affiliate (27,526,922) (2,490,499)
Equity in net losses of affiliate (135,155)
Net loss and comprehensive loss $ (27,662,077) $ (2,490,499)
Weighted average common shares outstanding - basic and diluted 162,058,082 156,800,164
Net loss per common share - basic and diluted $ (0.17) $ (0.02)
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Common Stock To Be Issued [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 15,605 $ 138,000 $ 10,990,538 $ (3,923,245) $ 7,220,898
Balance, shares at Dec. 31, 2020 156,046,000        
Common stock issued for services (Note 12) $ 12 359,988 360,000
Common stock issued for services,shares 125,000        
Common stock issued for cash (Note 12) $ 137 (138,000) 3,267,863 3,130,000
Common stock issued for cash, shares 1,373,500        
Net loss (2,490,499) (2,490,499)
Balance at Dec. 31, 2021 $ 15,754 14,618,389 (6,413,744) 8,220,399
Balance, shares at Dec. 31, 2021 157,544,500        
Common stock issued for services (Note 12) $ 603 18,850,629 18,851,232
Common stock issued for services,shares 6,036,990        
Common stock issued for cash (Note 12) $ 31 3,049,969 3,050,000
Common stock issued for cash, shares 312,500        
Net loss (27,662,077) (27,662,077)
Common stock and warrants issued for cash in private placement, net of issuance costs of $863,267 (Note 12) $ 952 9,135,781 9,136,733
Common stock and warrants issued for cash in private placement, shares 9,523,810        
Common stock cancelled that was issued for services (Note 12) $ (11) (17,440) (17,451)
Common stock cancelled that was issued for services (Note 11), shares (113,000)        
Balance at Dec. 31, 2022 $ 17,329 $ 45,637,328 $ (34,075,821) $ 11,578,836
Balance, shares at Dec. 31, 2022 173,304,800        
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statements of Changes in Stockholders' Equity (Parenthetical)
 12 Months Ended
Dec. 31, 2022
USD ($)
Statement of Stockholders' Equity [Abstract]  
Net of issuance cost $ 863,267
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (27,662,077) $ (2,490,499)
Adjustments to reconcile net cash used in operating activities:    
Change in fair value of voting agreement derivative 213,000
Equity in net losses of affiliate 135,155
Depreciation 704,681 751,783
Stock-based compensation 18,833,781 360,000
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 90,379 (149,153)
Accounts payable 4,883,896 (30,403)
Accrued liabilities 429,298 (98,303)
Accrued interest 106,117
Net cash used in operating activities (2,265,770) (1,656,575)
CASH FLOWS FROM INVESTING ACTIVITIES    
Deposits (1,157,587)
Purchase of equity method investment (2,689,115)
Purchase of property, plant, and equipment (10,522,242) (302,717)
Net cash used in investing activities (14,368,944) (302,717)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from related party 122,514
Payments to related party (112,920)
Proceeds from related party line of credit 5,191,057
Payments to related party line of credit (1,611,067)
Proceeds from issuance of common stock 3,050,000 3,130,000
issued in private placement, net of issuance costs 9,136,733
Net cash provided by financing activities 15,766,723 3,139,594
NET (DECREASE) INCREASE IN CASH (867,991) 1,180,302
CASH, BEGINNING OF YEAR 1,282,565 102,263
CASH, END OF YEAR 414,574 1,282,565
CASH PAID FOR    
Interest
Taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES    
Due to others for purchase of Common stock in Alterola Biotech, Inc. $ 1,650,000
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business and Organization
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business and Organization

 

1. Description of Business and Organization

 

Bright Green Corporation (Company) was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company is located in Grants, New Mexico. The Company holds the land, greenhouse and patents required in the growth, production, and research of medicinal plants.

 

On May 28, 2019, the Company entered into a merger agreement with Bright Green Grow Innovation, LLC (“BGGI”) (Note 7).

 

On October 30, 2020, Grants Greenhouse Growers, Inc. (GGGI), a New Mexico corporation, merged with the Company (Note 7).

 

On November 10, 2020, Naseeb, Inc. (Naseeb), a New Mexico corporation, merged with the Company (Note 7).

 

On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

 

On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

 

The Company is a start-up company at December 31, 2022 and has no revenue.

 

The Company’s operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company’s operations and ability to finance its operations.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern and Basis of Presentation
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern and Basis of Presentation

 

2. Going Concern and Basis of Presentation

 

The financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). US GAAP contemplates continuation of the Company as a going concern. For the fiscal years ended December 31, 2022 and 2021, the Company had no revenues from product sales and incurred a net loss of $27,662,077 and $2,490,499, respectively. Net cash used in operations for years ended 2022 and 2021 was $2,265,770 and $1,656,575, respectively. As of December 31, 2022, the Company had a working capital deficit and accumulated deficit of $7,030,929 and $34,075,821, respectively.

 

 

The Company is in its initial stages to start building facilities to grow, research and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the financial statements were authorized to be issued. The Company’s continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

 

In 2022, the Company raised $12,186,733 through common stock issuances. The Company also secured a $15,000,000 line of credit from a related party, has drawn $5,191,057 and paid down $1,611,067, leaving available $11.3 million to draw from that credit facility (Note 11). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

 

In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to, general economic conditions, competition, and regulatory matters. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates.

 

These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Capital Program announced on February 1, 2023 (Note 16). However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects, or that the Company will be able to successfully execute its operating plan.

 

The financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be cancelled with minimal fees, non-cancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

This disclosure is intended to inform users of the financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

 

3. Summary of Significant Accounting Policies

 

  A. Basis of Measurement

 

The financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is re-tired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

Building and improvement - declining balance method   10 year life
Furniture and fixtures - straight-line method   3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 7) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  E. Fair Value of Financial Instruments

  

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  ● Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;
     
  ●  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  ●  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of our cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2022 and 2021 due to their short-term nature.

 

The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):

 

   December 31, 2022 
Balance on December 31, 2021  $- 
Voting Agreement derivative asset   213,000 
Change in fair value   (213,000)
Balance on December 31, 2022  $- 

 

  F. Investments under the equity method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $78,193 and $68,571 for the years ended December 31, 2022 and 2021, respectively.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  K. Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of

 

 

3. Summary of Significant Accounting Policies (continued)

 

  M. Warrants (continued)

 

the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  2) Leases (continued)

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2022
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk

 

4. Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $187,821 in excess of the FDIC insured limit at December 31, 2022.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Deposits
 12 Months Ended
Dec. 31, 2022
Deposits

 

5. Deposits

 

Deposits are comprised of one down payment for a construction of equipment contract for which the Company has not yet taken title and one down payment for a construction contract for which the work has not started (Note 10).

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Merger Transactions
 12 Months Ended
Dec. 31, 2022
Investments, All Other Investments [Abstract]  
Merger Transactions

 

6. Equity Method Investment in Alterola

 

On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

 

The Secondary SPA provides that, as of the date thereof, the authorized shares of Alterola consist of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares are issued and outstanding. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to Bright Green for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. As of December 31, 2022, the Company has a liability to the Sellers of $1,650,000 due on April 28, 2023. The liability is not interest bearing and not secured. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement.

 

The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola.

 

Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement. The agreement will terminate upon the earlier of eight months from the date of the agreement or written notice by Bright Green.

 

Concurrently with the execution of the Voting Agreement, each Stockholder agrees to deliver to Bright Green an Irrevocable Proxy (“Proxy”). The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock.

 

The Company accounted for the transaction under the equity method and recoded the carrying value of the Company’s investment in Alterola common shares at cost, including transaction costs incurred to obtain the equity method investment of $339,115 in equity method investment in the balance sheet.

 

The following table provides summarized balance sheet information for Alterola as of December 31, 2022:

 

Schedule of Financial Statement Information

   December 31, 2022   December 31, 2021 
Current Assets  $192,011   $90,705 
Non-Current Assets   12,018,147    12,000,000 
Current Liabilities   1,822,696    1,217,811 
Non-Current Liabilities   151,255    169,038 
Equity   10,236,237    10,703,856 

 

The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022:

 

   December 31, 2022   

December 31, 2021

  
Total revenues  $-    $ -  
Net loss  $4,980,510    $ 3,460,815  

 

Our ownership percentage of 25% of Alterola allows us to have significant influence over the operations and decision making at Alterola. Accordingly, the investment is accounted for as an equity method investment. Our share of net loss from our investment in Alterola was $135,155 for the period from October 3, 2022 through the year ended December 31, 2022.

 

On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola (Note 16).

 

Voting Agreement

 

The Voting Agreement was initially measured at fair value utilizing the Black-Scholes-option-pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

 

As of December 31, 2022, the value of the option was impaired to nil to reflect the likelihood that the option would be exercised according to the terms set forth and prior to expiry.

 

7. Merger Transactions

 

  A. Bright Green Grow Innovations, LLC Merger

 

On May 28, 2019, the Company entered into a merger agreement with BGGI. Pursuant to the merger agreement, BGGI transferred to the Company two parcels of land and a greenhouse building having a total net carrying value of $9,128,851 in exchange for shares of the Company (Note 8). The land transfer consisted of a 70-acre lot with a greenhouse at 1033 George Hanosh Blvd., Grants, New Mexico 87020 and a 40-acre lot in the City of Grants, New Mexico. The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions

 

 

7. Merger Transactions (continued)

 

  A. Bright Green Grow Innovations, LLC Merger (continued)

 

of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical carrying values of BGGI.

 

  B. Grants Greenhouse Growers, Inc. Merger

 

On October 30, 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. (“GGG”) (the “GGG Merger Agreement”). Pursuant to the GGG Merger Agreement, GGG was merged into the Company in exchange for 1,000,000 shares of the Company. GGG had no assets or liabilities, other than the following options agreements:

 

  - A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
     
  - A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

 

The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. The asset acquisition was accounted for at the fair value of the options agreement of $103,837 determined using the Black Scholes Model and management had assessed the value of these options to be impaired due to uncertainty surrounding their recoverability.

 

  C. Naseeb, Inc. Merger

 

On November 10, 2020, the Company entered into a merger agreement with Naseeb, Inc. (“Naseeb”) and the sole shareholder of Naseeb, who is also a shareholder and Chairman of the Company. Pursuant to the Naseeb merger agreement, Naseeb was merged into the Company in exchange for 10,000,000 shares of the Company. Naseeb

 

 

7. Merger Transactions (continued)

 

  C. Naseeb, Inc. Merger (continued)

 

transferred to the Company their assistance that was used by the Company towards obtaining the following licenses and patents to the Company:

 

  - New Mexico Hemp License: Industrial Hemp is an agricultural plant that uses all the byproducts of the plant such as seeds and twigs in the production of hemp seed, hemp fiber, and other eco-friendly products.
     
  - New Mexico Board of Pharmacy Schedule 1 Bulk Manufacturers License: Securing the license was required as part of the application and consideration for a federal license. Additionally, being licensed as a Schedule 1 Bulk Manufacturer allows the Company to develop and distribute Schedule 1 drugs; an authorization precedent to the ability to grow, extract and distribute other cannabidiols, such as CBG and CBN. Moreover, with this license, the Company is exempt from the restrictions generally applicable to the cannabis industry, such as plant count and per plant taxes.
     
  - Federal Medical Marijuana License: The Company has a formal agreement with the Drug Enforcement Administration for the construction and operation of a federally licensed agricultural center to grow and distribute marijuana, or its chemical constituents, supplying legitimate researchers in the United States.
     
  - Patents: The patents held by the Company provide innovative medical therapies to a wide range of conditions. These patents can be sold, licensed, or directly marketed as clinical trials are conducted and approved by the FDA.

 

The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical cost of Naseeb of $1,000 (Note 9).
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant, and Equipment
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant, and Equipment

 

8. Property, Plant, and Equipment

 

The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

 

 

8. Property, Plant, and Equipment (continued)

 

Property, plant, and equipment at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Furniture and fixtures  $88,690    - 
Land   260,000    260,000 
Construction in progress   10,736,269    302,717 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   19,968,810    9,446,568 
Accumulated depreciation   (2,822,485)   (2,117,804)
Net property, plant, and equipment  $17,146,325    7,328,764 

 

The amount of interest costs capitalized and included in construction in progress totaled $106,117 and $nil at December 31, 2022 and 2021, respectively (Note 11).
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

 

9. Intangible Assets

 

Intangible assets at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Licenses (Note 7)  $1,000    1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000    1,000 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments

 

10. Commitments

 

During 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022 (Note 5). The remaining balance of $1,109,642 is due upon delivery. The Company also entered into and paid in full a construction contract for $47,944 as of December 31, 2022 (Note 5). The construction to be performed under this contract will occur in 2023.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Line of Credit Note
 12 Months Ended
Dec. 31, 2022
Related Party Line Of Credit Note  
Related Party Line of Credit Note

 

11.Related Party Line of Credit Note

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The Note provides that the Company may borrow up to $5.0 million, including an initial loan in the amount of $3.0 million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2.0 million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds form Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest

 

 

11. Related Party Line of Credit Note (continued)

 

on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10 million.

 

As of December 31, 2022, the Lender has funded the Company $5,191,057 with the Company paying back $1,611,067 of those funds. As of December 31, 2022, there was accrued interest of $106,117. The funds have been used for the construction in progress and interest expense of $106,117 has been capitalized (Note 8).

 

The note was drawn on for $392,194 to pay off the Due to Related Party and was paid down $880,000, subsequent to year end (Note 16). On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company (Note 16).

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note, leaving available $11.5 million to draw from that credit facility.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Stockholders’ Equity

 

12.Stockholders’ Equity

 

The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of December 31, 2022 and 2021, there were 173,304,800 and 157,544,500, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

 

During the twelve months ended December 31, 2022, the Company issued the following:

 

  - 12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;
     
  - 500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of (the “$4.00 Round”), to the Chief Financial Officer of the Company, in April 2022;
     
  - 5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share, were cancelled in April 2022;
     
  - 300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022;
     
  - 1,574,490 shares of common stock for services rendered in connection with the Direct Listing to the Company’s advisor, or its permitted designees, contemporaneous with the Direct Listing and consistent with the direct listing price of $8.00 per share in June 2022;
     
  - 108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were cancelled in June 2022;

 

 

12. Stockholders’ Equity (continued)

 

  - 9,523,810 shares of Common Stock and warrants to purchase up to an aggregate of 9,523,810 shares of Common Stock, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and
     
  -

3,962,500 shares of common stock for services rendered, with (i) 3,000,000 shares issued at a fair value of $1.25 per share, (ii) 87,500 shares at a fair value of $1.08 per share, and (iii) 875,000 shares at a fair value of $0.4695 per share, to the former Chief Executive Officer of the Company, in December 2022.

 

On September 7, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with investors. The combined purchase price of one Share and accompanying Warrant was $1.05. Subject to certain ownership limitations, the Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock (the “Exercise Price”), subject to adjustments as provided under the terms of the Warrants. The Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction related fees and expenses payable by the Company. On February 1, 2023, 200,000 of the Warrants were redeemed for $210,000 (Note 16).

 

In connection with the September Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September Private Placement went effective on September 21, 2022.

 

Transaction costs incurred related to the September Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

 

September Warrants

 

The measurement of fair value was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $1.65, exercise price of $1.05, term of five years, volatility of 174.3%, risk-free rate of 3.41%, probability of dilutive issuance of 15%, estimated timing of dilutive issuance of four and a half months, and expected time to conversion of five years). The grant date fair value of these Warrants were estimated to be $4,489,662 on September 12, 2022 of the gross proceeds and is reflected within additional paid-in capital as of December 31, 2022.

 

During the twelve months ended December 31, 2021, the Company issued the following:

 

  - 1,019,000 shares of common stock at a purchase price of $2.00 per share, for gross cash proceed of $2,038,000 to thirty accredited investors between January 2021 and October 2021, with (i) 184,000 shares issued in January 2021, which includes the 69,000 shares issued for cash proceeds of $138,000 received as of December 31, 2020, (ii) 100,000 shares issued in March 2021, (iii) 335,000 shares issued in May 2021, (iv) 250,000 shares issued in June 2021, and (v) 100,000 shares issued in September 2021 and 50,000 shares issued in October 2021 (the “$2.00 Round”);

 

 

12. Stockholders’ Equity (continued)

 

  - 188,000 shares of common stock at a purchase price of $3.00 per share, for gross cash proceeds of $564,000 to one hundred eighty-eight accredited investors in September and October 2021 with (i) 154,000 shares in September 2021, and (ii) 34,000 shares issued in October 2021 (the “$3.00 Round”);
     
  - 166,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $666,000, to 12 accredited investors in October and December 2021, with (i) 29,000 shares in October 2021, and (ii) 137,500 shares issued in December 2021 (the “$4.00 Round”);
     
  - 25,000 shares of common stock for services rendered, at a fair value of $2.00 per share determined using the per share purchase price of the $2.00 Round, to five consultants, with (i) 10,000 shares issued in January 2021 and (ii) 15,000 shares issued in May 2021;
     
  - 40,000 shares of common stock for services rendered, at a fair value of $2.00 per share determined using the per share purchase price of (the “$2.00 Round”), to three directors of the Company, with (i) 10,000 shares issued in January 2021 and (ii) 30,000 shares issued in February 2021;
     
  - 10,000 shares of common stock for services rendered, at fair value at $3.00 per share determined using the per share purchase price of (the “$3.00 Round”), to two directors of the Company, in September 2021; and
     
  - 50,000 shares of common stock for services rendered, at fair value at $4.00 per share determined using the per share purchase price of (the “$4.00 Round”), to three consultants in November 2021.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (continued)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes (continued)

  

13. Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2022 and 2021, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.

 

 

13. Income Taxes (continued)

 

The current and deferred income tax expenses for the years ended December 31, 2022 and 2021, were $nil. The provision for income taxes differs from that computed at a combined corporate tax rate of approximately 25.8% (2021 – 25.8%) as follows:

 

   2022   2021 
         
Loss before income taxes  $(27,662,077)  $(2,490,499)
           
The (benefit) provision for income taxes for 2022 and 2021 consists of the following:          
           
Current:          
Federal   -    - 
State   -    - 
Total current (benefit) provision   -    - 
           
Deferred:          
Federal   (5,727,839)   (515,114)
State   (1,309,220)   (117,740)
Total current (benefit) provision  $(7,037,059)  $(632,854)
Valuation allowance   7,037,059    632,854 
Total (benefit) provision  $-   $- 

 

The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

 

   2022   2021 
Other   728,201    546,393 
Net operating loss carry over   7,294,146    438,894 
Total deferred tax assets   8,022,347    985,287 
Less: valuation allowance   (8,022,347)   (985,287)
Deferred tax assets, net of valuation allowance  $-   $- 

 

As of December 31, 2022 and 2021, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2022 and 2021, the Company has approximately $28,271,882 and $1,701,141 respectively, of Federal net operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely and the state loss carryforward expires in 2039. The benefit from the non-capital loss carry-forward balance has not been recorded in the financial statements.

 

The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

 

14. Related Party Transactions

 

Other than the transactions disclosed elsewhere in the financial statements, the following are the other significant related party transactions and balances:

 

At December 31, 2022 and 2021, the due to related party balance totaled $392,194 and $392,194, respectively. The balance represents advances from the majority shareholder for payment of Company expenses. The amount is unsecured, non-interest bearing with no terms of repayment. The shareholder has agreed in writing that no payment will be required by the Company to the lender prior to January 31, 2023. On February 1, 2023, this loan was paid in full with a draw on the line of credit (Note 16).

 

 

14. Related Party Transactions (continued)

 

Included in common stock issued for services during the year ended December 31, 2022, were 3,962,500 shares of common stock issued to the former Chief Executive Officer of the Company (Note 12).

 

Included in common stock issued for services during the year ended December 31, 2022, were 500,000 shares of common stock issued to the Chief Financial Officer of the Company (Note 12).

 

Included in common stock issued for services during the year ended December 31, 2021, were 50,000 shares of common stock issued to the five directors of the Company (Note 12).

 

At December 31, 2022, $400,000 was due to the Company’s former interim Chief Executive Officer, who also is a shareholder. The amount, which includes $300,000 in accrued bonus is included in accrued liabilities in the Balance Sheet. The accrued bonus is expected to be paid in the first quarter of 2024 and is subject to Board of Director approvals.

 

At December 31, 2022, $65,856 was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.

 

At December 31, 2022, $60,000 was due to the Company’s former Chief Executive Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.

 

At December 31, 2022, the outstanding balance on the line of credit of $3,686,107 was due to a Lender, whose managing member is a member of the Board (Note 11). The amount is included in the related party line of credit note in the Balance Sheet.

 

The related party line of credit note was drawn on to pay in full, the related party loan balance of $392,194, and was paid down $880,000 subsequent to year end (Note 16).

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note (Note 16).
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Contingencies

 

15. Contingencies

 

In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the financial statements.

 

 

15. Contingencies (continued)

 

Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.

 

Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

 

16. Subsequent Events

 

The Company’s management has evaluated the subsequent events up to April 17, 2023. The date the financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events:

 

As of December 31, 2022, we notified the land owners of our intention to exercise the two Real Estate Option Agreements and are in process of negotiating final terms of acquisition. The acquisition has yet to be completed.

 

On January 31, 2023, LDS Capital LLC assigned the related party line of credit note to its sole member, an individual, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company.

 

On February 1, 2023, the related party line of credit note was used to pay in full, the related party loan balance of $392,194.

 

On February 1, 2023, the Company initiated their EB-5 Program, whereby they may issue up to an aggregate of 12,609,152 shares of common stock to accredited or institutional investors, at a price of $39.99 per share.

 

On February 1, 2023, 200,000 of the September Warrants were redeemed for $210,000.

 

On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 pursuant to the EB-5 Program.

 

On March 14, 2023, the Company drew an additional $200,000 on the June Note, leaving available $11.5 million to draw from that credit facility.

 

On March 27, 2023, we received an additional $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 pursuant to the EB-5 Program.

 

On March 31, 2023, the Company issued 875,000 shares to the former Chief Executive Officer, Terry Rafih, pursuant to his employment agreement.

 

On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola. 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Measurement

 

  A. Basis of Measurement

 

The financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.
Property, Plant, and Equipment

 

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is re-tired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

Building and improvement - declining balance method   10 year life
Furniture and fixtures - straight-line method   3 year life

 

Construction in progress is not depreciated until the asset is placed in service.
Long-lived Assets

 

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.
Intangible Assets

 

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 7) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

 

3. Summary of Significant Accounting Policies (continued)
Investments under the equity method

 

  E. Fair Value of Financial Instruments

  

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  ● Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;
     
  ●  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  ●  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of our cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2022 and 2021 due to their short-term nature.

 

The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):

 

   December 31, 2022 
Balance on December 31, 2021  $- 
Voting Agreement derivative asset   213,000 
Change in fair value   (213,000)
Balance on December 31, 2022  $- 

 

  F. Investments under the equity method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $78,193 and $68,571 for the years ended December 31, 2022 and 2021, respectively.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  K. Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of

 

 

3. Summary of Significant Accounting Policies (continued)

 

  M. Warrants (continued)

 

the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  2) Leases (continued)

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).
Advertising Costs

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $78,193 and $68,571 for the years ended December 31, 2022 and 2021, respectively.

 

 

3. Summary of Significant Accounting Policies (continued)
Income Taxes

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Basic and Diluted Earnings (Loss) per share

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.
Segment Reporting

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

 

3. Summary of Significant Accounting Policies (continued)
Use of Estimates

 

  K. Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Stock-based Compensation

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.
Warrants

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of

 

 

3. Summary of Significant Accounting Policies (continued)

 

  M. Warrants (continued)

 

the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.
Standards, Amendments, and Interpretations Adopted

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  2) Leases (continued)

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Estimated Useful Life

 

Building and improvement - declining balance method   10 year life
Furniture and fixtures - straight-line method   3 year life
Schedule of Changes in the Fair Value of Financial Assets

The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):

 

   December 31, 2022 
Balance on December 31, 2021  $- 
Voting Agreement derivative asset   213,000 
Change in fair value   (213,000)
Balance on December 31, 2022  $- 

 

  F. Investments under the equity method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant, and Equipment (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property Plant and Equipment

Property, plant, and equipment at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Furniture and fixtures  $88,690    - 
Land   260,000    260,000 
Construction in progress   10,736,269    302,717 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   19,968,810    9,446,568 
Accumulated depreciation   (2,822,485)   (2,117,804)
Net property, plant, and equipment  $17,146,325    7,328,764 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets at December 31, 2022 and 2021, consisted of the following:

 

   December 31, 2022   December 31, 2021 
Licenses (Note 7)  $1,000    1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000    1,000 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (continued) (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision

 

   2022   2021 
         
Loss before income taxes  $(27,662,077)  $(2,490,499)
           
The (benefit) provision for income taxes for 2022 and 2021 consists of the following:          
           
Current:          
Federal   -    - 
State   -    - 
Total current (benefit) provision   -    - 
           
Deferred:          
Federal   (5,727,839)   (515,114)
State   (1,309,220)   (117,740)
Total current (benefit) provision  $(7,037,059)  $(632,854)
Valuation allowance   7,037,059    632,854 
Total (benefit) provision  $-   $- 
Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards

The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:

 

   2022   2021 
Other   728,201    546,393 
Net operating loss carry over   7,294,146    438,894 
Total deferred tax assets   8,022,347    985,287 
Less: valuation allowance   (8,022,347)   (985,287)
Deferred tax assets, net of valuation allowance  $-   $- 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business and Organization (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Date of incorporation Apr. 16, 2019  
Revenue $ 0 $ 0
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern and Basis of Presentation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Line of Credit Facility [Line Items]    
Net income loss $ 27,662,077 $ 2,490,499
Net cash provided by used in operating activities 2,265,770 1,656,575
working capital 7,030,929  
Retained earnings accumulated deficit 34,075,821 6,413,744
Proceeds from Issuance or Sale of Equity 12,186,733  
Proceeds from Long-Term Lines of Credit 5,191,057
Repayments of Other Debt 1,611,067
Line of Credit Facility, Remaining Borrowing Capacity 11,300,000  
Secured Debt [Member]    
Line of Credit Facility [Line Items]    
Long-Term Line of Credit $ 15,000,000  
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Estimated Useful Life (Details)
 12 Months Ended
Dec. 31, 2022
Building [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 10 years
Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 3 years
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Changes in the Fair Value of Financial Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Beginning balance, assets fair value  
Voting Agreement derivative asset 213,000  
Change in fair value (213,000)
Ending balance, assets fair value
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Advertising cost $ 78,193 $ 68,571
Income tax examination, description The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination  
Revenue $ 0 $ 0
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Concentration of Credit Risk (Details Narrative)
Dec. 31, 2022
USD ($)
Risks and Uncertainties [Abstract]  
Cash FDIC insured amount $ 250,000
Excess of FDIC insured limit $ 187,821
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Financial Statement Information (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current Assets $ 492,421 $ 1,450,791  
Current Liabilities 7,523,350 167,962  
Non-Current Liabilities 3,686,107 392,194  
Equity 11,578,836 8,220,399 $ 7,220,898
Alterola Biotech Inc [Member]      
Current Assets 192,011 90,705  
Non-Current Assets 12,018,147 12,000,000  
Current Liabilities 1,822,696 1,217,811  
Non-Current Liabilities 151,255 169,038  
Equity $ 10,236,237 $ 10,703,856  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.1
The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Total revenues
Net loss (27,662,077) (2,490,499)
Alterola Biotech Inc [Member]    
Total revenues
Net loss $ 4,980,510 $ 3,460,815
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Merger Transactions (Details Narrative)
 6 Months Ended 12 Months Ended
Oct. 03, 2022
USD ($)
$ / shares
shares
Jan. 01, 2022
USD ($)
a
Oct. 30, 2020
shares
Oct. 21, 2020
USD ($)
May 28, 2019
USD ($)
a
Dec. 31, 2021
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
a
$ / shares
shares
Common Stock, Shares Authorized | shares 2,000,000,000         500,000,000   500,000,000
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001         $ 0.0001   $ 0.0001
Common Stock, Shares, Outstanding | shares 807,047,948         157,544,500   173,304,800
Stock Issued During Period, Shares, New Issues | shares 201,761,982              
Shares Issued, Price Per Share | $ / shares $ 3,999,999              
Liability to the Sellers               $ 1,650,000
Debt instrument, stated percentage 67.00%              
Stock $ 50,000,000              
Carrying value               339,115
Equity method investments $ 135,155           $ 3,990,960
Rist free rate               3.41%
Naseeb Inc. [Member]                
Exchange of shares | shares               10,000,000
Asset acquisition consideration transferred amount               $ 1,000
NEW MEXICO                
Area of land | a               70
Voting Agreement [Member]                
Dividend rate               0.00%
Rist free rate               4.00%
Expected term               6 months
Volatility rate               66.00%
Share based payment, description               the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.
Merger Agreement [Member] | Bright Green Grow Innovations LLC [Member]                
Sale of stock         $ 9,128,851      
Merger Agreement [Member] | Bright Green Grow Innovations LLC [Member] | NEW MEXICO                
Area of land | a         40      
Merger Agreement [Member] | Bright Green Grow Innovations LLC [Member] | Green House [Member] | NEW MEXICO                
Area of land | a         70      
GGG Merger Agreement [Member] | Real estate option agreement [Member] | Black Scholes Model [Member]                
Fair Value of Assets Acquired               $ 103,837
GGG Merger Agreement [Member] | Grants Greehouse Growers, Inc. [Member]                
Number of shares issued, shares | shares     1,000,000          
GGG Merger Agreement [Member] | Grants Greehouse Growers, Inc. [Member] | Real Estate Option Agreement One [Member]                
Area of land | a   330            
Payments for rent   $ 2,000       $ 1,750 $ 1,500  
GGG Merger Agreement [Member] | Grants Greehouse Growers, Inc. [Member] | Real Estate Option Agreement Two [Member]                
Area of land | a   175            
Payments for rent   $ 1,500   $ 1,000        
Price per acre   $ 5,000            
Alterola Biotech Inc [Member]                
Equity method investment, description The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock              
Ownership percentage               25.00%
Unsecured Line of Credit [Member]                
Debt instrument, stated percentage 25.00%              
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Property Plant and Equipment (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Furniture and fixtures $ 88,690
Land 260,000 260,000
Construction in progress 10,736,269 302,717
Building and improvement 8,883,851 8,883,851
Property, plant, and equipment gross 19,968,810 9,446,568
Accumulated depreciation (2,822,485) (2,117,804)
Net property, plant, and equipment $ 17,146,325 $ 7,328,764
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant, and Equipment (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
a
Dec. 31, 2021
USD ($)
Property, Plant and Equipment [Line Items]    
Interest costs capitalized | $ $ 106,117
NEW MEXICO    
Property, Plant and Equipment [Line Items]    
Area of land 70  
Venlo Style Green House [Member] | NEW MEXICO    
Property, Plant and Equipment [Line Items]    
Area of land 22  
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Intangible Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Licenses (Note 7) $ 1,000 $ 1,000
Accumulated amortization
Net intangible assets $ 1,000 $ 1,000
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Payments for purchase $ 2,219,285
Deposits 1,109,643
Deposits 1,109,642
Construction of contract paid $ 47,944
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Line of Credit Note (Details Narrative) - USD ($)
 12 Months Ended
Mar. 14, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 06, 2023
Feb. 01, 2023
Oct. 03, 2022
Jun. 05, 2022
Line of Credit Facility [Line Items]              
Interest rate stated percentage           67.00%  
Repayments of other debt   $ 1,611,067        
Accrued interest   106,117          
Interest costs capitalized   106,117        
Due to related party   392,194        
Drew from related party line of credit   $ 122,514        
Credit facility   11,300,000          
Subsequent Event [Member]              
Line of Credit Facility [Line Items]              
Drew from related party line of credit $ 200,000            
Credit facility $ 11,500,000            
Unsecured Line of Credit [Member]              
Line of Credit Facility [Line Items]              
Interest rate stated percentage           25.00%  
Unsecured Line of Credit [Member] | LDS Capital LLC [Member]              
Line of Credit Facility [Line Items]              
Line of credit facility, maximum borrowing amount             $ 5,000,000.0
Borrowing capacity   2,000,000.0         $ 3,000,000.0
Interest rate stated percentage             2.00%
Lender committed funds   $ 5,191,057          
Unsecured Line of Credit [Member] | LDS Capital LLC [Member] | Prime Rate [Member]              
Line of Credit Facility [Line Items]              
Interest rate stated percentage             2.00%
Line of Credit [Member]              
Line of Credit Facility [Line Items]              
Line of credit paid       $ 880,000      
Line of Credit [Member] | Subsequent Event [Member]              
Line of Credit Facility [Line Items]              
Borrowing capacity       880,000      
Due to related party         $ 392,194    
Line of credit paid       $ 880,000      
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
Feb. 01, 2023
Oct. 03, 2022
Sep. 12, 2022
Sep. 07, 2022
Apr. 30, 2022
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Mar. 27, 2023
Feb. 06, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Common stock, shares authorized     2,000,000,000         500,000,000 500,000,000    
Common stock, par value     $ 0.001         $ 0.0001 $ 0.0001    
Preferred stock, shares authorized               10,000,000      
Preferred stock, par value               $ 0.0001      
Common stock, shares issued               173,304,800 157,544,500    
Common stock, shares outstanding     807,047,948         173,304,800 157,544,500    
Issuance of shares     201,761,982                
Issued price per share     $ 3,999,999                
Proceeds from Issuance or Sale of Equity               $ 12,186,733      
Stock Issued During Period, Value, Issued for Services               18,851,232 $ 360,000    
Proceeds from issuance of common stock               3,050,000 3,130,000    
Warrants redeemed               213,000      
integration related costs               800,000      
Legal fees               55,617      
Escrow deposit               $ 7,650      
Share price               $ 1.65      
Warrant exercise price               $ 1.05      
Warrant term               5 years      
Volatility rate               174.30%      
Risk-free rate               3.41%      
Dilutive issuance rate               15.00%      
Warrants estimate value       $ 4,489,662              
Issuance of value               $ 3,050,000 $ 3,130,000    
Subsequent Event [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Common stock, shares issued                     22,005
Warrants redeemed   $ 200,000                  
Warrants redeemed   $ 210,000                  
Share price   $ 39.99               $ 39.99  
Chief Executive Officer [Member] | Subsequent Event [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares 875,000                    
Common Stock [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Common stock, shares authorized               500,000,000      
Issuance of shares               312,500 1,373,500    
Number of shares issed for services               6,036,990 125,000    
Stock Issued During Period, Value, Issued for Services               $ 603 $ 12    
Issuance of value               31 $ 137    
Common Stock [Member] | May 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 335,000    
Common Stock [Member] | September 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 100,000    
Common Stock [Member] | October 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of value                 $ 50,000    
Common Stock [Member] | Subsequent Event [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                     $ 39.99
Common Stock [Member] | Private Placement [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share           $ 4.00          
Number of shares issed for services           500,000          
Proceeds from issuance of common stock               $ 10,000,000      
Common Stock [Member] | One Accredited Investor [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares               12,500      
Issued price per share               $ 4.00      
Proceeds from Issuance or Sale of Equity               $ 50,000      
Common Stock [Member] | Directors [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share               $ 2.00      
Number of shares issed for services               5,000      
Common Stock [Member] | Two Accredited Investor [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares               300,000      
Issued price per share               $ 10.00      
Stock Issued During Period, Value, Issued for Services               $ 3,000,000      
Common Stock [Member] | Six Consultants [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share               $ 8.00      
Number of shares issed for services               1,574,490      
Common Stock [Member] | Consultants [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares               108,000      
Issued price per share               $ 0.069      
Common Stock [Member] | Chief Executive Officer [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issed for services               3,962,500      
Common Stock [Member] | Twenty Eight Accredited [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 1,019,000    
Common Stock [Member] | Twenty Eight Accredited [Member] | June 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 250,000    
Common Stock [Member] | Thirty Accredited [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 2.00    
Issuance of value                 $ 2,038,000    
Shares issued for cash proceeds                 69,000    
Common Stock [Member] | Thirty Accredited [Member] | January 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 184,000    
Common Stock [Member] | Thirty Accredited [Member] | December2020 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Proceeds from issuance of common stock                 $ 138,000    
Common Stock [Member] | Thirty Accredited [Member] | March 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 100,000    
Common Stock [Member] | One Hundred Eighty Eight Accredited [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 3.00    
Common Stock [Member] | One Hundred Eighty Eight Accredited [Member] | September 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 154,000    
Common Stock [Member] | One Hundred Eighty Eight Accredited [Member] | October 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 34,000    
Common Stock [Member] | One Hundred Eighty Eight Accredited [Member] | September and October 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 188,000    
Issued price per share                 $ 3.00    
Proceeds from issuance of common stock             $ 564,000        
Common Stock [Member] | Twelve Accredited [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 4.00    
Common Stock [Member] | Twelve Accredited [Member] | October 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 29,000    
Common Stock [Member] | Twelve Accredited [Member] | October and December 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 166,500    
Issued price per share                 $ 4.00    
Proceeds from issuance of common stock             $ 666,000        
Common Stock [Member] | Twelve Accredited [Member] | December 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares                 137,500    
Common Stock [Member] | Five Consultants [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 2.00    
Number of shares issed for services                 25,000    
Common Stock [Member] | Five Consultants [Member] | January 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issed for services                 10,000    
Common Stock [Member] | Five Consultants [Member] | May 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issed for services                 15,000    
Common Stock [Member] | Three Directors [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 2.00    
Number of shares issed for services                 40,000    
Common Stock [Member] | Three Directors [Member] | January 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issed for services                 10,000    
Common Stock [Member] | Three Directors [Member] | February 2021 [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issed for services                 30,000    
Common Stock [Member] | Two Directors [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 3.00    
Number of shares issed for services                 10,000    
Common Stock [Member] | Three Consultants [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share                 $ 4.00    
Number of shares issed for services                 50,000    
Warrant [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares               9,523,810      
Exercise price         $ 1.05            
Warrant [Member] | Securitues Purchase Agreement [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Exercise price         $ 1.05            
Warrant [Member] | Private Placement [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issuance of shares               9,523,810      
Common Stock One [Member] | Chief Executive Officer [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share               $ 1.25      
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture               3,000,000      
Common Stock Two [Member] | Chief Executive Officer [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share               $ 1.08      
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture               87,500      
Common Stock Three [Member] | Chief Executive Officer [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Issued price per share               $ 0.4695      
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture               875,000      
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Income Tax Provision (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Loss before income taxes $ (27,662,077) $ (2,490,499)
Current:    
Federal
State
Total current (benefit) provision
Deferred:    
Federal (5,727,839) (515,114)
State (1,309,220) (117,740)
Total current (benefit) provision (7,037,059) (632,854)
Valuation allowance 7,037,059 632,854
Total (benefit) provision
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Other $ 728,201 $ 546,393
Net operating loss carry over 7,294,146 438,894
Total deferred tax assets 8,022,347 985,287
Less: valuation allowance (8,022,347) (985,287)
Deferred tax assets, net of valuation allowance
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (continued) (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]    
Current and deferred income tax expenses
Tax rate 25.80% 25.80%
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Operating loss carryforwards $ 28,271,882 $ 1,701,141
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details Narrative) - USD ($)
 12 Months Ended
Mar. 14, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 06, 2023
Feb. 01, 2023
Due to related party   $ 392,194 $ 392,194    
Long-term line of credit   3,686,107    
Due to related party   392,194    
Drew from related party line of credit   $ 122,514    
Subsequent Event [Member]          
Drew from related party line of credit $ 200,000        
Line of Credit [Member]          
Line of credit paid       $ 880,000  
Line of Credit [Member] | Subsequent Event [Member]          
Due to related party         $ 392,194
Line of credit paid       $ 880,000  
Chief Executive Officer [Member] | Accounts Payable [Member]          
Accrued payroll   60,000      
Chief Financial Officer [Member] | Accrued Liabilities [Member]          
Accrued payroll   400,000      
Accrued liabilities   300,000      
Chief Financial Officer [Member] | Accounts Payable [Member]          
Accrued payroll   $ 65,856      
Five Directors [Member]          
Issuance of service shares     50,000    
Common Stock [Member]          
Issuance of service shares   6,036,990 125,000    
Common Stock [Member] | Chief Executive Officer [Member]          
Issuance of service shares   3,962,500      
Common Stock [Member] | Chief Financial Officer [Member]          
Issuance of service shares   500,000      
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Contingencies (Details Narrative)
 12 Months Ended
Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Contingency, taken by defendant description (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI
Chief Executive Officer [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Contingency, taken by defendant description Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company.
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details Narrative) - USD ($)
 12 Months Ended
Mar. 31, 2023
Mar. 27, 2023
Mar. 14, 2023
Feb. 01, 2023
Feb. 01, 2023
Oct. 03, 2022
Dec. 31, 2022
Dec. 31, 2021
Feb. 06, 2023
Feb. 02, 2023
Subsequent Event [Line Items]                    
Due to related parties             $ 392,194    
Share price             $ 1.65      
Warrants redeemed             $ 213,000      
Shares issued             173,304,800 157,544,500    
Price per share           $ 3,999,999        
Drew from related party line of credit             $ 122,514    
Credit facility             $ 11,300,000      
Common stock issued for cash, shares           201,761,982        
Common Stock [Member]                    
Subsequent Event [Line Items]                    
Common stock issued for cash, shares             312,500 1,373,500    
Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Shares issued   22,005     12,609,152          
Share price   $ 39.99   $ 39.99 $ 39.99          
Warrants                   200,000
Warrants redeemed       $ 210,000            
Shares issued                 22,005  
Drew from related party line of credit     $ 200,000              
Credit facility     $ 11,500,000              
Investments   $ 880,000                
Subsequent Event [Member] | Chief Executive Officer [Member]                    
Subsequent Event [Line Items]                    
Common stock issued for cash, shares 875,000                  
Subsequent Event [Member] | Common Stock [Member]                    
Subsequent Event [Line Items]                    
Price per share                 $ 39.99  
Line of Credit [Member]                    
Subsequent Event [Line Items]                    
Line of credit paid                 $ 880,000  
Line of Credit [Member] | Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Due to related parties       $ 392,194 $ 392,194          
Line of credit paid                 880,000  
Line of credit current borrowing capacity                 $ 880,000  
XML 63 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001886799 2022-01-01 2022-12-31 0001886799 2022-06-30 0001886799 2023-04-14 0001886799 2022-12-31 0001886799 2021-12-31 0001886799 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember 2020-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2020-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001886799 us-gaap:RetainedEarningsMember 2020-12-31 0001886799 2020-12-31 0001886799 us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-12-31 0001886799 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001886799 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001886799 us-gaap:CommonStockMember 2022-12-31 0001886799 BGXX:CommonStockToBeIssuedMember 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-12-31 0001886799 us-gaap:SecuredDebtMember 2022-12-31 0001886799 us-gaap:BuildingMember 2022-01-01 2022-12-31 0001886799 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001886799 2022-10-03 0001886799 2022-10-02 2022-10-03 0001886799 BGXX:UnsecuredLineOfCreditMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-02 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:VotingAgreementMember 2022-01-01 2022-12-31 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember BGXX:MergerAgreementMember 2019-05-27 2019-05-28 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember stpr:NM BGXX:GreenHouseMember BGXX:MergerAgreementMember 2019-05-28 0001886799 BGXX:BrightGreenGrowInnovationsLlcMember stpr:NM BGXX:MergerAgreementMember 2019-05-28 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:GGGMergerAgreementMember 2020-10-28 2020-10-30 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember BGXX:GGGMergerAgreementMember 2021-01-01 2021-06-30 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember BGXX:GGGMergerAgreementMember 2021-07-01 2021-12-31 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember BGXX:GGGMergerAgreementMember 2022-01-01 2022-01-01 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember BGXX:GGGMergerAgreementMember 2022-01-01 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GGGMergerAgreementMember 2022-01-01 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GGGMergerAgreementMember 2020-10-21 2020-10-21 0001886799 BGXX:GrantsGreehouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember BGXX:GGGMergerAgreementMember 2022-01-01 2022-01-01 0001886799 BGXX:RealEstateOptionAgreementMember BGXX:GGGMergerAgreementMember BGXX:BlackScholesModelMember 2022-01-01 2022-12-31 0001886799 BGXX:NaseebIncMember 2022-12-31 0001886799 BGXX:NaseebIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2021-01-01 2021-12-31 0001886799 stpr:NM BGXX:VenloStyleGreenHouseMember 2022-12-31 0001886799 stpr:NM 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember us-gaap:PrimeRateMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-01-01 2022-12-31 0001886799 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-02-01 0001886799 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-03-14 2023-03-14 0001886799 us-gaap:SubsequentEventMember 2023-03-14 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:OneAccreditedInvestorMember us-gaap:CommonStockMember 2022-12-31 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 BGXX:DirectorsMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:DirectorsMember us-gaap:CommonStockMember 2022-12-31 0001886799 BGXX:TwoAccreditedInvestorMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:TwoAccreditedInvestorMember us-gaap:CommonStockMember 2022-12-31 0001886799 BGXX:SixConsultantsMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:SixConsultantsMember us-gaap:CommonStockMember 2022-12-31 0001886799 BGXX:ConsultantsMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:ConsultantsMember us-gaap:CommonStockMember 2022-12-31 0001886799 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockOneMember 2022-01-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockOneMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockTwoMember 2022-01-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockTwoMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockThreeMember 2022-01-01 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember BGXX:CommonStockThreeMember 2022-12-31 0001886799 us-gaap:WarrantMember BGXX:SecurituesPurchaseAgreementMember 2022-09-06 2022-09-07 0001886799 us-gaap:WarrantMember 2022-09-06 2022-09-07 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2023-01-29 2023-02-01 0001886799 2022-09-12 2022-09-12 0001886799 BGXX:TwentyEightAccreditedMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThirtyAccreditedMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:ThirtyAccreditedMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThirtyAccreditedMember BGXX:JanuaryTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThirtyAccreditedMember BGXX:DecemberTwentyTwentyMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThirtyAccreditedMember BGXX:MarchTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:MayTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwentyEightAccreditedMember BGXX:JuneTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:SeptemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:OctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberAndOctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001886799 BGXX:OneHundredEightyEightAccreditedMember BGXX:SeptemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:OneHundredEightyEightAccreditedMember BGXX:OctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:OneHundredEightyEightAccreditedMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:TwelveAccreditedMember BGXX:OctoberAndDecemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001886799 BGXX:TwelveAccreditedMember BGXX:OctoberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwelveAccreditedMember BGXX:DecemberTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwelveAccreditedMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:FiveConsultantsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:FiveConsultantsMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:FiveConsultantsMember BGXX:JanuaryTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:FiveConsultantsMember BGXX:MayTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThreeDirectorsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThreeDirectorsMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:ThreeDirectorsMember BGXX:JanuaryTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThreeDirectorsMember BGXX:FebruaryTwentyTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwoDirectorsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:TwoDirectorsMember us-gaap:CommonStockMember 2021-12-31 0001886799 BGXX:ThreeConsultantsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001886799 BGXX:ThreeConsultantsMember us-gaap:CommonStockMember 2021-12-31 0001886799 us-gaap:DomesticCountryMember 2022-12-31 0001886799 us-gaap:DomesticCountryMember 2021-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001886799 BGXX:FiveDirectorsMember 2021-01-01 2021-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccruedLiabilitiesMember 2022-12-31 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2022-12-31 0001886799 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001886799 us-gaap:SubsequentEventMember 2023-01-31 2023-02-01 0001886799 us-gaap:SubsequentEventMember 2023-02-01 0001886799 us-gaap:SubsequentEventMember 2023-02-02 0001886799 us-gaap:LineOfCreditMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-02-06 0001886799 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-02-06 0001886799 us-gaap:SubsequentEventMember 2023-03-27 0001886799 us-gaap:SubsequentEventMember 2023-03-27 2023-03-27 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-03-30 2023-03-31 iso4217:USD shares iso4217:USD shares utr:acre pure 0001886799 false FY 10-K true 2022-12-31 --12-31 2022 false 001-41395 BRIGHT GREEN CORPORATION DE 83-4600841 1033 George Hanosh Boulevard Grants NM 87020 (833) 658-1799 Common stock, $0.0001 par value per share BGXX NASDAQ No No Yes Yes Non-accelerated Filer true true false false false 141818084 174423810 Amherst, NY SRCO, C.P.A., Professional Corporation 6722 414574 1282565 77847 168226 492421 1450791 1157587 3990960 17146325 7328764 1000 1000 22788293 8780555 5033831 149935 447325 18027 1650000 392194 7523350 167962 392194 3686107 3686107 392194 11209457 560156 0.0001 0.0001 500000000 500000000 173304800 173304800 157544500 157544500 17329 15754 45637328 14618389 -34075821 -6413744 11578836 8220399 22788293 8780555 26609241 1738716 704681 751783 27313922 2490499 -27313922 -2490499 213000 213000 -27526922 -2490499 -27526922 -2490499 -135155 -27662077 -2490499 162058082 156800164 -0.17 -0.02 156046000 15605 138000 10990538 -3923245 7220898 125000 12 359988 360000 1373500 137 -138000 3267863 3130000 -2490499 -2490499 157544500 15754 14618389 -6413744 8220399 157544500 15754 14618389 -6413744 8220399 312500 31 3049969 3050000 863267 9523810 952 9135781 9136733 6036990 603 18850629 18851232 -113000 -11 -17440 -17451 -27662077 -27662077 173304800 17329 45637328 -34075821 11578836 173304800 17329 45637328 -34075821 11578836 -27662077 -2490499 213000 135155 704681 751783 18833781 360000 -90379 149153 4883896 -30403 429298 -98303 -106117 -2265770 -1656575 1157587 2689115 10522242 302717 -14368944 -302717 122514 112920 5191057 1611067 3050000 3130000 9136733 15766723 3139594 -867991 1180302 1282565 102263 414574 1282565 1650000 <p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zU6ROaNhDkP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_823_zEuu6vUfwYy9">Description of Business and Organization</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bright Green Corporation (Company) was incorporated on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231_z7a8QZGZ7Ty" title="Date of incorporation">April 16, 2019</span>, under the Delaware General Corporation Law. The Company is located in Grants, New Mexico. The Company holds the land, greenhouse and patents required in the growth, production, and research of medicinal plants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 28, 2019, the Company entered into a merger agreement with Bright Green Grow Innovation, LLC (“BGGI”) (Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2020, Grants Greenhouse Growers, Inc. (GGGI), a New Mexico corporation, merged with the Company (Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 10, 2020, Naseeb, Inc. (Naseeb), a New Mexico corporation, merged with the Company (Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a start-up company at December 31, 2022 and has <span id="xdx_90A_eus-gaap--Revenues_do_c20220101__20221231_zK9N3bfebud7" title="Revenue">no</span> revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company’s operations and ability to finance its operations.</span></p> 2019-04-16 0 <p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z1FDSxJUHmy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_826_zCm8Xxaj4zDk">Going Concern and Basis of Presentation</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). US GAAP contemplates continuation of the Company as a going concern. For the fiscal years ended December 31, 2022 and 2021, the Company had no revenues from product sales and incurred a net loss of $<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_z8STxoeUXY5" title="Net income loss">27,662,077</span> and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20210101__20211231_zbIwaRCk8Gg6" title="Net income loss">2,490,499</span>, respectively. Net cash used in operations for years ended 2022 and 2021 was $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20220101__20221231_zSM1xo6wuXt9" title="Net cash provided by used in operating activities">2,265,770</span> and $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20210101__20211231_zcvHgY3LxUkf" title="Net cash provided by used in operating activities">1,656,575</span>, respectively. As of December 31, 2022, the Company had a working capital deficit and accumulated deficit of $<span id="xdx_903_ecustom--WorkingCapital_iNI_di_c20221231_zAYBeN5RN964" title="working capital">7,030,929</span> and $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zHcUDmQP0qUd" title="Retained earnings accumulated deficit">34,075,821</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is in its initial stages to start building facilities to grow, research and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the financial statements were authorized to be issued. The Company’s continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In 2022, the Company raised $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220101__20221231_z1MeqXiSKWn7">12,186,733</span> through common stock issuances. The Company also secured a $<span id="xdx_902_eus-gaap--LineOfCredit_iI_c20221231__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zGsvvJuuD4r1">15,000,000</span> line of credit from a related party, has drawn $<span id="xdx_901_eus-gaap--ProceedsFromLongTermLinesOfCredit_c20220101__20221231_zvqnWoC8HJl1">5,191,057</span> and paid down $<span id="xdx_90F_eus-gaap--RepaymentsOfOtherDebt_c20220101__20221231_zKfuokdFkcp9">1,611,067</span>, leaving available $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn5n6_c20221231_zx4AbX3yvCij">11.3</span> million to draw from that credit facility (Note 11). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to, general economic conditions, competition, and regulatory matters. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Capital Program announced on February 1, 2023 (Note 16). However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects, or that the Company will be able to successfully execute its operating plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be cancelled with minimal fees, non-cancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This disclosure is intended to inform users of the financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -27662077 -2490499 -2265770 -1656575 -7030929 -34075821 12186733 15000000 5191057 1611067 11300000 <p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zUh7SyOLHlWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_828_zdffuq1wd949">Summary of Significant Accounting Policies</span></span></span></td></tr> </table> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmMz2IHiKIeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zCasr0Vsak13">Basis of Measurement</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.</span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZg1RFpYnTuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_z2FrFWkulprj">Property, Plant, and Equipment</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is re-tired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:</span></p> <p id="xdx_890_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zfjIV6D6PS91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zH3u9laVUE47" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zXq1ii5F5l54" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOAmZFn13H1i" title="Estimated useful life">3</span> year life</span></td></tr> </table> <p id="xdx_8A7_zFtvX9sRzOP" style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress is not depreciated until the asset is placed in service.</span></p> <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUZW4kRZtOYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zCZrM4pMbnr">Long-lived Assets</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.</span></p> <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zIyDabE5X93j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zfZdQUcZwYsl">Intangible Assets</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consist of certain licenses (Note 7) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zkS69K2DlT94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zy0GYC97kVdc">Fair Value of Financial Instruments</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of our cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2022 and 2021 due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_zWabC8aPM5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zwBJGdY81307" style="display: none">Schedule of Changes in the Fair Value of Financial Assets</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance on December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iS_c20220101__20221231_zVmiLxBrZcHc" style="text-align: right" title="Beginning balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Voting Agreement derivative asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zbw1w4Ggm3Jg" style="width: 18%; text-align: right" title="Voting Agreement derivative asset">213,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ChangeInFairValueOfVotingAgreementDerivative_iN_di_c20220101__20221231_zzJV5KAcrK3h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(213,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance on December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iE_c20220101__20221231_zgWTXAQZXpqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zwAoBV0RI1V2">Investments under the equity method</span> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><i>Derivative Financial Instruments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.</p> <p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zjfRCJnbLJWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zR73skfo8fX2">Advertising Costs</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are charged to operations when incurred. Advertising costs totaled $<span id="xdx_901_eus-gaap--AdvertisingExpense_c20220101__20221231_zUfR6Gj4lEn9" title="Advertising cost">78,193</span> and $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_zVo5d9pOjfP4" title="Advertising cost">68,571</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zpgivP10B3F1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zNTSCNLrHfH2">Income Taxes</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. <span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231_zR9ILTx2bhtg" title="Income tax examination, description">The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination</span>. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zkvKMRcIFXE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_z9uDYIDgT3B2">Basic and Diluted Earnings (Loss) per share</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.</span></p> <p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zECbOHZVjH1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zUMuDYgwT48">Segment Reporting</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has <span id="xdx_90B_eus-gaap--Revenues_do_c20220101__20221231_zAlxYxRQkakc" title="Revenue"><span id="xdx_900_eus-gaap--Revenues_do_c20210101__20211231_zBmCK76XiQ62" title="Revenue">no</span></span> revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_84A_eus-gaap--UseOfEstimates_zVonxPeM9Sfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z71weYIrXZAl">Use of Estimates</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zEXnbEzJKcqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_z9FvzVRbg5Sd">Stock-based Compensation</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.</span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSUe7zemG7Nc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zZtWRFfJDvk7">Warrants</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.</span></p> <p id="xdx_840_ecustom--NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_zZANwvrkV9Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zvErmVcyjin2">Standards, Amendments, and Interpretations Adopted</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Modification of Equity-Classified Written Call Options </span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Standards, Amendments, and Interpretations Adopted (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair Value Measurement</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).</span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmMz2IHiKIeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zCasr0Vsak13">Basis of Measurement</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.</span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZg1RFpYnTuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_z2FrFWkulprj">Property, Plant, and Equipment</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is re-tired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:</span></p> <p id="xdx_890_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zfjIV6D6PS91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zH3u9laVUE47" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zXq1ii5F5l54" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOAmZFn13H1i" title="Estimated useful life">3</span> year life</span></td></tr> </table> <p id="xdx_8A7_zFtvX9sRzOP" style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress is not depreciated until the asset is placed in service.</span></p> <p id="xdx_890_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_zfjIV6D6PS91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zH3u9laVUE47" style="display: none">Summary of Estimated Useful Life</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and improvement - declining balance method</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zXq1ii5F5l54" title="Estimated useful life">10</span> year life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures - straight-line method</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOAmZFn13H1i" title="Estimated useful life">3</span> year life</span></td></tr> </table> P10Y P3Y <p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUZW4kRZtOYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zCZrM4pMbnr">Long-lived Assets</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.</span></p> <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zIyDabE5X93j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zfZdQUcZwYsl">Intangible Assets</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consist of certain licenses (Note 7) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zkS69K2DlT94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zy0GYC97kVdc">Fair Value of Financial Instruments</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of our cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of December 31, 2022 and 2021 due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_zWabC8aPM5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zwBJGdY81307" style="display: none">Schedule of Changes in the Fair Value of Financial Assets</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance on December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iS_c20220101__20221231_zVmiLxBrZcHc" style="text-align: right" title="Beginning balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Voting Agreement derivative asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zbw1w4Ggm3Jg" style="width: 18%; text-align: right" title="Voting Agreement derivative asset">213,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ChangeInFairValueOfVotingAgreementDerivative_iN_di_c20220101__20221231_zzJV5KAcrK3h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(213,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance on December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iE_c20220101__20221231_zgWTXAQZXpqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zwAoBV0RI1V2">Investments under the equity method</span> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><i>Derivative Financial Instruments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.</p> <p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zjfRCJnbLJWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zR73skfo8fX2">Advertising Costs</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are charged to operations when incurred. Advertising costs totaled $<span id="xdx_901_eus-gaap--AdvertisingExpense_c20220101__20221231_zUfR6Gj4lEn9" title="Advertising cost">78,193</span> and $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_zVo5d9pOjfP4" title="Advertising cost">68,571</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zpgivP10B3F1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zNTSCNLrHfH2">Income Taxes</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. <span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231_zR9ILTx2bhtg" title="Income tax examination, description">The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination</span>. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zkvKMRcIFXE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_z9uDYIDgT3B2">Basic and Diluted Earnings (Loss) per share</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.</span></p> <p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zECbOHZVjH1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zUMuDYgwT48">Segment Reporting</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has <span id="xdx_90B_eus-gaap--Revenues_do_c20220101__20221231_zAlxYxRQkakc" title="Revenue"><span id="xdx_900_eus-gaap--Revenues_do_c20210101__20211231_zBmCK76XiQ62" title="Revenue">no</span></span> revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p id="xdx_84A_eus-gaap--UseOfEstimates_zVonxPeM9Sfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z71weYIrXZAl">Use of Estimates</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zEXnbEzJKcqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_z9FvzVRbg5Sd">Stock-based Compensation</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.</span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSUe7zemG7Nc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zZtWRFfJDvk7">Warrants</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.</span></p> <p id="xdx_840_ecustom--NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_zZANwvrkV9Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zvErmVcyjin2">Standards, Amendments, and Interpretations Adopted</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Modification of Equity-Classified Written Call Options </span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Standards, Amendments, and Interpretations Adopted (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair Value Measurement</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_zWabC8aPM5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of our Level 3 financial assets that are measured at fair value on a recurring basis (See Note 6 for further details):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zwBJGdY81307" style="display: none">Schedule of Changes in the Fair Value of Financial Assets</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance on December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iS_c20220101__20221231_zVmiLxBrZcHc" style="text-align: right" title="Beginning balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Voting Agreement derivative asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zbw1w4Ggm3Jg" style="width: 18%; text-align: right" title="Voting Agreement derivative asset">213,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ChangeInFairValueOfVotingAgreementDerivative_iN_di_c20220101__20221231_zzJV5KAcrK3h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(213,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance on December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iE_c20220101__20221231_zgWTXAQZXpqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, assets fair value"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zwAoBV0RI1V2">Investments under the equity method</span> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. The Company generally recognizes its share of the equity method investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely from the Company’s reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><i>Derivative Financial Instruments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s Balance Sheet.</p> 213000 213000 <p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zjfRCJnbLJWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zR73skfo8fX2">Advertising Costs</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are charged to operations when incurred. Advertising costs totaled $<span id="xdx_901_eus-gaap--AdvertisingExpense_c20220101__20221231_zUfR6Gj4lEn9" title="Advertising cost">78,193</span> and $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_zVo5d9pOjfP4" title="Advertising cost">68,571</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> 78193 68571 <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zpgivP10B3F1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zNTSCNLrHfH2">Income Taxes</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. <span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231_zR9ILTx2bhtg" title="Income tax examination, description">The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination</span>. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zkvKMRcIFXE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_z9uDYIDgT3B2">Basic and Diluted Earnings (Loss) per share</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.</span></p> <p id="xdx_845_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zECbOHZVjH1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zUMuDYgwT48">Segment Reporting</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at December 31, 2022 and 2021 and has <span id="xdx_90B_eus-gaap--Revenues_do_c20220101__20221231_zAlxYxRQkakc" title="Revenue"><span id="xdx_900_eus-gaap--Revenues_do_c20210101__20211231_zBmCK76XiQ62" title="Revenue">no</span></span> revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> 0 0 <p id="xdx_84A_eus-gaap--UseOfEstimates_zVonxPeM9Sfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z71weYIrXZAl">Use of Estimates</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, valuation of option related to equity investment, going concern assessment and assignment of the useful lives of property, plant and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zEXnbEzJKcqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_z9FvzVRbg5Sd">Stock-based Compensation</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.</span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSUe7zemG7Nc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zZtWRFfJDvk7">Warrants</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations and comprehensive loss.</span></p> <p id="xdx_840_ecustom--NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_zZANwvrkV9Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zvErmVcyjin2">Standards, Amendments, and Interpretations Adopted</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Modification of Equity-Classified Written Call Options </span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods withing those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Summary of Significant Accounting Policies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Standards, Amendments, and Interpretations Adopted (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leases (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of December 31, 2022, the Company has one month to month lease, whereas the new standard does not apply.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair Value Measurement</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).</span></p> <p id="xdx_80B_eus-gaap--ConcentrationRiskDisclosureTextBlock_zPiGz9EnBsPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82A_zIqFE2VdXqEi">Concentration of Credit Risk</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z79yNBx5Tpdb" title="Cash FDIC insured amount">250,000</span>. The Company had $<span id="xdx_909_eus-gaap--TimeDepositLiabilityAboveUsInsuranceLimit_iI_c20221231_zGMzpLKFjJhl" title="Excess of FDIC insured limit">187,821</span> in excess of the FDIC insured limit at December 31, 2022.</span></p> 250000 187821 <p id="xdx_800_eus-gaap--DepositLiabilitiesDisclosuresTextBlock_zvJHhfHsIgd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_823_zsYDeUmknZ0e">Deposits</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Deposits are comprised of one down payment for a construction of equipment contract for which the Company has not yet taken title and one down payment for a construction contract for which the work has not started (Note 10).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80D_eus-gaap--InvestmentTextBlock_zoxztsImWPVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_82B_zGOgpveqRdz8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Method Investment in Alterola</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Secondary SPA provides that, as of the date thereof, the authorized shares of Alterola consist of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221003_zQ2HzIi2bG86">2,000,000,000</span> shares of common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221003_zIpFRKY8Pzr2">0.001</span> par value, of which <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221003_zHZCkJhmUgr9">807,047,948</span> shares are issued and outstanding. The Sellers Transferred Shares consisted of, in aggregate, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221002__20221003_zZn4XxaSphw7">201,761,982</span> shares of Common Stock, which were sold to Bright Green for a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221003_zygqo85sxzu6">3,999,999</span>, pursuant to the payment schedule set forth in the Secondary SPA. As of December 31, 2022, the Company has a liability to the Sellers of $<span id="xdx_90E_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_c20221231_zzQrcld9XCug" title="Liability to the Sellers">1,650,000</span> due on April 28, 2023. The liability is not interest bearing and not secured. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Sellers held <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20221003_zZJD7BmZH4qf" title="Debt instrument, stated percentage">67</span>% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221003__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember_zTQcpKl1lqt9" title="Debt instrument, stated percentage">25</span>% of the total outstanding shares of Alterola.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement. The agreement will terminate upon the earlier of eight months from the date of the agreement or written notice by Bright Green.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Concurrently with the execution of the Voting Agreement, each Stockholder agrees to deliver to Bright Green an Irrevocable Proxy (“Proxy”). <span id="xdx_901_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20221002__20221003__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zgOhKUccCUB6" title="Equity method investment, description">The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $<span id="xdx_909_ecustom--EnterpriseValueCash_iI_pn6n6_c20221003_zycESA4Ekn7f" title="Stock">50</span> million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company accounted for the transaction under the equity method and recoded the carrying value of the Company’s investment in Alterola common shares at cost, including transaction costs incurred to obtain the equity method investment of $<span id="xdx_90F_eus-gaap--EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_iI_c20221231_zRelhD6AFre2" title="Carrying value">339,115</span> in equity method investment in the balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p id="xdx_89C_esrt--ScheduleOfCondensedFinancialStatementsTable_zLICCaAt7aF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The following table provides summarized balance sheet information for Alterola as of December 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0 0 0 0.5in; text-align: justify"><span id="xdx_8BE_zrYltFsLGrb2">Schedule of Financial Statement Information</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20221231__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zPw4zi8lm0nj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zLlUGj4OgNH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsCurrent_iI_zxoqwQ5C1Wgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">192,011</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">90,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsNoncurrent_iI_zT6RG6HfKfpk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-Current Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,018,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_iI_zATXYyTYir6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,822,696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,217,811</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_iI_zzKKYhjCKRmf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151,255</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,038</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockholdersEquity_iI_zaopNMALXkqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,236,237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,703,856</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p id="xdx_896_esrt--ScheduleOfCondensedFinancialStatementsTable_zU0L1Y7U330g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_zoaiWbaB4Hwf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zGJGXDTMrYa5" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zJ5xIv1ZcHF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_hdei--LegalEntityAxis__custom--AlterolaBiotechIncMember_zhm4Ih8MDOXl" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">4,980,510</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right; width: 18%">3,460,815</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td></tr> </table> <p id="xdx_8A1_zK9rMhf9sZNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Our ownership percentage of <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlterolaBiotechIncMember_zjkSPBu2FMFj" title="Ownership percentage">25</span>% of Alterola allows us to have significant influence over the operations and decision making at Alterola. Accordingly, the investment is accounted for as an equity method investment. Our share of net loss from our investment in Alterola was $<span id="xdx_900_eus-gaap--EquityMethodInvestments_iI_c20221003_z78N5T28OB93" title="Equity method investments">135,155</span> for the period from October 3, 2022 through the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola (Note 16).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Voting Agreement was initially measured at fair value utilizing the Black-Scholes-option-pricing model based on the following assumptions: dividend rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zZPSVZjYxL7j" title="Dividend rate">0.0</span>%, risk free rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zQ8UIlXTAS7d" title="Rist free rate">4.0</span>%, term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_ztBxsnfd8Ik9" title="Expected term">0.5</span> years, volatility of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zLryit9Kl4E3" title="Volatility rate">66.0</span>%, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--VotingAgreementMember_zoPNV6YVpLU4" title="Share based payment, description">the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the value of the option was impaired to nil to reflect the likelihood that the option would be exercised according to the terms set forth and prior to expiry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_829_zaC34P5wrwvc">Merger Transactions</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Bright Green Grow Innovations, LLC Merger</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 28, 2019, the Company entered into a merger agreement with BGGI. Pursuant to the merger agreement, BGGI transferred to the Company two parcels of land and a greenhouse building having a total net carrying value of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20190527__20190528__srt--ConsolidatedEntitiesAxis__custom--BrightGreenGrowInnovationsLlcMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zWgCMkCc78Yc" title="Sale of stock">9,128,851</span> in exchange for shares of the Company (Note 8). The land transfer consisted of a <span id="xdx_902_eus-gaap--AreaOfLand_iI_uAcre_c20190528__srt--ConsolidatedEntitiesAxis__custom--BrightGreenGrowInnovationsLlcMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--GreenHouseMember__srt--StatementGeographicalAxis__stpr--NM_zrTf9Pjkw4Wi" title="Transfer of land for shares">70</span>-acre lot with a greenhouse at 1033 George Hanosh Blvd., Grants, New Mexico 87020 and a <span id="xdx_905_eus-gaap--AreaOfLand_iI_uAcre_c20190528__srt--ConsolidatedEntitiesAxis__custom--BrightGreenGrowInnovationsLlcMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--StatementGeographicalAxis__stpr--NM_zX1hZfbmqW6c" title="Transfer of land for shares">40</span>-acre lot in the City of Grants, New Mexico. The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Merger Transactions (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Bright Green Grow Innovations, LLC Merger (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical carrying values of BGGI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grants Greenhouse Growers, Inc. Merger</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. (“GGG”) (the “GGG Merger Agreement”). Pursuant to the GGG Merger Agreement, GGG was merged into the Company in exchange for <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20201028__20201030__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zOtBbqD3FI1k" title="Number of shares issued, shares">1,000,000</span> shares of the Company. GGG had no assets or liabilities, other than the following options agreements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementOneMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zJqqMWq6916" title="Real estate monthly payment">1,500</span> monthly payments up until June 30, 2021, and $<span id="xdx_903_eus-gaap--PaymentsForRent_c20210701__20211231__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementOneMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zCHhJP3nXmoc" title="Payments for rent">1,750</span> monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $<span id="xdx_906_eus-gaap--PaymentsForRent_c20220101__20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementOneMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zQpEa9gvJtf4" title="Rental for real estate">2,000</span> monthly payments, with the option to purchase <span id="xdx_906_eus-gaap--AreaOfLand_iI_uAcre_c20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementOneMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zH9UJRHLOnV6" title="Area of land">330</span> acres for $<span id="xdx_909_ecustom--PurchasePriceOptionOfLand_iI_pid_c20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementTwoMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_z33qOBkSSii" title="Price per acre">5,000</span> per acre.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $<span id="xdx_906_eus-gaap--PaymentsForRent_c20201021__20201021__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementTwoMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zgPncZ3zY0I4">1,000</span> monthly payments, with a one-year extension starting on January 1, 2022 for $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20220101__20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementTwoMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_ziy7yk5JFvql" title="Payments for rent">1,500</span> monthly payments, with the option to purchase <span id="xdx_907_eus-gaap--AreaOfLand_iI_uAcre_c20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementTwoMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zSrWBSoCt6Sg" title="Area of land">175</span> acres for $<span id="xdx_909_ecustom--PurchasePriceOptionOfLand_iI_pid_c20220101__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementTwoMember__srt--ConsolidatedEntitiesAxis__custom--GrantsGreehouseGrowersIncMember_zKazrg6yGQg3" title="Price per acre">5,000</span> per acre.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. The asset acquisition was accounted for at the fair value of the options agreement of $<span id="xdx_90D_eus-gaap--FairValueOfAssetsAcquired_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--GGGMergerAgreementMember__us-gaap--RealEstatePropertiesAxis__custom--RealEstateOptionAgreementMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesModelMember_zY8oH67PJjbb">103,837 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determined using the Black Scholes Model and management had assessed the value of these options to be impaired due to uncertainty surrounding their recoverability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Naseeb, Inc. Merger</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 10, 2020, the Company entered into a merger agreement with Naseeb, Inc. (“Naseeb”) and the sole shareholder of Naseeb, who is also a shareholder and Chairman of the Company. Pursuant to the Naseeb merger agreement, Naseeb was merged into the Company in exchange for <span id="xdx_903_eus-gaap--SharesIssued_iI_c20221231__dei--LegalEntityAxis__custom--NaseebIncMember_zu7jZl2HD9Sc" title="Exchange of shares">10,000,000</span> shares of the Company. Naseeb</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Merger Transactions (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Naseeb, Inc. Merger (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transferred to the Company their assistance that was used by the Company towards obtaining the following licenses and patents to the Company:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New Mexico Hemp License:</i> Industrial Hemp is an agricultural plant that uses all the byproducts of the plant such as seeds and twigs in the production of hemp seed, hemp fiber, and other eco-friendly products.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New Mexico Board of Pharmacy Schedule 1 Bulk Manufacturers License:</i> Securing the license was required as part of the application and consideration for a federal license. Additionally, being licensed as a Schedule 1 Bulk Manufacturer allows the Company to develop and distribute Schedule 1 drugs; an authorization precedent to the ability to grow, extract and distribute other cannabidiols, such as CBG and CBN. Moreover, with this license, the Company is exempt from the restrictions generally applicable to the cannabis industry, such as plant count and per plant taxes. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal Medical Marijuana License:</i> The Company has a formal agreement with the Drug Enforcement Administration for the construction and operation of a federally licensed agricultural center to grow and distribute marijuana, or its chemical constituents, supplying legitimate researchers in the United States.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents: </i>The patents held by the Company provide innovative medical therapies to a wide range of conditions. These patents can be sold, licensed, or directly marketed as clinical trials are conducted and approved by the FDA.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed that the merger transaction did not qualify as a business combination in accordance with the provisions of ASC 805. The Company accounted for the merger as an acquisition of assets. Since, under ASC 850, the merger was considered as a related party transaction by virtue of common ownership and management, the assets transferred to the Company have been accounted for at historical cost of Naseeb of $<span id="xdx_907_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_c20220101__20221231__dei--LegalEntityAxis__custom--NaseebIncMember_zpXA49R8EKh9" title="Asset acquisition consideration transferred amount">1,000</span> (Note 9).</span></p> 2000000000 0.001 807047948 201761982 3999999 1650000 0.67 0.25 The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock 50000000 339115 192011 90705 12018147 12000000 1822696 1217811 151255 169038 10236237 10703856 4980510 3460815 0.25 135155 0.000 0.040 P0Y6M 0.660 the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999. 9128851 70 40 1000000 1500 1750 2000 330 5000 1000 1500 175 5000 103837 10000000 1000 <p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zPG5zWtxGdu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_82D_zsYh0G5LZa48">Property, Plant, and Equipment</span></span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns an expansive <span id="xdx_902_eus-gaap--AreaOfLand_iI_uAcre_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VenloStyleGreenHouseMember__srt--StatementGeographicalAxis__stpr--NM_zJg2u3CMFHpf" title="Area of land">22</span>-acre modern Dutch “Venlo style” glass greenhouse situated on <span id="xdx_901_eus-gaap--AreaOfLand_iI_uAcre_c20221231__srt--StatementGeographicalAxis__stpr--NM_z9yVJI8dUxR7" title="Area of land">70</span> acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Property, Plant, and Equipment (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDSBcMeNFSKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment at December 31, 2022 and 2021, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zIDsOE4psK8l" style="display: none">Schedule of Property Plant and Equipment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_z5NA5Bk46vZe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_zVLMAoLIgUGf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzv61_maPPAEGzOAj_zrj7SGEtOXo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Land_iI_maPPAEGzv61_maPPAEGzOAj_zgnTrlViTSL2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzv61_maPPAEGzOAj_zbBmwUdz1oJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,736,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302,717</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BuildingsAndImprovementsGross_iI_maPPAEGzv61_maPPAEGzOAj_zFrhsFzYdUv4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Building and improvement</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENzAvU_mtPPAEGzOAj_znbEp82NRDQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,968,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,446,568</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzAvU_zEDkEXD33zq3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,822,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,117,804</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzAvU_zRzYdBwsKDu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property, plant, and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,146,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,328,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zqeQOwBy6wVk" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of interest costs capitalized and included in construction in progress totaled $<span id="xdx_905_eus-gaap--InterestCostsCapitalized_c20220101__20221231_pp0p0" title="Interest costs capitalized">106,117</span> and $<span id="xdx_90A_eus-gaap--InterestCostsCapitalized_dxL_c20210101__20211231_zKvgS72Anime" title="Interest costs capitalized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0610">nil</span></span> at December 31, 2022 and 2021, respectively (Note 11).</span></p> 22 70 <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDSBcMeNFSKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment at December 31, 2022 and 2021, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zIDsOE4psK8l" style="display: none">Schedule of Property Plant and Equipment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_z5NA5Bk46vZe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_zVLMAoLIgUGf" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzv61_maPPAEGzOAj_zrj7SGEtOXo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Land_iI_maPPAEGzv61_maPPAEGzOAj_zgnTrlViTSL2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_maPPAEGzv61_maPPAEGzOAj_zbBmwUdz1oJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,736,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302,717</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BuildingsAndImprovementsGross_iI_maPPAEGzv61_maPPAEGzOAj_zFrhsFzYdUv4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Building and improvement</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,883,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENzAvU_mtPPAEGzOAj_znbEp82NRDQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant, and equipment gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,968,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,446,568</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzAvU_zEDkEXD33zq3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,822,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,117,804</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzAvU_zRzYdBwsKDu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net property, plant, and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,146,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,328,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 88690 260000 260000 10736269 302717 8883851 8883851 19968810 9446568 2822485 2117804 17146325 7328764 106117 <p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zSPjsIsHbeWd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zygFOtaZXHF2">Intangible Assets</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z0hsWyh4MII5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets at December 31, 2022 and 2021, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zAS6TyO6vLy1" style="display: none">Schedule of Intangible Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zDtxhoxssFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zPqBmSMWK1q9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maIANEGzAKK_zzj461V5sAU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Licenses (Note 7)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIANEGzAKK_z5E4xLKwa6oc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_maAzyIt_mtIANEGzAKK_z4b1dOi0nYTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z0hsWyh4MII5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets at December 31, 2022 and 2021, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zAS6TyO6vLy1" style="display: none">Schedule of Intangible Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zDtxhoxssFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zPqBmSMWK1q9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maIANEGzAKK_zzj461V5sAU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Licenses (Note 7)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIANEGzAKK_z5E4xLKwa6oc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_maAzyIt_mtIANEGzAKK_z4b1dOi0nYTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1000 1000 1000 1000 <p id="xdx_808_eus-gaap--CommitmentsDisclosureTextBlock_zb9iYEvFfxT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82F_z5Ks1RumaxO6">Commitments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During 2022, the Company entered a contract to purchase equipment for $<span id="xdx_90F_eus-gaap--PaymentsForPurchaseOfOtherAssets1_c20220101__20221231_zOEB6SD4EUye" title="Payments for purchase">2,219,285</span>. The Company made a deposit totaling $<span id="xdx_90A_ecustom--PaymentsForAcquirePropertyDeposit_c20220101__20221231_zSctDJjhGVsh" title="Deposits">1,109,643</span> as of December 31, 2022 (Note 5). The remaining balance of $<span id="xdx_90B_eus-gaap--PaymentsForDeposits_c20220101__20221231_zpH9gkjfMSt" title="Deposits">1,109,642</span> is due upon delivery. The Company also entered into and paid in full a construction contract for $<span id="xdx_901_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20221231_z6UXAaviJYUg" title="Construction of contract paid">47,944</span> as of December 31, 2022 (Note 5). The construction to be performed under this contract will occur in 2023.</p> 2219285 1109643 1109642 47944 <p id="xdx_80B_ecustom--RelatedPartyLineOfCreditTextBlock_zzPCWM358ZLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_82A_zry4YqztdAQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related Party Line of Credit Note</span></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The Note provides that the Company may borrow up to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zPgD84Rvb6Ha" title="Line of credit facility, maximum borrowing amount">5.0</span> million, including an initial loan in the amount of $<span id="xdx_902_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_z1lclPBpYZSf" title="Line of credit loan amount">3.0</span> million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zv9UyKTHDO1b" title="Borrowing capacity">2.0</span> million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds form Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related Party Line of Credit Note (continued)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zweTk4MFvMif" title="Interest rate stated percentage">2</span>% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220605__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zZvvca5PpA1d" title="Interest rate stated percentage">2</span>% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10 million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Lender has funded the Company $<span id="xdx_904_eus-gaap--IncreaseDecreaseInSecuritiesLendingPayable_c20220101__20221231__us-gaap--CreditFacilityAxis__custom--UnsecuredLineOfCreditMember__us-gaap--LineOfCreditFacilityAxis__custom--LDSCapitalLLCMember_zk2eptVJKW8g" title="Lender committed funds">5,191,057</span> with the Company paying back $<span id="xdx_903_eus-gaap--RepaymentsOfOtherDebt_pp0p0_c20220101__20221231_zJuqaOghkKp6" title="Repayments of other debt">1,611,067</span> of those funds. As of December 31, 2022, there was accrued interest of $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20221231_zBlbRO0JbOo8" title="Accrued interest">106,117</span>. The funds have been used for the construction in progress and interest expense of $<span id="xdx_904_eus-gaap--InterestCostsCapitalized_c20220101__20221231_zcKHUBWtPXFj" title="Interest costs capitalized">106,117</span> has been capitalized (Note 8).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The note was drawn on for $<span id="xdx_908_eus-gaap--DueToRelatedPartiesCurrent_iI_c20230201__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zygmN5b87th3" title="Due to related party">392,194</span> to pay off the Due to Related Party and was paid down $<span id="xdx_905_eus-gaap--LineOfCreditFacilityFairValueOfAmountOutstanding_iI_c20230206__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcgpDMkXDezh" title="Line of credit paid">880,000</span>, subsequent to year end (Note 16). On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company (Note 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2023, the Company drew an additional $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20230314__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z843sysHGmY" title="Drew from related party line of credit">200,000</span> on the June Note, leaving available $<span id="xdx_908_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn5n6_c20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCeS1iybhrb3" title="Credit facility">11.5</span> million to draw from that credit facility.</span></p> 5000000.0 3000000.0 2000000.0 0.02 0.02 5191057 1611067 106117 106117 392194 880000 200000 11500000 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zIKazohMPuS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_82B_z7v9Az5BtfKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity</span></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlT9oGnYzoui" title="Common stock, shares authorized">500,000,000</span> shares of $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_z6lZpdzF3md5" title="Common stock, par value">0.0001</span> par value common stock and <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zHPCR0nQ4Epl" title="Preferred stock, shares authorized">10,000,000</span> shares of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zCtA602SGSSj" title="Preferred stock, par value">0.0001</span> par value preferred stock. As of December 31, 2022 and 2021, there were <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zHRgztjp9FDc" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zHG093Ac1QFb" title="Common stock, shares outstanding">173,304,800</span></span> and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zHD8SHIdMXmi" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zKiE5oeWO9r4" title="Common stock, shares outstanding">157,544,500</span></span>, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the twelve months ended December 31, 2022, the Company issued the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zBHkuf1vIm7e">12,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_znkBTp4yGojj">4.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, for gross cash proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneAccreditedInvestorMember_zXgkIru83ig6">50,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, to one accredited investor in January 2022;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220401__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLw5PGtF1jg9">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for services rendered, at a fair value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pip0_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3dB8VUpD9md">4.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share determined using the per share purchase price of (the “$4.00 Round”), to the Chief Financial Officer of the Company, in April 2022;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zIztlT9TjNmi">5,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zaeipAiTUx3d">2.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, were cancelled in April 2022;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zpihxJvazx07">300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at a purchase price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zR5XG1e6OPij">10.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, for gross cash proceeds of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorMember_zpARmzazs0m3">3,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, to two accredited investors in May 2022; </span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--SixConsultantsMember_z8zR52YuDSz5">1,574,490 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for services rendered in connection with the Direct Listing to the Company’s advisor, or its permitted designees, contemporaneous with the Direct Listing and consistent with the direct listing price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--SixConsultantsMember_zwBAdNc0HO4d">8.00</span> per share in June 2022;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.5in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zP5WD1NykQu3">108,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zAmeuVoB8smj">0.069 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share determined using an asset approach, were cancelled in June 2022;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqGIuM1ui1K6" title="Issuance of shares">9,523,810</span> shares of Common Stock and warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z7LJ8xXVHgD6" title="Issuance of shares">9,523,810</span> shares of Common Stock, in a private placement offering, in September 2022 (the “September 2022 Private Placement”); and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeR9R5xtVBm1">3,962,500</span> shares of common stock for services rendered, with (i) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z44hYCO3RdH">3,000,000</span> shares issued at a fair value of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxZT6Y3gIVx9" title="Issued price per share">1.25</span> per share, (ii) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zMIAsIsAEfNg">87,500</span> shares at a fair value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zD4KlljpJ36c" title="Issued price per share">1.08</span> per share, and (iii) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zzVDteZmvUm">875,000</span> shares at a fair value of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdhmLxLk3NAd" title="Issued price per share">0.4695</span> per share, to the former Chief Executive Officer of the Company, in December 2022.</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 7, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with investors. The combined purchase price of one Share and accompanying Warrant was $<span id="xdx_904_eus-gaap--WarrantExercisePriceIncrease_c20220906__20220907__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecurituesPurchaseAgreementMember_zXIbOACPGpy1">1.05</span>. Subject to certain ownership limitations, the Warrants are exercisable immediately after issuance at an exercise price equal to $<span id="xdx_900_eus-gaap--WarrantExercisePriceIncrease_c20220906__20220907__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCoVbuVxnEa9" title="Exercise price">1.05</span> per share of Common Stock (the “Exercise Price”), subject to adjustments as provided under the terms of the Warrants. The Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zam0NJyhRVU1" title="Issuance of common stock">10</span> million before deducting transaction related fees and expenses payable by the Company<span style="letter-spacing: -0.1pt">. </span>On February 1, 2023, <span id="xdx_909_eus-gaap--AdjustmentOfWarrantsGrantedForServices_c20230129__20230201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8EvCPe4HfMh" title="Warrants redeemed">200,000</span> of the Warrants were redeemed for $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20230129__20230201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjJjEJPgIffk" title="Warrants redeemed">210,000</span> (Note 16). </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the September Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September Private Placement went effective on September 21, 2022. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs incurred related to the September Private Placement include the following: (i) placement agent fees of $<span id="xdx_900_eus-gaap--BusinessCombinationIntegrationRelatedCosts_c20220101__20221231_zEjXqCjIubK4" title="integration related costs">800,000</span>, (ii) legal expenses of $<span id="xdx_905_eus-gaap--LegalFees_c20220101__20221231_zZeWsE372Dmf" title="Legal fees">55,617</span>, and (iii) escrow agent expenses of $<span id="xdx_90E_eus-gaap--EscrowDeposit_iI_c20221231_zFQdqTJXhWy" title="Escrow deposit">7,650</span>. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>September Warrants </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The measurement of fair value was determined utilizing a Monte Carlo simulation considering all relevant assumptions current at the date of issuance (i.e., share price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20221231_zHBrcKAl6skc" title="Share price">1.65</span>, exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231_zcWpk7iUpC48" title="Warrant exercise price">1.05</span>, term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20221231_zTp4ka8N6NEf" title="Warrant term">five years</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_uPure_c20220101__20221231_zseKFgYXFSTc" title="Volatility rate">174.3</span>%, risk-free rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231_zyhVKfSd8YIf" title="Risk-free rate">3.41</span>%, probability of dilutive issuance of <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDilutiveIssuanceRate_dp_uPure_c20220101__20221231_zUJgK2egVOx1" title="Dilutive issuance rate">15</span>%, estimated timing of dilutive issuance of four and a half months, and expected time to conversion of five years). The grant date fair value of these Warrants were estimated to be $<span id="xdx_90E_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20220912__20220912_zX7ZJoxK18H9" title="Warrants estimate value">4,489,662</span> on September 12, 2022 of the gross proceeds and is reflected within additional paid-in capital as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the twelve months ended December 31, 2021, the Company issued the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwentyEightAccreditedMember_zycbbjBZPs07" title="Issuance of shares">1,019,000</span> shares of common stock at a purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember_zai0vqkyb2m8" title="Issued price per share">2.00</span> per share, for gross cash proceed of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember_zMgPSP62GzM9" title="Issuance of value">2,038,000</span> to thirty accredited investors between January 2021 and October 2021, with (i) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zpMx8byJmZ3f" title="Issuance of shares">184,000</span> shares issued in January 2021, which includes the <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssued_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember_zMlv3tlN3eF5" title="Shares issued for cash proceeds">69,000</span> shares issued for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember__us-gaap--AwardDateAxis__custom--DecemberTwentyTwentyMember_zuYG8WLQoWj9">138,000</span> received as of December 31, 2020, (ii) <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember__us-gaap--AwardDateAxis__custom--MarchTwentyTwentyOneMember_zyRKusdOP9xb" title="Issuance of shares">100,000</span> shares issued in March 2021, (iii) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MayTwentyTwentyOneMember_zAtLEyt2mKn1" title="Issuance of shares">335,000</span> shares issued in May 2021, (iv) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwentyEightAccreditedMember__us-gaap--AwardDateAxis__custom--JuneTwentyTwentyOneMember_z0oLRFqLqHxg" title="Issuance of shares">250,000</span> shares issued in June 2021, and (v) <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--SeptemberTwentyTwentyOneMember_zR6l9ouXOoX7" title="Issuance of shares">100,000</span> shares issued in September 2021 and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--OctoberTwentyTwentyOneMember_zdgFafCTqyNb" title="Issuance of value">50,000</span> shares issued in October 2021 (the “$<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThirtyAccreditedMember_zQxxWco1mKza" title="Issued price per share">2.00</span> Round”);</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stockholders’ Equity (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember__us-gaap--AwardDateAxis__custom--SeptemberAndOctoberTwentyTwentyOneMember_zqXOcMu8F5G6" title="Issuance of shares">188,000</span> shares of common stock at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember__us-gaap--AwardDateAxis__custom--SeptemberAndOctoberTwentyTwentyOneMember_z4XN4ZcVbRr6" title="Issued price per share">3.00</span> per share, for gross cash proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember__us-gaap--AwardDateAxis__custom--SeptemberAndOctoberTwentyTwentyOneMember_zo69gpeRtNFh">564,000</span> to one hundred eighty-eight accredited investors in September and October 2021 with (i) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember__us-gaap--AwardDateAxis__custom--SeptemberTwentyTwentyOneMember_zorU0Vp47sAk" title="Issuance of shares">154,000</span> shares in September 2021, and (ii) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember__us-gaap--AwardDateAxis__custom--OctoberTwentyTwentyOneMember_zS1Ndqnkafo3" title="Issuance of shares">34,000</span> shares issued in October 2021 (the “$<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OneHundredEightyEightAccreditedMember_zw4XqlYfFWK7" title="Issued price per share">3.00</span> Round”);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember__us-gaap--AwardDateAxis__custom--OctoberAndDecemberTwentyTwentyOneMember_zv2ruwU2Vh61" title="Issuance of shares">166,500</span> shares of common stock at a purchase price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember__us-gaap--AwardDateAxis__custom--OctoberAndDecemberTwentyTwentyOneMember_zy6txW7mieM4" title="Issued price per share">4.00</span> per share, for gross cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember__us-gaap--AwardDateAxis__custom--OctoberAndDecemberTwentyTwentyOneMember_zqZDyDLdp4d2" title="Proceeds from issuance of common stock">666,000</span>, to 12 accredited investors in October and December 2021, with (i) <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember__us-gaap--AwardDateAxis__custom--OctoberTwentyTwentyOneMember_z2HcDAaw5phc" title="Issuance of shares">29,000</span> shares in October 2021, and (ii) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember__us-gaap--AwardDateAxis__custom--DecemberTwentyTwentyOneMember_z2eE5oXvs6yf" title="Issuance of shares">137,500</span> shares issued in December 2021 (the “$<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedMember_zswGW4NFUdob" title="Issued price per share">4.00</span> Round”);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FiveConsultantsMember_z8G73lslyiJe">25,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FiveConsultantsMember_zp2HTpafeA47" title="Shares issued price per share">2.00</span> per share determined using the per share purchase price of the $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FiveConsultantsMember_zXC6PuQ8Czia" title="Issued price per share">2.00</span> Round, to five consultants, with (i) <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FiveConsultantsMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zq4oLwiVXa04" title="Shares issued">10,000</span> shares issued in January 2021 and (ii) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--FiveConsultantsMember__us-gaap--AwardDateAxis__custom--MayTwentyTwentyOneMember_zbUzOz6FeK27" title="Shares issued">15,000</span> shares issued in May 2021;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zKX2DD0nLI83">40,000</span> shares of common stock for services rendered, at a fair value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zW3Yx1BkOhha" title="Shares issued price per share">2.00</span> per share determined using the per share purchase price of (the “$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zFh60NE1LtD4" title="Issued price per share">2.00</span> Round”), to three directors of the Company, with (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyOneMember_zSKTGfdahvL5" title="Shares issued">10,000</span> shares issued in January 2021 and (ii) <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember__us-gaap--AwardDateAxis__custom--FebruaryTwentyTwentyOneMember_z5ZUb18jVZ18" title="Shares issued">30,000</span> shares issued in February 2021;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zzK4c7dvB4U1">10,000</span> shares of common stock for services rendered, at fair value at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zGnSgxL3U571" title="Shares issued price per share">3.00</span> per share determined using the per share purchase price of (the “$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zMKts7X6iJT7" title="Issued price per share">3.00</span> Round”), to two directors of the Company, in September 2021; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_zRdEGJRNIGEj" title="Number of shares issed for services">50,000</span> shares of common stock for services rendered, at fair value at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_zL2ehtr9VZH9" title="Shares issued price per share">4.00</span> per share determined using the per share purchase price of (the “$<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_zaQtLl8sthTd" title="Issued price per share">4.00</span> Round”), to three consultants in November 2021.</span></td></tr> </table> 500000000 0.0001 10000000 0.0001 173304800 173304800 157544500 157544500 12500 4.00 50000 500000 4.00 5000 2.00 300000 10.00 3000000 1574490 8.00 108000 0.069 9523810 9523810 3962500 3000000 1.25 87500 1.08 875000 0.4695 1.05 1.05 10000000 200000 210000 800000 55617 7650 1.65 1.05 P5Y 1.743 0.0341 0.15 4489662 1019000 2.00 2038000 184000 69000 138000 100000 335000 250000 100000 50000 2.00 188000 3.00 564000 154000 34000 3.00 166500 4.00 666000 29000 137500 4.00 25000 2.00 2.00 10000 15000 40000 2.00 2.00 10000 30000 10000 3.00 3.00 50000 4.00 4.00 <p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zfPdwYn7W2jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_823_zB9W40CNA0Ni">Income Taxes</span></span><b/></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2022 and 2021, based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zNIngA7RoxO2">Income Taxes (continued)</span></span><b/></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The current and deferred income tax expenses for the years ended December 31, 2022 and 2021, were $<span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zbcXVfm0STp2" title="Current and deferred income tax expenses::XDX::-"><span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20210101__20211231_zqZcxX00Cbrc" title="Current and deferred income tax expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0815"><span style="-sec-ix-hidden: xdx2ixbrl0817">nil</span></span></span></span>. The provision for income taxes differs from that computed at a combined corporate tax rate of approximately <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20220101__20221231_z7giBqZckeh" title="Tax rate">25.8</span>% (2021 – <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20210101__20211231_zksmVFhIwISb" title="Tax rate">25.8</span>%) as follows:</span></p> <p id="xdx_898_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zO5EbvyvPNza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8BB_z24qgTvdhLSb" style="display: none">Schedule of Income Tax Provision</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zxTnG8CCBXCj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_zGSs3pImLeo3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_ze073VdBstf3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss before income taxes</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(27,662,077</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(2,490,499</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The (benefit) provision for income taxes for 2022 and 2021 consists of the following:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zxYsoJC5eRc3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzz1e_zb3TseGB7WD7" style="vertical-align: bottom; background-color: White"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzz1e_zL8UuSBRdI9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzz1e_maITEBzG4H_z1TT3yTDxyb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total current (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z8xOZ8bvlYpg" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_zu9S6scI0vgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,727,839</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(515,114</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_zYzyyhfotvt4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,309,220</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(117,740</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmoD_maITEBzG4H_zAvp4G0HSyhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total current (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(632,854</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ValuationAllowancesOfIncomeTaxExpenseBenefit_i01N_di_msITEBzG4H_z6NXcRi0mZH3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">632,854</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzG4H_z2JR0320Qaog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zV9iyjBtu37k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="display: none"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock_zh8Ep2FeNDhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z04REWI4DI23" style="display: none">Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zDbZZdWTS0Sg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zlnBaKUu2wKf" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqzZ_zcBuG74WuZs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Other</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">728,201</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">546,393</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqzZ_zGHf31mBGam1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Net operating loss carry over</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,294,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">438,894</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqzZ_zD0I8XsKaM02" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,022,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">985,287</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zNBi11dQKwj1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,022,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(985,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_zgU8aOURUg4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zZiG2DYG4384" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. Management has based its assessment on the Company’s lack of profitable operating history. As of December 31, 2022 and 2021, the Company has approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zoRFfHLBGeBc" title="Operating loss carryforwards">28,271,882</span> and $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ziqv9zKF8kse" title="Operating loss carryforwards">1,701,141</span> respectively, of Federal net operating losses available to reduce taxable income of future years. The federal loss carryforward expires indefinitely and the state loss carryforward expires in 2039. The benefit from the non-capital loss carry-forward balance has not been recorded in the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to U.S. federal jurisdiction and the state of New Mexico income taxes. Management has not filed federal or state income tax returns due to incurring cumulative losses. Therefore, the Company’s actual tax position may differ from their book position. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense.</span></p> 0.258 0.258 <p id="xdx_898_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zO5EbvyvPNza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8BB_z24qgTvdhLSb" style="display: none">Schedule of Income Tax Provision</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zxTnG8CCBXCj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210101__20211231_zGSs3pImLeo3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_ze073VdBstf3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss before income taxes</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(27,662,077</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(2,490,499</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The (benefit) provision for income taxes for 2022 and 2021 consists of the following:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zxYsoJC5eRc3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzz1e_zb3TseGB7WD7" style="vertical-align: bottom; background-color: White"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzz1e_zL8UuSBRdI9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzz1e_maITEBzG4H_z1TT3yTDxyb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total current (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z8xOZ8bvlYpg" style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_zu9S6scI0vgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,727,839</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(515,114</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmoD_zYzyyhfotvt4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,309,220</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(117,740</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmoD_maITEBzG4H_zAvp4G0HSyhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total current (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(632,854</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ValuationAllowancesOfIncomeTaxExpenseBenefit_i01N_di_msITEBzG4H_z6NXcRi0mZH3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,037,059</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">632,854</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzG4H_z2JR0320Qaog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><b>Total (benefit) provision</b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> -27662077 -2490499 -5727839 -515114 -1309220 -117740 -7037059 -632854 -7037059 -632854 <p id="xdx_89B_ecustom--ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock_zh8Ep2FeNDhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal and state tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z04REWI4DI23" style="display: none">Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zDbZZdWTS0Sg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zlnBaKUu2wKf" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzqzZ_zcBuG74WuZs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Other</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">728,201</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">546,393</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzqzZ_zGHf31mBGam1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Net operating loss carry over</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,294,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">438,894</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzqzZ_zD0I8XsKaM02" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,022,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">985,287</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zNBi11dQKwj1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,022,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(985,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_zgU8aOURUg4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 728201 546393 7294146 438894 8022347 985287 8022347 985287 28271882 1701141 <p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWKATxhG4Cf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_822_zAJidZLHbFYl">Related Party Transactions</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the transactions disclosed elsewhere in the financial statements, the following are the other significant related party transactions and balances:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022 and 2021, the due to related party balance totaled $<span id="xdx_905_eus-gaap--DueToOfficersOrStockholdersCurrent_iI_pp0p0_c20221231_zKP5c8MVcTgb" title="Due to related party">392,194</span> and $<span id="xdx_903_eus-gaap--DueToOfficersOrStockholdersCurrent_iI_pp0p0_c20211231_zpy9K6ADRtE8" title="Due to related party">392,194</span>, respectively. The balance represents advances from the majority shareholder for payment of Company expenses. The amount is unsecured, non-interest bearing with no terms of repayment. The shareholder has agreed in writing that no payment will be required by the Company to the lender prior to January 31, 2023. On February 1, 2023, this loan was paid in full with a draw on the line of credit (Note 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related Party Transactions (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Included in common stock issued for services during the year ended December 31, 2022, were <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfVCIHHnJsJh" title="Issuance of shares">3,962,500</span> shares of common stock issued to the former Chief Executive Officer of the Company (Note 12).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in common stock issued for services during the year ended December 31, 2022, were <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zPix1dfjTJT4" title="Issuance of shares">500,000</span> shares of common stock issued to the Chief Financial Officer of the Company (Note 12).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in common stock issued for services during the year ended December 31, 2021, were <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__srt--TitleOfIndividualAxis__custom--FiveDirectorsMember_zsV5tivwzZhk" title="Issuance of service shares">50,000</span> shares of common stock issued to the five directors of the Company (Note 12).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, $<span id="xdx_905_eus-gaap--DueFromOfficersOrStockholders_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_zTsH8Nhdp5v5" title="Due from officers or stockholders">400,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was due to the Company’s former interim Chief Executive Officer, who also is a shareholder. The amount, which includes $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember_zivSvjPnam69" title="Accrued liabilities">300,000</span> in accrued bonus is included in accrued liabilities in the Balance Sheet. The accrued bonus is expected to be paid in the first quarter of 2024 and is subject to Board of Director approvals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, $<span id="xdx_908_eus-gaap--DueFromOfficersOrStockholders_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zSGusUGgVsu9" title="Related party transaction">65,856</span> was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, $<span id="xdx_900_eus-gaap--DueFromOfficersOrStockholders_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zz8spWMmmWw2" title="Accrued payroll">60,000</span> was due to the Company’s former Chief Executive Officer, who also is a shareholder. The amount is included in accounts payable in the Balance Sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, the outstanding balance on the line of credit of $<span id="xdx_902_eus-gaap--LongTermLineOfCredit_iI_c20221231_zQHz6Rwz3Uj7" title="Long-term line of credit">3,686,107</span> was due to a Lender, whose managing member is a member of the Board (Note 11). The amount is included in the related party line of credit note in the Balance Sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related party line of credit note was drawn on to pay in full, the related party loan balance of $<span id="xdx_903_eus-gaap--DueToRelatedPartiesCurrent_iI_c20230201__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpUF5wPoNyU4" title="Due to related party">392,194</span>, and was paid down $<span id="xdx_903_eus-gaap--LineOfCreditFacilityFairValueOfAmountOutstanding_iI_c20230206__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhcWGACMuka2" title="Line of credit paid">880,000</span> subsequent to year end (Note 16).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2023, the Company drew an additional $<span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20230314__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgV6gsUGAPg6" title="Drew from related party line of credit">200,000</span> on the June Note (Note 16).</span></p> 392194 392194 3962500 500000 50000 400000 300000 65856 60000 3686107 392194 880000 200000 <p id="xdx_801_eus-gaap--LossContingencyDisclosures_zouNs7vOoMai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_824_zxjuusupgt47">Contingencies</span> </span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the <span id="xdx_90B_eus-gaap--LossContingencyActionsTakenByDefendant_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWXCBNTubT1k" title="Contingency, taken by defendant description">Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company.</span> Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to <span id="xdx_90F_eus-gaap--LossContingencyActionsTakenByDefendant_c20220101__20221231_zSXgrYMdA14g" title="Contingency, taken by defendant description">(i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI</span>. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.</span></p> Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zE0bVN8DeEv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_82B_zie7XGLrRLx1">Subsequent Events</span></span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has evaluated the subsequent events up to April 17, 2023. The date the financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following constitute material subsequent events: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">As of December 31, 2022, we notified the land owners of our intention to exercise the two Real Estate Option Agreements and are in process of negotiating final terms of acquisition. The acquisition has yet to be completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2023, LDS Capital LLC assigned the related party line of credit note to its sole member, an individual, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2023, the related party line of credit note was used to pay in full, the related party loan balance of $<span id="xdx_90D_eus-gaap--DueToRelatedPartiesCurrent_iI_c20230201__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUMN4PbQbSHi" title="Due to related parties">392,194</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2023, the Company initiated their EB-5 Program, whereby they may issue up to an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230131__20230201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4VJ4c0ojzjd" title="Number of shares of stock issued">12,609,152</span> shares of common stock to accredited or institutional investors, at a price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20230201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQvtrjhFlEEc" title="Share price">39.99</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2023, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3F3ugzcAAbg" title="Warrants">200,000</span> of the September Warrants were redeemed for $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20230129__20230201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhah8k6LpVjc" title="Warrants redeemed">210,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityFairValueOfAmountOutstanding_iI_c20230206__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zIJrDezeCJt6" title="Line of credit paid">880,000</span> in exchange for an $<span id="xdx_903_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230206__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zarDlWEHgK0i" title="Line of credit current borrowing capacity">880,000</span> investment for <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20230206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAcoMuTphcLh" title="Shares issued">22,005</span> shares of the Company’s common stock valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5EcnGeT5DX" title="Price per share">39.99</span> pursuant to the EB-5 Program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2023, the Company drew an additional $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20230314__20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn49GG8CnkKf" title="Drew from related party line of credit">200,000</span> on the June Note, leaving available $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn5n6_c20230314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEilZ3VMiHa2" title="Credit facility">11.5</span> million to draw from that credit facility.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On March 27, 2023, we received an additional $<span id="xdx_90B_eus-gaap--Investments_iI_c20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7urYBSMHMsj" title="Investments">880,000</span> investment for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230327__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHONUBjYnO3e" title="Shares issued">22,005</span> shares of the Company’s common stock valued at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zU29QSD0Nyvi" title="Share price">39.99</span> pursuant to the EB-5 Program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">On March 31, 2023, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230330__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRFmsjQWP6p1" title="Number of shares issued">875,000</span> shares to the former Chief Executive Officer, Terry Rafih, pursuant to his employment agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2023, we announced our intention to acquire the remaining issued and outstanding common stock of Alterola. </span></p> 392194 12609152 39.99 200000 210000 880000 880000 22005 39.99 200000 11500000 880000 22005 39.99 875000 EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

,"2.[3ZXLQ]%JWTJ6O\';?0;4$L#!!0 ( M ,V%D5:7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 141 232 1 false 63 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://brightgreen.us/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://brightgreen.us/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://brightgreen.us/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss Sheet http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss Condensed Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity Sheet http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity Condensed Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical) Sheet http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical Condensed Statements of Changes in Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Statements of Cash Flows Sheet http://brightgreen.us/role/StatementsOfCashFlows Condensed Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Description of Business and Organization Sheet http://brightgreen.us/role/DescriptionOfBusinessAndOrganization Description of Business and Organization Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern and Basis of Presentation Sheet http://brightgreen.us/role/GoingConcernAndBasisOfPresentation Going Concern and Basis of Presentation Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Concentration of Credit Risk Sheet http://brightgreen.us/role/ConcentrationOfCreditRisk Concentration of Credit Risk Notes 11 false false R12.htm 00000012 - Disclosure - Deposits Sheet http://brightgreen.us/role/Deposits Deposits Notes 12 false false R13.htm 00000013 - Disclosure - Merger Transactions Sheet http://brightgreen.us/role/MergerTransactions Merger Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Property, Plant, and Equipment Sheet http://brightgreen.us/role/PropertyPlantAndEquipment Property, Plant, and Equipment Notes 14 false false R15.htm 00000015 - Disclosure - Intangible Assets Sheet http://brightgreen.us/role/IntangibleAssets Intangible Assets Notes 15 false false R16.htm 00000016 - Disclosure - Commitments Sheet http://brightgreen.us/role/Commitments Commitments Notes 16 false false R17.htm 00000017 - Disclosure - Related Party Line of Credit Note Sheet http://brightgreen.us/role/RelatedPartyLineOfCreditNote Related Party Line of Credit Note Notes 17 false false R18.htm 00000018 - Disclosure - Stockholders??? Equity Sheet http://brightgreen.us/role/StockholdersEquity Stockholders??? Equity Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes (continued) Sheet http://brightgreen.us/role/IncomeTaxesContinued Income Taxes (continued) Notes 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions Sheet http://brightgreen.us/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Contingencies Sheet http://brightgreen.us/role/Contingencies Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://brightgreen.us/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000026 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://brightgreen.us/role/PropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) Tables http://brightgreen.us/role/PropertyPlantAndEquipment 25 false false R26.htm 00000027 - Disclosure - Intangible Assets (Tables) Sheet http://brightgreen.us/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://brightgreen.us/role/IntangibleAssets 26 false false R27.htm 00000028 - Disclosure - Income Taxes (continued) (Tables) Sheet http://brightgreen.us/role/IncomeTaxesContinuedTables Income Taxes (continued) (Tables) Tables http://brightgreen.us/role/IncomeTaxesContinued 27 false false R28.htm 00000029 - Disclosure - Description of Business and Organization (Details Narrative) Sheet http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative Description of Business and Organization (Details Narrative) Details http://brightgreen.us/role/DescriptionOfBusinessAndOrganization 28 false false R29.htm 00000030 - Disclosure - Going Concern and Basis of Presentation (Details Narrative) Sheet http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative Going Concern and Basis of Presentation (Details Narrative) Details http://brightgreen.us/role/GoingConcernAndBasisOfPresentation 29 false false R30.htm 00000031 - Disclosure - Summary of Estimated Useful Life (Details) Sheet http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails Summary of Estimated Useful Life (Details) Details 30 false false R31.htm 00000032 - Disclosure - Schedule of Changes in the Fair Value of Financial Assets (Details) Sheet http://brightgreen.us/role/ScheduleOfChangesInFairValueOfFinancialAssetsDetails Schedule of Changes in the Fair Value of Financial Assets (Details) Details 31 false false R32.htm 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000034 - Disclosure - Concentration of Credit Risk (Details Narrative) Sheet http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative Concentration of Credit Risk (Details Narrative) Details http://brightgreen.us/role/ConcentrationOfCreditRisk 33 false false R34.htm 00000035 - Disclosure - Schedule of Financial Statement Information (Details) Sheet http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails Schedule of Financial Statement Information (Details) Details 34 false false R35.htm 00000036 - Disclosure - The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details) Sheet http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details) Details 35 false false R36.htm 00000037 - Disclosure - Merger Transactions (Details Narrative) Sheet http://brightgreen.us/role/MergerTransactionsDetailsNarrative Merger Transactions (Details Narrative) Details http://brightgreen.us/role/MergerTransactions 36 false false R37.htm 00000038 - Disclosure - Schedule of Property Plant and Equipment (Details) Sheet http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property Plant and Equipment (Details) Details 37 false false R38.htm 00000039 - Disclosure - Property, Plant, and Equipment (Details Narrative) Sheet http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant, and Equipment (Details Narrative) Details http://brightgreen.us/role/PropertyPlantAndEquipmentTables 38 false false R39.htm 00000040 - Disclosure - Schedule of Intangible Assets (Details) Sheet http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails Schedule of Intangible Assets (Details) Details 39 false false R40.htm 00000041 - Disclosure - Commitments (Details Narrative) Sheet http://brightgreen.us/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://brightgreen.us/role/Commitments 40 false false R41.htm 00000042 - Disclosure - Related Party Line of Credit Note (Details Narrative) Sheet http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative Related Party Line of Credit Note (Details Narrative) Details http://brightgreen.us/role/RelatedPartyLineOfCreditNote 41 false false R42.htm 00000043 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://brightgreen.us/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://brightgreen.us/role/StockholdersEquity 42 false false R43.htm 00000044 - Disclosure - Schedule of Income Tax Provision (Details) Sheet http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails Schedule of Income Tax Provision (Details) Details 43 false false R44.htm 00000045 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) Sheet http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details) Details 44 false false R45.htm 00000046 - Disclosure - Income Taxes (continued) (Details Narrative) Sheet http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative Income Taxes (continued) (Details Narrative) Details http://brightgreen.us/role/IncomeTaxesContinuedTables 45 false false R46.htm 00000047 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://brightgreen.us/role/RelatedPartyTransactions 46 false false R47.htm 00000048 - Disclosure - Contingencies (Details Narrative) Sheet http://brightgreen.us/role/ContingenciesDetailsNarrative Contingencies (Details Narrative) Details http://brightgreen.us/role/Contingencies 47 false false R48.htm 00000049 - Disclosure - Subsequent Events (Details Narrative) Sheet http://brightgreen.us/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://brightgreen.us/role/SubsequentEvents 48 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 28, 9888, 11921, 12473, 12581 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 29, 9905 [dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 12404 [dq-0542-Deprecated-Concept] Concept DueFromOfficersOrStockholders in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 12447, 12455, 12461 form10-k.htm bgxx-20221231.xsd bgxx-20221231_cal.xml bgxx-20221231_def.xml bgxx-20221231_lab.xml bgxx-20221231_pre.xml ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex4-2.htm form10-k_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 18, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 471, "http://xbrl.sec.gov/dei/2022": 38 }, "contextCount": 141, "dts": { "calculationLink": { "local": [ "bgxx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "bgxx-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "bgxx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "bgxx-20221231_pre.xml" ] }, "schema": { "local": [ "bgxx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 406, "entityCount": 1, "hidden": { "http://brightgreen.us/20221231": 10, "http://fasb.org/us-gaap/2022": 59, "http://xbrl.sec.gov/dei/2022": 3, "total": 72 }, "keyCustom": 20, "keyStandard": 212, "memberCustom": 45, "memberStandard": 17, "nsprefix": "BGXX", "nsuri": "http://brightgreen.us/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://brightgreen.us/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Concentration of Credit Risk", "menuCat": "Notes", "order": "11", "role": "http://brightgreen.us/role/ConcentrationOfCreditRisk", "shortName": "Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Deposits", "menuCat": "Notes", "order": "12", "role": "http://brightgreen.us/role/Deposits", "shortName": "Deposits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Merger Transactions", "menuCat": "Notes", "order": "13", "role": "http://brightgreen.us/role/MergerTransactions", "shortName": "Merger Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Property, Plant, and Equipment", "menuCat": "Notes", "order": "14", "role": "http://brightgreen.us/role/PropertyPlantAndEquipment", "shortName": "Property, Plant, and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "15", "role": "http://brightgreen.us/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments", "menuCat": "Notes", "order": "16", "role": "http://brightgreen.us/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BGXX:RelatedPartyLineOfCreditTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Related Party Line of Credit Note", "menuCat": "Notes", "order": "17", "role": "http://brightgreen.us/role/RelatedPartyLineOfCreditNote", "shortName": "Related Party Line of Credit Note", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BGXX:RelatedPartyLineOfCreditTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "18", "role": "http://brightgreen.us/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Income Taxes (continued)", "menuCat": "Notes", "order": "19", "role": "http://brightgreen.us/role/IncomeTaxesContinued", "shortName": "Income Taxes (continued)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://brightgreen.us/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "20", "role": "http://brightgreen.us/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Contingencies", "menuCat": "Notes", "order": "21", "role": "http://brightgreen.us/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "22", "role": "http://brightgreen.us/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Property, Plant, and Equipment (Tables)", "menuCat": "Tables", "order": "25", "role": "http://brightgreen.us/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant, and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "26", "role": "http://brightgreen.us/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Income Taxes (continued) (Tables)", "menuCat": "Tables", "order": "27", "role": "http://brightgreen.us/role/IncomeTaxesContinuedTables", "shortName": "Income Taxes (continued) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Description of Business and Organization (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "shortName": "Description of Business and Organization (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Going Concern and Basis of Presentation (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "shortName": "Going Concern and Basis of Presentation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "BGXX:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://brightgreen.us/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_BuildingMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Summary of Estimated Useful Life (Details)", "menuCat": "Details", "order": "30", "role": "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails", "shortName": "Summary of Estimated Useful Life (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "BGXX:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_BuildingMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Changes in the Fair Value of Financial Assets (Details)", "menuCat": "Details", "order": "31", "role": "http://brightgreen.us/role/ScheduleOfChangesInFairValueOfFinancialAssetsDetails", "shortName": "Schedule of Changes in the Fair Value of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Concentration of Credit Risk (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative", "shortName": "Concentration of Credit Risk (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Financial Statement Information (Details)", "menuCat": "Details", "order": "34", "role": "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "shortName": "Schedule of Financial Statement Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_AlterolaBiotechIncMember102428781", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details)", "menuCat": "Details", "order": "35", "role": "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "shortName": "The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_AlterolaBiotechIncMember", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-10-03", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Merger Transactions (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "shortName": "Merger Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Property Plant and Equipment (Details)", "menuCat": "Details", "order": "37", "role": "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails", "shortName": "Schedule of Property Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Property, Plant, and Equipment (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "shortName": "Property, Plant, and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_VenloStyleGreenHouseMember_stpr_NM", "decimals": "INF", "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Acre", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Intangible Assets (Details)", "menuCat": "Details", "order": "39", "role": "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails", "shortName": "Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Commitments (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://brightgreen.us/role/CommitmentsDetailsNarrative", "shortName": "Commitments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-10-03", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Related Party Line of Credit Note (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "shortName": "Related Party Line of Credit Note (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "BGXX:RelatedPartyLineOfCreditTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-10-03", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Income Tax Provision (Details)", "menuCat": "Details", "order": "43", "role": "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "shortName": "Schedule of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BGXX:ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details)", "menuCat": "Details", "order": "44", "role": "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails", "shortName": "Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BGXX:ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Income Taxes (continued) (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative", "shortName": "Income Taxes (continued) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToOfficersOrStockholdersCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToOfficersOrStockholdersCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LossContingencyDisclosures", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyActionsTakenByDefendant", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Contingencies (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://brightgreen.us/role/ContingenciesDetailsNarrative", "shortName": "Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LossContingencyDisclosures", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyActionsTakenByDefendant", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://brightgreen.us/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-03-272023-03-27_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "shortName": "Condensed Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentOfFinancingAndStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentOfFinancingAndStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Condensed Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://brightgreen.us/role/StatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "BGXX:EquityInNetLossesOfAffiliate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Description of Business and Organization", "menuCat": "Notes", "order": "8", "role": "http://brightgreen.us/role/DescriptionOfBusinessAndOrganization", "shortName": "Description of Business and Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Going Concern and Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://brightgreen.us/role/GoingConcernAndBasisOfPresentation", "shortName": "Going Concern and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "BGXX_AlterolaBiotechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alterola Biotech Inc [Member]", "label": "Alterola Biotech Inc [Member]" } } }, "localname": "AlterolaBiotechIncMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "domainItemType" }, "BGXX_BlackScholesModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Black Scholes Model [Member].", "label": "Black Scholes Model [Member]" } } }, "localname": "BlackScholesModelMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_BrightGreenGrowInnovationsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bright Green Grow Innovations LLC [Member].", "label": "Bright Green Grow Innovations LLC [Member]" } } }, "localname": "BrightGreenGrowInnovationsLlcMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ChangeInFairValueOfVotingAgreementDerivative": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in Fair Value of Voting Agreement Derivative", "negatedLabel": "Change in fair value", "verboseLabel": "Change in fair value of voting agreement derivative" } } }, "localname": "ChangeInFairValueOfVotingAgreementDerivative", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/ScheduleOfChangesInFairValueOfFinancialAssetsDetails", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BGXX_CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and warrants issued shares for cash in private placements", "label": "Common stock and warrants issued for cash in private placement, shares" } } }, "localname": "CommonStockAndWarrantsIssuedSharesForCashInPrivatePlacements", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "BGXX_CommonStockAndWarrantsIssuedValueForCashInPrivatePlacements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock and warrants issued value for cash in private placements", "label": "Common stock and warrants issued for cash in private placement, net of issuance costs of $863,267 (Note 12)" } } }, "localname": "CommonStockAndWarrantsIssuedValueForCashInPrivatePlacements", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "BGXX_CommonStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock One [Member]", "label": "Common Stock One [Member]" } } }, "localname": "CommonStockOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_CommonStockThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Three [Member]", "label": "Common Stock Three [Member]" } } }, "localname": "CommonStockThreeMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock To Be Issued [Member]", "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "BGXX_CommonStockTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Two [Member]", "label": "Common Stock Two [Member]" } } }, "localname": "CommonStockTwoMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants [Member]", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_DecemberTwentyTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December2020 [Member]", "label": "December2020 [Member]" } } }, "localname": "DecemberTwentyTwentyMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_DecemberTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2021 [Member]", "label": "December 2021 [Member]" } } }, "localname": "DecemberTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors [Member]", "label": "Directors [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_DisclosureRelatedPartyLineOfCreditNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Line Of Credit Note" } } }, "localname": "DisclosureRelatedPartyLineOfCreditNoteAbstract", "nsuri": "http://brightgreen.us/20221231", "xbrltype": "stringItemType" }, "BGXX_DueToOthersCurrent": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due to others current.", "label": "Due to others (Note 6)" } } }, "localname": "DueToOthersCurrent", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BGXX_EnterpriseValueCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Enterprise value cash.", "label": "Stock" } } }, "localname": "EnterpriseValueCash", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BGXX_EquityInNetLossesOfAffiliate": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity in net losses of affiliate.", "label": "EquityInNetLossesOfAffiliate", "verboseLabel": "Equity in net losses of affiliate" } } }, "localname": "EquityInNetLossesOfAffiliate", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BGXX_FebruaryTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 2021 [Member]", "label": "February 2021 [Member]" } } }, "localname": "FebruaryTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_FiveConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Consultants [Member]", "label": "Five Consultants [Member]" } } }, "localname": "FiveConsultantsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_FiveDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Directors [Member]", "label": "Five Directors [Member]" } } }, "localname": "FiveDirectorsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_GGGMergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GGG Merger Agreement [Member].", "label": "GGG Merger Agreement [Member]" } } }, "localname": "GGGMergerAgreementMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_GrantsGreehouseGrowersIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grants Greehouse Growers, Inc. [Member]", "label": "Grants Greehouse Growers, Inc. [Member]" } } }, "localname": "GrantsGreehouseGrowersIncMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_GreenHouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Green House [Member].", "label": "Green House [Member]" } } }, "localname": "GreenHouseMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income loss from continuing operations including portion attributable to noncontrolling interest equity in net losses of affiliate.", "label": "Equity in net losses of affiliate" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BGXX_JanuaryTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2021 [Member]", "label": "January 2021 [Member]" } } }, "localname": "JanuaryTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_JuneTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2021 [Member]", "label": "June 2021 [Member]" } } }, "localname": "JuneTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_LDSCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LDS Capital LLC [Member]", "label": "LDS Capital LLC [Member]" } } }, "localname": "LDSCapitalLLCMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_MarchTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2021 [Member]", "label": "March 2021 [Member]" } } }, "localname": "MarchTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_MayTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2021 [Member]", "label": "May 2021 [Member]" } } }, "localname": "MayTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_MergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger Agreement [Member].", "label": "Merger Agreement [Member]" } } }, "localname": "MergerAgreementMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_NaseebIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Naseeb Inc. [Member]", "label": "Naseeb Inc. [Member]" } } }, "localname": "NaseebIncMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Accounting Pronouncements Adopted Policy [Policy Text Block]", "label": "Standards, Amendments, and Interpretations Adopted" } } }, "localname": "NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BGXX_OctoberAndDecemberTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October and December 2021 [Member]", "label": "October and December 2021 [Member]" } } }, "localname": "OctoberAndDecemberTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_OctoberTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2021 [Member]", "label": "October 2021 [Member]" } } }, "localname": "OctoberTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_OneAccreditedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Accredited Investor [Member]", "label": "One Accredited Investor [Member]" } } }, "localname": "OneAccreditedInvestorMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_OneHundredEightyEightAccreditedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Hundred Eighty Eight Accredited [Member]", "label": "One Hundred Eighty Eight Accredited [Member]" } } }, "localname": "OneHundredEightyEightAccreditedMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_PaymentsForAcquirePropertyDeposit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for acquire property deposit.", "label": "PaymentsForAcquirePropertyDeposit", "verboseLabel": "Deposits" } } }, "localname": "PaymentsForAcquirePropertyDeposit", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BGXX_PaymentsForAcquirePropertyDeposits": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for acquire property deposits", "label": "PaymentsForAcquirePropertyDeposits", "negatedLabel": "Deposits" } } }, "localname": "PaymentsForAcquirePropertyDeposits", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BGXX_ProceedsFromIssuanceOfCommonStockAndWarrants": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and warrants.", "label": "Proceeds from issuance of common stock and warrants," } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BGXX_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment estimated useful life [Table Text Block].", "label": "Summary of Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "BGXX_PurchasePriceOptionOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price option of land", "label": "Price per acre" } } }, "localname": "PurchasePriceOptionOfLand", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BGXX_RealEstateOptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate option agreement [Member].", "label": "Real estate option agreement [Member]" } } }, "localname": "RealEstateOptionAgreementMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_RealEstateOptionAgreementOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Option Agreement One [Member]", "label": "Real Estate Option Agreement One [Member]" } } }, "localname": "RealEstateOptionAgreementOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_RealEstateOptionAgreementTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Option Agreement Two [Member]", "label": "Real Estate Option Agreement Two [Member]" } } }, "localname": "RealEstateOptionAgreementTwoMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_RelatedPartyLineOfCreditTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Line Of Credit [Text Block]", "label": "Related Party Line of Credit Note" } } }, "localname": "RelatedPartyLineOfCreditTextBlock", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNote" ], "xbrltype": "textBlockItemType" }, "BGXX_ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of federal and state tax effects of temporary difference and carryforwards [Table Text Block]", "label": "Schedule of Federal and State Tax Effects of Temporary Differences and Carryforwards" } } }, "localname": "ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferenceAndCarryforwardsTableTextBlock", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedTables" ], "xbrltype": "textBlockItemType" }, "BGXX_SecurituesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securitues Purchase Agreement [Member]", "label": "Securitues Purchase Agreement [Member]" } } }, "localname": "SecurituesPurchaseAgreementMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_SeptemberAndOctoberTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September and October 2021 [Member]", "label": "September and October 2021 [Member]" } } }, "localname": "SeptemberAndOctoberTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_SeptemberTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 [Member]", "label": "September 2021 [Member]" } } }, "localname": "SeptemberTwentyTwentyOneMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDilutiveIssuanceRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected dissuance rate.", "label": "Dilutive issuance rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDilutiveIssuanceRate", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "BGXX_SixConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six Consultants [Member]", "label": "Six Consultants [Member]" } } }, "localname": "SixConsultantsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_StockCancelledDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock cancelled during period value issued for services", "label": "Common stock cancelled that was issued for services (Note 12)" } } }, "localname": "StockCancelledDuringPeriodValueIssuedForServices", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "BGXX_StockCancelledDuringSharesValueIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock cancelled during period shares issued for services", "label": "Common stock cancelled that was issued for services (Note 11), shares" } } }, "localname": "StockCancelledDuringSharesValueIssuedForServices", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "BGXX_StockIssuedDuringPeriodSharesNewIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued New Issue.", "label": "Shares issued for cash proceeds" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssued", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BGXX_ThirtyAccreditedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thirty Accredited [Member]", "label": "Thirty Accredited [Member]" } } }, "localname": "ThirtyAccreditedMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ThreeConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Consultants [Member]", "label": "Three Consultants [Member]" } } }, "localname": "ThreeConsultantsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ThreeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Directors [Member]", "label": "Three Directors [Member]" } } }, "localname": "ThreeDirectorsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_TwelveAccreditedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twelve Accredited [Member]", "label": "Twelve Accredited [Member]" } } }, "localname": "TwelveAccreditedMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_TwentyEightAccreditedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Eight Accredited [Member]", "label": "Twenty Eight Accredited [Member]" } } }, "localname": "TwentyEightAccreditedMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_TwoAccreditedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Accredited Investor [Member]", "label": "Two Accredited Investor [Member]" } } }, "localname": "TwoAccreditedInvestorMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_TwoDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Directors [Member]", "label": "Two Directors [Member]" } } }, "localname": "TwoDirectorsMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_UnsecuredLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Line of Credit [Member]", "label": "Unsecured Line of Credit [Member]" } } }, "localname": "UnsecuredLineOfCreditMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_ValuationAllowancesOfIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance of income tax provision.", "label": "ValuationAllowancesOfIncomeTaxExpenseBenefit", "negatedLabel": "Valuation allowance" } } }, "localname": "ValuationAllowancesOfIncomeTaxExpenseBenefit", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "BGXX_VenloStyleGreenHouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Venlo Style Green House [Member].", "label": "Venlo Style Green House [Member]" } } }, "localname": "VenloStyleGreenHouseMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_VotingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting Agreement [Member]", "label": "Voting Agreement [Member]" } } }, "localname": "VotingAgreementMember", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BGXX_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "WorkingCapital", "negatedLabel": "working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://brightgreen.us/20221231", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r363", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r363", "r365", "r366" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r363", "r365", "r366" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r363", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r363", "r365", "r366" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://brightgreen.us/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r157", "r282", "r283", "r284", "r285", "r305", "r341", "r393", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r157", "r282", "r283", "r284", "r285", "r305", "r341", "r393", "r396", "r397" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r157", "r372" ], "lang": { "en-us": { "role": { "label": "The following table provides summarized income statement information for Alterola for the twelve months ended December 31, 2022:" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsTables" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r203", "r204", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r349", "r351", "r398" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r203", "r204", "r327", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r349", "r351", "r398" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r387", "r438" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "stpr_NM": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW MEXICO" } } }, "localname": "NM", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r350" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities (Note 14)" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r112", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r68", "r136" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r143", "r144", "r292", "r293", "r294", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r11" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital (Note 12)" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r252", "r253", "r254", "r384", "r385", "r386", "r435" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for noncash service expenses paid for by granting of warrants.", "label": "Warrants redeemed" } } }, "localname": "AdjustmentOfWarrantsGrantedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising cost" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": { "auth_ref": [ "r431", "r432", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.", "label": "Asset acquisition consideration transferred amount" } } }, "localname": "AssetAcquisitionConsiderationTransferredOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r119", "r138", "r154", "r186", "r196", "r200", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r282", "r284", "r291", "r350", "r394", "r395", "r439" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r133", "r139", "r154", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r282", "r284", "r291", "r350", "r394", "r395", "r439" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Current Assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "periodEndLabel": "Ending balance, assets fair value", "periodStartLabel": "Beginning balance, assets fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfChangesInFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r154", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r282", "r284", "r291", "r394", "r395", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non-Current Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BankingAndThriftDisclosureTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial services specifically banking and thrift entities at the end of the reporting period.", "label": "Banking and Thrift Disclosure [Text Block]" } } }, "localname": "BankingAndThriftDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Measurement" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r67" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and improvement" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "integration related costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r325", "r326", "r350", "r373" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r37", "r43", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH, END OF YEAR", "periodStartLabel": "CASH, BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r102" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r384", "r385", "r435" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheetsParenthetical", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r350" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $.0001 par value; 500,000,000 stock authorized; 173,304,800 and 157,544,500 stock issued and outstanding at December 31, 2022 and December 31, 2021, respectively (Note 12)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionContractCostProgressPaymentOffset": { "auth_ref": [ "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of progress payment netted against construction contract cost.", "label": "Construction of contract paid" } } }, "localname": "ConstructionContractCostProgressPaymentOffset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r67" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r382", "r428", "r430" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r267", "r275", "r382" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current (benefit) provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r382", "r428", "r430" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r230" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, stated percentage", "verboseLabel": "Interest rate stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r382", "r429", "r430" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r41", "r93", "r268", "r274", "r275", "r382" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total current (benefit) provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r382", "r429", "r430" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r263" ], "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r91", "r427" ], "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry over" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r91", "r427" ], "calculation": { "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfFederalAndStateTaxEffectsOfTemporaryDifferencesAndCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesDisclosuresTextBlock": { "auth_ref": [ "r111", "r115", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.", "label": "Deposits" } } }, "localname": "DepositLiabilitiesDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/Deposits" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r376" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits (Note 5 and 10)" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r41", "r66" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromOfficersOrStockholders": { "auth_ref": [ "r104", "r105", "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.", "label": "Accrued payroll" } } }, "localname": "DueFromOfficersOrStockholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r6", "r104", "r118", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related party" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r16", "r221", "r222", "r223", "r227", "r228", "r229", "r302", "r383" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related party (Note 14)", "terseLabel": "Due to related parties", "verboseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r23", "r221", "r222", "r223", "r227", "r228", "r229", "r302", "r383" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "verboseLabel": "Due to related party (Note 14)" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r147", "r163", "r164", "r165", "r166", "r167", "r171", "r172", "r174", "r175", "r176", "r177", "r288", "r289", "r315", "r318", "r346" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share - basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Earnings (Loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r276", "r425" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r79", "r131", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r168", "r170", "r178", "r208", "r245", "r252", "r253", "r254", "r270", "r271", "r287", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the principal activities of an investee accounted for under the equity method.", "label": "Equity method investment, description" } } }, "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Carrying value" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r57", "r187", "r374" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity method investment (Note 6)", "verboseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r110", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r41", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Voting Agreement derivative asset", "verboseLabel": "Warrants redeemed" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfChangesInFairValueOfFinancialAssetsDetails", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Investments under the equity method" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r137", "r209" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "auth_ref": [ "r63" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.", "label": "Licenses (Note 7)" } } }, "localname": "FiniteLivedLicenseAgreementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r67" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r65", "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r106", "r113", "r127", "r186", "r195", "r199", "r201", "r316", "r348" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss before income taxes and equity in net losses of affiliate" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r94", "r154", "r161", "r186", "r195", "r199", "r201", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r289", "r291", "r348", "r394" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Loss before equity in net losses of affiliate" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r155", "r260", "r261", "r266", "r272", "r277", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes (continued)" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinued" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income tax examination, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r156", "r169", "r170", "r185", "r259", "r273", "r278", "r319" ], "calculation": { "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense", "totalLabel": "Total (benefit) provision", "verboseLabel": "Current and deferred income tax expenses" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative", "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r142", "r257", "r258", "r261", "r262", "r265", "r269" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r40" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r40" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.", "label": "Lender committed funds" } } }, "localname": "IncreaseDecreaseInSecuritiesLendingPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r62", "r310", "r311", "r312", "r314", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r60", "r61" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets (Note 9)", "totalLabel": "Net intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest costs capitalized" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r148", "r150", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r388", "r389", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Merger Transactions" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Land": { "auth_ref": [ "r375" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r154", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r283", "r284", "r285", "r291", "r347", "r394", "r439", "r440" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r109", "r121", "r350", "r381", "r390", "r437" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r134", "r154", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r283", "r284", "r285", "r291", "r350", "r394", "r439", "r440" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Current Liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r3", "r4", "r5", "r7", "r8", "r154", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r283", "r284", "r285", "r291", "r394", "r439", "r440" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Non-Current Liabilities", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities.", "label": "Liability to the Sellers" } } }, "localname": "LiabilitiesRelatedToInvestmentContractsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r7", "r108", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r17", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Borrowing capacity", "verboseLabel": "Line of credit current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of credit paid" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r17", "r380" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of credit facility, maximum borrowing amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "verboseLabel": "Credit facility" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r17", "r380" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r22", "r76", "r77" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Related party line of credit note (Note 11)", "verboseLabel": "Long-term line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyActionsTakenByDefendant": { "auth_ref": [ "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "Describe actions taken by the defendant in the legal matter.", "label": "Contingency, taken by defendant description" } } }, "localname": "LossContingencyActionsTakenByDefendant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r149" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r149" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r39", "r42" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash provided by used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r42", "r114", "r126", "r132", "r140", "r141", "r145", "r154", "r161", "r163", "r164", "r165", "r166", "r169", "r170", "r173", "r186", "r195", "r199", "r201", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r289", "r291", "r348", "r394" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net income loss", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Loss before income taxes" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/ScheduleOfIncomeTaxProvisionDetails", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Warrants" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r186", "r195", "r199", "r201", "r348" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Description of Business and Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r29", "r128" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "totalLabel": "Total Other Expense" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expense" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Net of issuance cost" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForDeposits": { "auth_ref": [ "r378", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.", "label": "Payments for Deposits", "verboseLabel": "Deposits" } } }, "localname": "PaymentsForDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPurchaseOfOtherAssets1": { "auth_ref": [ "r36", "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid to purchase other assets as part of operating activities.", "label": "Payments for purchase" } } }, "localname": "PaymentsForPurchaseOfOtherAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Purchase of equity method investment" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r31" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant, and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r231" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r377" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r32" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r32" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "issued in private placement, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r33" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from related party line of credit", "verboseLabel": "Proceeds from Long-Term Lines of Credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r33" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party", "verboseLabel": "Drew from related party line of credit" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r71", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant, and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r67", "r135" ], "calculation": { "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant, and equipment gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r69", "r122", "r317", "r350" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant, and equipment (Note 8)", "totalLabel": "Net property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r69", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, Plant, and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Property Ownership [Axis]" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties." } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r34" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedLabel": "Payments to related party line of credit", "verboseLabel": "Repayments of other debt" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative", "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r34" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payments to related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r80", "r120", "r323", "r324", "r350" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained earnings accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r131", "r158", "r159", "r160", "r162", "r168", "r170", "r208", "r252", "r253", "r254", "r270", "r271", "r287", "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r183", "r184", "r194", "r197", "r198", "r202", "r203", "r205", "r246", "r247", "r313" ], "calculation": { "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenues", "totalLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r146", "r154", "r183", "r184", "r194", "r197", "r198", "r202", "r203", "r205", "r207", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r291", "r316", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/DescriptionOfBusinessAndOrganizationDetailsNarrative", "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in the Fair Value of Financial Assets" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IncomeTaxesContinuedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.", "label": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/PropertyPlantAndEquipmentDetailsNarrative", "http://brightgreen.us/role/SummaryOfEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://brightgreen.us/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Description of method used to estimate fair value of award under share-based payment arrangement.", "label": "Share based payment, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Rist free rate", "verboseLabel": "Risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "verboseLabel": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Exchange of shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share", "verboseLabel": "Issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r79", "r131", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r168", "r170", "r178", "r208", "r245", "r252", "r253", "r254", "r270", "r271", "r287", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r158", "r159", "r160", "r178", "r313" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/FollowingTableProvidesSummarizedIncomeStatementInformationForAlterolaForTwelveMonthsEndedDecember312022Details", "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Warrants estimate value" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r9", "r10", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Number of shares issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services,shares", "terseLabel": "Issuance of service shares", "verboseLabel": "Number of shares issed for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, shares", "terseLabel": "Issuance of shares", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r9", "r10", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services (Note 12)", "verboseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash (Note 12)", "verboseLabel": "Issuance of value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r56", "r350", "r381", "r390", "r437" ], "calculation": { "http://brightgreen.us/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets", "http://brightgreen.us/role/ScheduleOfFinancialStatementInformationDetails", "http://brightgreen.us/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r153", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r298", "r307" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r298", "r307" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r298", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r298", "r307" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative", "http://brightgreen.us/role/RelatedPartyTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative", "http://brightgreen.us/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern and Basis of Presentation" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/GoingConcernAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH PAID FOR" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimeDepositLiabilityAboveUsInsuranceLimit": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of uninsured time deposit liability in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit or similar state deposit insurance regime in United States of America (US). Excludes time deposit that is otherwise uninsured.", "label": "Excess of FDIC insured limit" } } }, "localname": "TimeDepositLiabilityAboveUsInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/ConcentrationOfCreditRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfInvestments": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of investments transferred from the entity's investments in noncash transactions.", "label": "Due to others for purchase of Common stock in Alterola Biotech, Inc." } } }, "localname": "TransferOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative", "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r179", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/MergerTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/RelatedPartyLineOfCreditNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Exercise price" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r171", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://brightgreen.us/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "942", "URI": "https://asc.fasb.org/topic&trid=2209208", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6487514&loc=d3e32427-158581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/subtopic&trid=2127163", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/subtopic&trid=2127197", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=6471471&loc=d3e48698-109348", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(e)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(f)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r354": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r356": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r363": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r364": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r365": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r366": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r367": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r368": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r369": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r371": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org/topic&trid=75115024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org/topic&trid=2197064", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 71 0001493152-23-012561-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-012561-xbrl.zip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Ð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